2-amino-N-(amino-oxo-aryl-λ6-sulfanylidene)acetamide compounds and their therapeutic uses

By developing 2-amino-N-(amino-oxo-aryl-λ6-sulfurite)acetamide compounds, the shortcomings of existing antibacterial drugs on targeted therapeutic agents for bacterial aminoacyl-tRNA synthetase are solved, and the treatment of the targeted therapeutic agents of bacterial aminoacyl-tRNA synthetases has been achieved. Selective inhibition of bacterial leucyl-tRNA synthetase provides new methods and drugs for the treatment of bacterial infection.

CN114846000BActive Publication Date: 2025-01-03OXFORD DRUG DESIGN LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080088355.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-19
Filing Date
2020-12-18
Publication Date
2025-01-03
Estimated Expiration
2040-12-18

Smart Images

  • Figure CN114846000B_ABST
    Figure CN114846000B_ABST
Patent Text Reader

Abstract

The present invention relates generally to the field of therapeutic compounds. More specifically, the present invention relates to certain 2-amino-N-(amino-oxo-aryl-λ 6 -sulfinyl) acetamide compounds (referred to herein as ANASIA compounds), which particularly inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetases (aaRS) (e.g., bacterial leucyl-tRNA synthetases, LeuRS). The present invention also relates to pharmaceutical compositions comprising such compounds, as well as the use of such compounds and compositions to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetases in vitro and in vivo; to treat conditions that are improved by inhibiting (e.g., selectively inhibiting) bacterial aminoacyl-tRNA synthetases; to treat bacterial infections, etc. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application is related to U.S. Provisional Patent Application No. 62 / 950,311 filed on December 19, 2019, the contents of which are incorporated herein by reference in their entirety. Technical Field

[0003] The present invention relates generally to the field of therapeutic compounds. More specifically, the present invention relates to certain 2-amino-N-(amino-oxo-aryl-λ 6 -sulfanylidene) acetamide compounds (referred to herein as ANASIA compounds) that particularly inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetases (aaRSs) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also relates to pharmaceutical compositions comprising such compounds, as well as the use of such compounds and compositions for inhibiting (e.g., selectively inhibiting) bacterial aminoacyl-tRNA synthetases in vitro and in vivo; treating conditions that are improved by inhibiting (e.g., selectively inhibiting) bacterial aminoacyl-tRNA synthetases; treating bacterial infections, etc. Background Art

[0004] Numerous publications are cited herein to more fully describe and disclose the present invention and the prior art to which the present invention relates. These references are hereby incorporated by reference into the present disclosure in their entireties to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference.

[0005] Throughout this specification, including the appended claims, unless the context requires otherwise, the word "comprise" and variations such as "comprises" and "comprising" will be understood to imply the inclusion of stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps.

[0006] It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a pharmaceutical carrier" includes mixtures of two or more such carriers, etc.

[0007] Ranges are often expressed herein as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when a value is expressed as an approximation by preceding it with "about," it is understood that the particular value forms another embodiment.

[0008] This disclosure includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly mentioned is prior art.

[0009] Bacterial aminoacyl-tRNA synthetases

[0010] The widespread development of resistance to currently used antimicrobial drugs has stimulated the search for novel chemotherapeutic agents that can slow or completely prevent the development of resistance. This can be achieved by targeting functional bacterial proteins whose mutations lead to reduced bacterial fitness.

[0011] Bacterial enzymes called aminoacyl-tRNA synthetases (aaRSs) have been implicated as targets for drug development. See, for example, Gadakh et al., 2012; Vondenhoff et al., 2011; and Pham et al., 2014.

[0012] The aminoacyl-tRNA synthetase (aaRS) family of enzymes catalyzes the addition of protein-producing amino acids to their cognate tRNAs. The product aminoacyl-tRNA participates in the translation of messenger RNA into protein at the ribosome. The aaRS mechanism proceeds as follows: it binds ATP and the corresponding amino acid to form an aminoacyl-adenylate intermediate, releasing inorganic pyrophosphate (PPi). The adenylate-aaRS complex binds to the appropriate tRNA molecule and transfers the amino acid from the aminoacyl-AMP to the 2'-OH or 3'-OH of the last tRNA nucleotide at the 3' end.

[0013] The mechanism can be summarized as the following series of reactions:

[0014] Amino acid + ATP → aminoacyl-AMP + PPi

[0015] Aminoacyl-AMP + tRNA → Aminoacyl-tRNA + AMP

[0016] Two classes of aminoacyl-tRNA synthetases (aaRSs) are known: "class I" (which have two highly conserved sequence motifs and aminoacylate at the 2'-OH of the terminal adenosine nucleotide on the tRNA) and "class II" (which have three highly conserved sequence motifs and aminoacylate at the 3'-OH of the terminal adenosine on the tRNA). Among the known aminoacyl-tRNA synthetases are: alanyl-tRNA synthetase; arginyl-tRNA synthetase; aspartyl-tRNA synthetase; glutamyl-tRNA synthetase; glycyl-tRNA synthetase; histidyl-RNA synthetase; isoleucyl-tRNA synthetase; leucyl-tRNA synthetase; lysyl-tRNA synthetase; methionyl-tRNA synthetase; phenylalanyl-tRNA synthetase; seryl-tRNA synthetase; threonyl-tRNA synthetase; tryptophanyl-tRNA synthetase; tyrosyl-tRNA synthetase; and valyl-tRNA synthetase.

[0017] Bacterial aminoacyl-tRNA synthetases (aaRSs) have several characteristics that make them promising broad-spectrum antibacterial drug targets; they are essential for survival, found in all bacterial pathogens, and in many cases, their structures are sufficiently distinct from their eukaryotic counterparts to allow for selective targeting (see, e.g., Hurdle et al., 2005; Ochsner et al., 2007). In addition, these enzymes have been validated both chemically and clinically as useful targets for antibacterial chemotherapy.

[0018] However, despite the promise of this array of targets, to date, only one aaRS inhibitor with a relatively limited indication has been approved for the management of bacterial infections. Specifically, mupirocin (also known as Bactroban and Centany; shown below) is an isoleucyl-tRNA synthetase inhibitor that has been approved for use as a topical agent for nasal colonization of Staphylococcus aureus and for the treatment of superficial skin infections (see, e.g., Laupland et al., 2003).

[0019]

[0020] Several inhibitors of other bacterial tRNA synthetases have been developed; however, none of these inhibitors are currently approved for pharmaceutical use.

[0021] The present inventors have identified a novel class of small molecule inhibitors of bacterial aminoacyl-tRNA synthetases, specifically bacterial leucyl-tRNA synthetase, which may be used to treat a variety of conditions, including bacterial infections.

[0022] Known compounds

[0023] Jirgensons et al., 2016 describe certain N-acyl-arylsulfonamide derivatives of the following formula as aminoacyl-tRNA synthetase inhibitors that are particularly useful in treating bacterial infections.

[0024]

[0025] Finn et al., 2018 describe certain 2-amino-N-(arylsulfinyl)-acetamide compounds of the formula below as inhibitors of bacterial aminoacyl-tRNA synthetases, which are particularly useful in treating bacterial infections.

[0026]

[0027] In contrast to these known compounds, the aminoacyl-tRNA synthetase inhibitors described herein have the following formula:

[0028] Summary of the Invention

[0029] One aspect of the present invention relates to certain 2-amino-N-(amino-oxo-aryl-λ 6 -sulfanyl)acetamide compounds (referred to herein as ANASIA compounds).

[0030] Another aspect of the present invention relates to a composition (eg, a pharmaceutical composition) comprising an ANASIA compound as described herein and a pharmaceutically acceptable carrier or diluent.

[0031] Another aspect of the present invention relates to a method of preparing a composition (eg, a pharmaceutical composition) comprising the step of admixing an ANASIA compound as described herein and a pharmaceutically acceptable carrier or diluent.

[0032] Another aspect of the present invention relates to a method of inhibiting (e.g., selectively inhibiting) a bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS, etc.) in vitro or in vivo, comprising contacting the synthetase with an effective amount of an ANASIA compound as described herein.

[0033] Another aspect of the present invention relates to a method of inhibiting (e.g., selectively inhibiting) the function of a bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS, etc.) in a cell (e.g., a bacterial cell) in vitro or in vivo, comprising contacting the cell with an effective amount of an ANASIA compound as described herein.

[0034] Another aspect of the invention relates to an ANASIA compound as described herein for use in a method of treating the human or animal body by therapy, such as for use in a method of treating a condition (eg, a disease) as described herein.

[0035] Another aspect of the invention relates to the use of an ANASIA compound as described herein in the manufacture of a medicament, eg, for use in a method of treatment, eg, for use in a method of treating a condition (eg, a disease) as described herein.

[0036] Another aspect of the invention relates to a method of treatment, e.g., a method of treating a condition (e.g., a disease) as described herein, comprising administering to a subject in need of treatment a therapeutically effective amount of an ANASIA compound as described herein, preferably in the form of a pharmaceutical composition.

[0037] In one embodiment, the treatment is treatment of a condition in the human or animal body that is ameliorated by inhibition (eg, selective inhibition) of a bacterial aminoacyl-tRNA synthetase (aaRS) (eg, bacterial leucyl-tRNA synthetase, LeuRS).

[0038] In one embodiment, the treatment is treatment of a bacterial infection.

[0039] Another aspect of the invention relates to a kit comprising (a) an ANASIA compound as described herein, preferably provided as a pharmaceutical composition and provided in a suitable container and / or with suitable packaging; and (b) instructions, such as written instructions, on how to administer the compound.

[0040] Another aspect of the present invention relates to an ANASIA compound obtainable by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.

[0041] Another aspect of the present invention relates to an ANASIA compound obtained by a synthesis method as described herein, or a method comprising a synthesis method as described herein.

[0042] Another aspect of the present invention relates to novel intermediates as described herein, which are suitable for use in the synthetic methods described herein.

[0043] Another aspect of the present invention relates to the use of such novel intermediates as described herein in the synthetic methods described herein.

[0044] Those skilled in the art will appreciate that features and preferred embodiments of one aspect of the invention will also be relevant to other aspects of the invention. DETAILED DESCRIPTION

[0045] Compound

[0046] One aspect of the present invention relates to what can be generally described as 2-amino-N-(amino-oxo-aryl- 6 -sulfenyl)acetamide compounds. A simple example of such compounds is 2-amino-N-(amino-oxo-phenyl-λ 6 -sulfanylidene)acetamide, as shown below.

[0047]

[0048] The compound is characterized by a -S(=O)(NH2)=NH-C(=O)-C(NH2)< linkage, has an aromatic group (referred to herein as -A) attached to the sulfur atom (on the far left), and has two groups (referred to herein as -R 1 and -R 2 ) is connected to the α carbon atom (on the far right).

[0049] The -NH2 group attached to the sulfur atom may be optionally substituted with one or two substituents (e.g., -NR N1 R N2 Thus, more generally, the compound is -S(=O)(NR N1 R N2 )=NH-C(=O)-C(NH2)< linkage is characteristic.

[0050] Therefore, one aspect of the present invention relates to compounds of the following formula, and pharmaceutically acceptable salts, hydrates and solvates thereof, wherein -A, -R N1 、-R N2 、-R 1 and -R 2 As defined herein (for convenience, collectively referred to herein as "2-amino-N-(amino-oxo-aryl-λ 6 -sulfenyl)acetamide compounds" or "ANASIA compounds"):

[0051]

[0052] The left-hand group AS(=O)(NR N1 R N2)=NH- can be conveniently viewed as an arylsulfonimide amide moiety. The right-hand side group -C(=O)-CR 1 R 2 -NH2 can be conveniently considered as an α-amino acid residue.

[0053]

[0054] Some embodiments of the present invention include the following:

[0055] (1) A compound selected from the group consisting of the following compounds, and pharmaceutically acceptable salts, hydrates, and solvates thereof:

[0056]

[0057] in:

[0058] -A independently is -A C or -A H ;

[0059] -A C is independently phenyl or naphthyl, and is optionally substituted by one or more substituents -R X replace;

[0060] -A H Independently C 5-12 heteroaryl, and optionally substituted by one or more -R X replace;

[0061] And among them:

[0062] Each -R X Independently selected from:

[0063] -R XX 、-R XXU 、-R XXV ,

[0064] -F, -Cl, -Br, -I,

[0065] -OH, -OR XX ,

[0066] -L XX -OH, -L XX -OR XX ,

[0067] -CF3, -CHF2, -OCF3, -OCHF2,

[0068] -NH2, -NHR XX 、-NR XX 2. -R XM ,

[0069] -L XX -NH2、-L XX -NHR XX 、-L XX -NR XX 2、-L XX -R XM ,

[0070] -C(=O)OH、-C(=O)OR XX 、-OC(=O)R XX ,

[0071] -C(=O)NH2、-C(=O)NHR XX 、-C(=O)NR XX 2、-C(=O)R XM ,

[0072] -NHC(=O)R XX 、-NR XN C(=O)R XX ,

[0073] -NHC(=O)NH2、-NHC(=O)NHR XX 、-NHC(=O)NR XX 2、-NHC(=O)R XM ,

[0074] -NR XN C(=O)NH2、-NR XN C(=O)NHR XX 、-NR XN C(=O)NR XX 2、-NR XN C(=O)R XM ,

[0075] -NHC(=O)OR XX 、-NR XN C(=O)OR XX ,

[0076] -OC(=O)NH2、-OC(=O)NHR XX 、-OC(=O)NR XX 2、-OC(=O)R XM ,

[0077] -NHC(=NH)NH2,

[0078] -C(=O)R XX ,

[0079] -S(=O)NH2、-S(=O)NHRXX 、-S(=O)NR XX 2. -S(=O)R XM ,

[0080] -S(=O)2NH2, -S(=O)2NHR XX 、-S(=O)2NR XX 2. -S(=O)2R XM ,

[0081] -NHS(=O)R XX 、-NR XN S(=O)R XX ,

[0082] -NHS(=O)2R XX 、-NR XN S(=O)2R XX ,

[0083] -S(=O)R XX 、-S(=O)2R XX ,

[0084] -SH, -SR XX , -CN and -NO2;

[0085] And additionally, two adjacent groups -R X When present, they may together form:

[0086] -O-CH2-O-, -O-CH2CH2-O-, -CH2-CH2-O-, -CH2-CH2CH2-O-,

[0087] -CH2-O-CH2- or -CH2-CH2-O-CH2-;

[0088] in:

[0089] Each -L XX - is a straight chain or branched saturated C 1-4 alkylene;

[0090] Each -R XX are independently straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of: -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0091] Each -R XXU are independently linear or branched C 2-4 alkenyl;

[0092] Each -RXXV are independently linear or branched C 2-4 Alkynyl;

[0093] Each -R XN Is a straight chain or branched chain saturated C 1-4 alkyl;

[0094] Each -R XM are independently azetidinyl, pyrrolidyl, piperidinyl, piperazinyl, morpholinyl, azepanyl or diazepanyl, and:

[0095] Optionally substituted with one or more groups selected from:

[0096] -R XMM 、-C(=O)R XMM 、-C(=O)OR XMM and -S(=O)2R XMM ;

[0097] Each of these -R XMM are independently straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of: -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0098] -R 1 are independently -H or -R 11 ;

[0099] -R 11 Independently -R 11A or -R 11B ;

[0100] -R 11A Independently it is:

[0101] -R A1 、-R A2 、-R A3 、-R A4 、-R A5 、-L A -R A2 、-L A -R A3 、-L A -R A4 or -L A -R A5 ;

[0102] Each -R A1 Is a straight chain or branched chain saturated C 1-6 alkyl, and optionally substituted by one or more groups -RAA2 replace;

[0103] Each -R A2 Is saturated C 3-6 Cycloalkyl, and optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace;

[0104] Each -R A3 Non-aromatic C 3-7 heterocyclyl, and optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace;

[0105] Each -R A4 is independently phenyl or naphthyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace;

[0106] Each -R A5 It is C 5-10 heteroaryl, and optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace;

[0107] Each -L A - is a straight chain or branched saturated C 1-4 alkylene;

[0108] Each -R AA1 Independently selected from:

[0109] -R AA ,

[0110] -L AA -OH, -L AA -OR AA ,

[0111] -L AA -NH2、-L AA -NHR AA 、-L AA -N(R AA )2 and -L AA -R AM ;

[0112] Each -R AA2 Independently selected from:

[0113] -F, -Cl, -Br, -I,

[0114] -OH, -OR AA ,

[0115] -CF3、-CHF2、-OCF3、-OCHF2、

[0116] -NH2、-NHR AA 、-N(R AA ) 2、-R AM ,

[0117] -C(=O)OH、-C(=O)OR AA 、-AD(=O)R AA ,

[0118] -C(=O)NH2、-C(=O)NHR AA 、-C(=O)N(R AA )2、-C(=O)R AM ,

[0119] -NHC(=O)R AA 、-NR AN C(=O)R AA ,

[0120] -NHC(=O)NH2、-NHC(=O)NHR AA 、-NHC(=O)N(R AA )2、-NHC(=O)R AM ,

[0121] -NR AN C(=O)NH2、-NR AN C(=O)NHR AA 、-NR AN C(=O)N(R AA )2,

[0122] -NR AN C(=O)R AM ,

[0123] -NHC(=O)OR AA 、-NR AN C(=O)OR AA ,

[0124] -OC(=O)NH2、-OC(=O)NHR AA 、-OC(=O)N(R AA )2、-AD(=O)R AM ,

[0125] -NHC(=NH)NH2,

[0126] -C(=O)R AA ,

[0127] -S(=O)NH2, -S(=O)NHR AA 、-S(=O)N(R AA )2、-S(=O)R AM ,

[0128] -S(=O)2NH2, -S(=O)2NHR AA 、-S(=O)2N(R AA )2、-S(=O)2R AM ,

[0129] -NHS(=O)R AA 、-NR AN S(=O)R AA ,

[0130] -NHS(=O)2R AA 、-NR AN S(=O)2R AA ,

[0131] -S(=O)R AA 、-S(=O)2R AA ,

[0132] -SH, -SR AA , -CN and -NO2;

[0133] in:

[0134] Each -L AA - is a straight chain or branched saturated C 1-4 alkylene;

[0135] Each -R AA are independently straight-chain or branched saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0136] Each -R AN Is a straight chain or branched chain saturated C 1-4 alkyl;

[0137] Each -R AM are independently azetidinyl, pyrrolidyl, piperidinyl, piperazinyl, morpholinyl, azepanyl or diazepanyl, and:

[0138] Optionally substituted with one or more groups selected from:

[0139] -R AMM 、-C(=O)RAMM 、-C(=O)OR AMM and -S(=O)2R AMM ;

[0140] Each of these -R AMM are independently straight-chain or branched saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0141] -R 11B Independently selected from:

[0142] -F, -Cl, -Br, -I,

[0143] -OH, -OR BB ,

[0144] -CF3, -CHF2, -OCF3, -OCHF2,

[0145] -NH2, -NHR BB 、-NR BB 2. -R BM ,

[0146] -C(=O)OH, -C(=O)OR BB 、-OC(=O)R BB ,

[0147] -C(=O)NH2, -C(=O)NHR BB 、-C(=O)NR BB 2. -C(=O)R BM ,

[0148] -NHC(=O)R BB 、-NR BN C(=O)R BB ,

[0149] -NHC(=O)NH2, -NHC(=O)NHR BB 、-NHC(=O)NR BB 2. -NHC(=O)R BM ,

[0150] -NR BN C(=O)NH2, -NR BN C(=O)NHR BB 、-NR BN C(=O)NR BB 2. -NR BN C(=O)RBM ,

[0151] -NHC(=O)OR BB 、-NR BN C(=O)OR BB ,

[0152] -OC(=O)NH2, -OC(=O)NHR BB 、-OC(=O)NR BB 2. -OC(=O)R BM ,

[0153] -NHC(=NH)NH2,

[0154] -C(=O)R BB ,

[0155] -S(=O)NH2, -S(=O)NHR BB 、-S(=O)NR BB 2. -S(=O)R BM ,

[0156] -S(=O)2NH2, -S(=O)2NHR BB 、-S(=O)2NR BB 2. -S(=O)2R BM ,

[0157] -NHS(=O)R BB 、-NR BN S(=O)R BB ,

[0158] -NHS(=O)2R BB 、-NR BN S(=O)2R BB ,

[0159] -S(=O)R BB 、-S(=O)2R BB ,

[0160] -SH, -SR BB , -CN and -NO2;

[0161] in:

[0162] Each -R BB are independently straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of: -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0163] Each -RBN Is a straight chain or branched chain saturated C 1-4 alkyl;

[0164] Each -R BM are independently azetidinyl, pyrrolidyl, piperidinyl, piperazinyl, morpholinyl, azepanyl or diazepanyl, and:

[0165] Optionally substituted with one or more groups selected from:

[0166] -R BMM 、-C(=O)R BMM 、-C(=O)OR BMM and -S(=O)2R BMM ;

[0167] Each of these -R BMM are independently straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of: -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0168] -R 2 are independently -H or -R 22 ;

[0169] -R 22 Independently -R 22C or -R 22D ;

[0170] -R 22C Independently it is:

[0171] -R C1 、-R C2 、-R C3 、-R C4 、-R C5 、-L C -R C2 、-L C -R C3 、-L C -R C4 or -L C -R C5 ;

[0172] Each -R C1 Is a straight chain or branched chain saturated C 1-6 alkyl, and optionally substituted by one or more groups -R CC2 replace;

[0173] Each -R C2 Is saturated C 3-6Cycloalkyl, and optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace;

[0174] Each -R C3 Non-aromatic C 3-7 heterocyclyl, and optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace;

[0175] Each -R C4 is independently phenyl or naphthyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace;

[0176] Each -R C5 It is C 5-10 heteroaryl, and optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace;

[0177] Each -L C - is a straight chain or branched saturated C 1-4 alkylene;

[0178] Each -R CC1 Independently selected from:

[0179] -R CC ,

[0180] -L CC -OH, -L CC -OR CC ,

[0181] -L CC -NH2, -L CC -NHR CC 、-L CC -N(R CC )2 and -L CC -R CM ;

[0182] Each -R CC2 Independently selected from:

[0183] -F, -Cl, -Br, -I,

[0184] -OH, -OR CC ,

[0185] -CF3, -CHF2, -OCF3, -OCHF2,

[0186] -NH2、-NHR CC 、-N(R CC )2、-R CM ,

[0187] -C(=O)OH、-C(=O)OR CC 、-OC(=O)R CC ,

[0188] -C(=O)NH2、-C(=O)NHR CC 、-C(=O)N(R CC )2、-C(=O)R CM ,

[0189] -NHC(=O)R CC 、-NR CN C(=O)R CC ,

[0190] -NHC(=O)NH2、-NHC(=O)NHR CC 、-NHC(=O)N(R CC )2、-NHC(=O)R CM ,

[0191] -NR CN C(=O)NH2、-NR CN C(=O)NHR CC 、-NR CN C(=O)N(R CC )2,

[0192] -NR CN C(=O)R CM ,

[0193] -NHC(=O)OR CC 、-NR CN C(=O)OR CC ,

[0194] -OC(=O)NH2、-OC(=O)NHR CC 、-OC(=O)N(R CC )2、-OC(=O)R CM ,

[0195] -NHC(=NH)NH2,

[0196] -C(=O)R CC ,

[0197] -S(=O)NH2、-S(=O)NHR CC 、-S(=O)N(R CC)2、-S(=O)R CM ,

[0198] -S(=O)2NH2, -S(=O)2NHR CC 、-S(=O)2N(R CC )2、-S(=O)2R CM ,

[0199] -NHS(=O)R CC 、-NR CN S(=O)R CC ,

[0200] -NHS(=O)2R CC 、-NR CN S(=O)2R CC ,

[0201] -S(=O)R CC 、-S(=O)2R CC ,

[0202] -SH, -SR CC , -CN and -NO2;

[0203] in:

[0204] Each -L CC - is a straight chain or branched saturated C 1-4 alkylene;

[0205] Each -R CC are independently straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of: -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0206] Each -R CN Is a straight chain or branched chain saturated C 1-4 alkyl;

[0207] Each -R CM are independently azetidinyl, pyrrolidyl, piperidinyl, piperazinyl, morpholinyl, azepanyl or diazepanyl, and:

[0208] Optionally substituted with one or more groups selected from:

[0209] -R CMM 、-C(=O)R CMM 、-C(=O)OR CMM and -S(=O)2R CMM ;

[0210] Each of these -R CMM are independently straight-chain or branched saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0211] -R 22D Independently selected from:

[0212] -F, -Cl, -Br, -I,

[0213] -OH, -OR DD ,

[0214] -CF3, -CHF2, -OCF3, -OCHF2,

[0215] -NH2, -NHR DD 、-NR DD 2. -R DM ,

[0216] -C(=O)OH, -C(=O)OR DD 、-OC(=O)R DD ,

[0217] -C(=O)NH2, -C(=O)NHR DD 、-C(=O)NR DD 2. -C(=O)R DM ,

[0218] -NHC(=O)R DD 、-NR DN C(=O)R DD ,

[0219] -NHC(=O)NH2, -NHC(=O)NHR DD 、-NHC(=O)NR DD 2. -NHC(=O)R DM ,

[0220] -NR DN C(=O)NH2, -NR DN C(=O)NHR DD 、-NR DN C(=O)NR DD 2. -NR DN C(=O)R DM ,

[0221] -NHC(=O)OR DD 、-NRDN C(=O)OR DD ,

[0222] -OC(=O)NH2, -OC(=O)NHR DD 、-OC(=O)NR DD 2. -OC(=O)R DM ,

[0223] -NHC(=NH)NH2,

[0224] -C(=O)R DD ,

[0225] -S(=O)NH2, -S(=O)NHR DD 、-S(=O)NR DD 2. -S(=O)R DM ,

[0226] -S(=O)2NH2, -S(=O)2NHR DD 、-S(=O)2NR DD 2. -S(=O)2R DM ,

[0227] -NHS(=O)R DD 、-NR DN S(=O)R DD ,

[0228] -NHS(=O)2R DD 、-NR DN S(=O)2R DD ,

[0229] -S(=O)R DD 、-S(=O)2R DD ,

[0230] -SH, -SR DD , -CN and -NO2;

[0231] in:

[0232] Each -R DD are independently straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of: -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0233] Each -R DN Is a straight chain or branched chain saturated C 1-4 alkyl;

[0234] Each -R DM are independently azetidinyl, pyrrolidyl, piperidinyl, piperazinyl, morpholinyl, azepanyl or diazepanyl, and:

[0235] Optionally substituted with one or more groups selected from:

[0236] -R DMM 、-C(=O)R DMM 、-C(=O)OR DMM and -S(=O)2R DMM ;

[0237] Each of these -R DMM are independently straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of: -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3;

[0238] or -R 1 with -R 2 Together with the carbon atom to which it is attached, it forms a saturated C 3-6 Cycloalkyl or non-aromatic C 3-7 heterocyclyl, and optionally substituted by one or more groups -R CC2 replace;

[0239] And among them:

[0240] -R N1 are independently -H or -R N ;

[0241] -R N2 are independently -H or -R N ;

[0242] Each -R N are independently straight or branched chain saturated C 1-6 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of: -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3; or

[0243] -R N1 With R N2 Connect together to form C 2-6 Alkylene.

[0244] For convenience, the following table lists the various groups mentioned above.

[0245]

[0246] For the avoidance of doubt, it is contemplated that -S(=O)(NR N1 R N2 )=NH-C(=O)-C(NH2)<-NH2 group attached to carbon atom in linkage Unmodified (e.g., unsubstituted; unprotected, etc.). However, the group may be protonated, i.e., to form -NH3 + .

[0247] Additionally, for the avoidance of doubt, it is contemplated that -S(=O)(NR N1 R N2 )=NH-C(=O)-C(NH2)< in the linkage any Partial Won't However, in certain embodiments, as described herein, -R N1 with -R N2 Together with the nitrogen atom to which it is attached, it can form a ring.

[0248] Also, for the avoidance of doubt, -A and -R are expected 1 Together or -A and -R 2 do not form part of a ring. For example, -A and -R 1 Won't In addition, by removing -S(=O)(NR N1 R N2 )=NH-C(=O)-C(NH2)(R 2 )-linked. Similarly, it is expected that -A and -R 2 Won't In addition, by removing -S(=O)(NR N1 R N2 )=NH-C(=O)-C(NH2)(R 2 However, in certain embodiments, as described herein, -R 1 with -R 2 Together with the carbon atom to which it is attached, it can form a ring.

[0249] Similarly, for the avoidance of doubt, -A and -R are expected N1 Together or -A and -R N2 Connected together No Similarly, for the avoidance of doubt, it is expected that -R 1 and -R N1 Together or -R 1 and -R N2 Connected together No Similarly, for the avoidance of doubt, it is expected that -R 2 and -R N1 Together or -R2 and -R N2 Connected together No Form part of a ring.

[0250] It should be noted that the compounds have at least one chiral center, specifically a sulfur atom forming part of the sulfonimide amide group, indicated by an asterisk (*) in the formula below. Unless otherwise indicated, the sulfur atom at this position may be in the (R) or (S) configuration.

[0251]

[0252] It should also be noted that depending on the group -R 1 and -R 2 The compound may have another chiral center, specifically, -R 1 and -R 2 The carbon atom to which it is attached is indicated by a pound sign (#) in the following formulas. Unless otherwise indicated, the carbon atom at this position may be in the (R) or (S) configuration.

[0253]

[0254] For the avoidance of doubt, and unless otherwise stated, reference to one or more compounds without specifying the configuration of one or two chiral centers is intended to encompass all possible configurations. For example, the following formula (without specifying stereochemistry):

[0255]

[0256] All four diastereomers are intended to be covered:

[0257]

[0258] Similarly, the following formula (stereochemistry at the sulfur atom is not specified):

[0259]

[0260] Both diastereomers are intended to be covered:

[0261]

[0262] It should be noted that depending on -R N1 and -R N2 The identity of the sulfonimide amide linkage may exist in tautomerism, as shown below. The compounds are primarily depicted herein in one tautomeric form. However, unless otherwise stated, reference to one or more compounds having one tautomeric form is intended to encompass both tautomeric forms.

[0263]

[0264] It should be noted that, in principle, stereoisomerism (e.g., cis, trans, E, Z) may exist about the S=N double bond, as shown below. The compounds are primarily depicted herein in one configuration. However, unless otherwise indicated, reference to one or more compounds having one configuration is intended to encompass both configurations.

[0265]

[0266] Group-A

[0267] (2) The compound according to (1), wherein -A is -A C .

[0268] (3) The compound according to (1), wherein -A is -A H .

[0269] Group-A C

[0270] (4) The compound according to any one of (1) to (3), wherein -A C When present, phenyl or naphthyl, and optionally substituted by 1, 2 or 3 -R X replace.

[0271] (5) The compound according to any one of (1) to (3), wherein -A C When present, phenyl is optionally substituted by one or more -R X replace.

[0272] (6) The compound according to any one of (1) to (3), wherein -A C When present, phenyl is optionally substituted by 1, 2 or 3 substituents -R X replace.

[0273] (7) The compound according to any one of (1) to (3), wherein -A C When present, independently selected from:

[0274]

[0275] Each of these -R X1 、-R X2 、-R X3 、-R X4 and -R X5 Independently as about-R X defined.

[0276] (8) The compound according to any one of (1) to (3), wherein -AC When present, independently selected from:

[0277]

[0278]

[0279] Each of these -R X1 、-R X2 、-R X3 、-R X4 and -R X5 Independently as about-R X defined.

[0280] (9) The compound according to any one of (1) to (3), wherein -A C When present, independently selected from:

[0281]

[0282] Each of these -R X1 、-R X2 and -R X3 Independently as about-R X defined.

[0283] (10) The compound according to any one of (1) to (3), wherein -A C When present, independently selected from:

[0284]

[0285] Each of these -R X1 、-R X2 and -R X3 Independently as about-R X defined.

[0286] (11) The compound according to any one of (1) to (3), wherein -A C When present it is:

[0287]

[0288] Where -R X1 Independently as about-R X defined.

[0289] (12) The compound according to any one of (1) to (3), wherein -A C When present it is:

[0290]

[0291] Where -R X2Independently as about-R X defined.

[0292] (13) The compound according to any one of (1) to (3), wherein -A C When present it is:

[0293]

[0294] Where -R X3 Independently as about-R X defined.

[0295] (14) The compound according to any one of (1) to (3), wherein -A C When present it is phenyl.

[0296] (15) The compound according to any one of (1) to (3), wherein -A C When present, it is naphthyl and is optionally substituted by one or more -R X replace.

[0297] (16) The compound according to any one of (1) to (3), wherein -A C When present, it is naphthyl and is optionally substituted by 1, 2 or 3 substituents -R X replace.

[0298] (17) The compound according to any one of (1) to (3), wherein -A C When present, it is naphthyl.

[0299] (18) The compound according to any one of (1) to (3), wherein -A C When present, it is naphthalen-1-yl and is optionally substituted by one or more substituents -R X replace.

[0300] (19) The compound according to any one of (1) to (3), wherein -A C When present, it is naphthalen-2-yl and is optionally substituted by one or more substituents -R X replace.

[0301]

[0302] (20) The compound according to any one of (1) to (3), wherein -A C When present it is naphthalen-1-yl.

[0303] (21) The compound according to any one of (1) to (3), wherein -A C When present it is naphthalen-2-yl.

[0304] Group-A H

[0305] (22) The compound according to any one of (1) to (21), wherein -A H When present, it is C 5-10 heteroaryl, and optionally substituted by one or more -R X replace.

[0306] (23) The compound according to any one of (1) to (21), wherein -A H When present, it is C 5-10 heteroaryl, and optionally substituted by 1, 2 or 3 -R X replace.

[0307] (24) The compound according to any one of (1) to (21), wherein -A H When present, it is C 5-6 Heteroaryl or C 9-10 heteroaryl, and optionally substituted by one or more -R X replace.

[0308] (25) The compound according to any one of (1) to (21), wherein -A H When present, it is furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, thienylpyridinyl, thienylthienyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl or benzopyranyl, and is optionally substituted by one or more substituents -R X replace.

[0309] (26) The compound according to any one of (1) to (21), wherein -A H When present, it is furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl or benzopyranyl, and is optionally substituted by one or more substituents -R X replace.

[0310] Monocyclic groups:

[0311] (27) The compound according to any one of (1) to (21), wherein -AH When present, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, and is optionally substituted by one or more -R X replace.

[0312] (28) The compound according to any one of (1) to (21), wherein -A H When present is pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, and is optionally substituted by one or more -R X replace.

[0313] (29) The compound according to any one of (1) to (21), wherein -A H When present, it is pyridyl, thienyl or thiazolyl, and is optionally substituted by one or more substituents -R X replace.

[0314] (30) The compound according to any one of (1) to (21), wherein -A H When present, it is thienyl and is optionally substituted by one or more -R X replace.

[0315] (31) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0316]

[0317]

[0318] Each of these -R X2 、-R X3 、-R X4 and -R X5 Independently as about-R X defined.

[0319] (32) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0320]

[0321] Each of these -R X3 、-R X4 and -R X5 Independently as about-R X defined.

[0322] (33) The compound according to any one of (1) to (21), wherein -AH When present, independently selected from:

[0323]

[0324] Each of these -R X2 、-R X3 、-R X4 and -R X5 Independently as about-R X defined.

[0325] (34) The compound according to any one of (1) to (21), wherein -A H When present, it is thien-2-yl and is optionally substituted by one or more substituents -R X replace.

[0326] (35) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0327]

[0328] Each of these -R X3 、-R X4 and -R X5 Independently as about-R X defined.

[0329] (36) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0330]

[0331] Each of these -R X3 and -R X4 Independently as about-R X defined.

[0332] (37) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0333]

[0334] Each of these -R X3 and -R X4 Independently as about-R X defined.

[0335] (38) The compound according to any one of (1) to (21), wherein -A HWhen present, it is thien-3-yl and is optionally substituted by one or more substituents -R X replace.

[0336] (39) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0337]

[0338] Each of these -R X2 、-R X4 and -R X5 Independently as about-R X defined.

[0339] (40) The compound according to any one of (1) to (21), wherein -A H When present it is:

[0340]

[0341] Where -R X5 As about -R X defined.

[0342] (41) The compound according to any one of (1) to (21), wherein -A H When present, it is thiazolyl and is optionally substituted by one or more -R X replace.

[0343] (42) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0344]

[0345] Each of these -R X2 、-R X4 and -R X5 Independently as about-R X defined.

[0346] (43) The compound according to any one of (1) to (21), wherein -A H When present, it is thiazol-2-yl and is optionally substituted by one or more -R X replace.

[0347] (44) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0348]

[0349] Each of these -R X4 and -R X5 Independently as about-R X defined.

[0350] (45) The compound according to any one of (1) to (21), wherein -A H When present, it is thiazol-4-yl and is optionally substituted by one or more -R X replace.

[0351] (46) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0352]

[0353] Each of these -R X2 and -R X5 Independently as about-R X defined.

[0354] (47) The compound according to any one of (1) to (21), wherein -A H When present, it is thiazol-5-yl and is optionally substituted by one or more -R X replace.

[0355] (48) The compound according to any one of (1) to (21), wherein -A H When present, independently selected from:

[0356]

[0357] Each of these -R X2 and -R X4 Independently as about-R X defined.

[0358] (49) The compound according to any one of (1) to (21), wherein -A H When present, it is independently pyrazolyl or imidazolyl, and is optionally substituted by one or more substituents -R X replace.

[0359] (50) The compound according to any one of (1) to (21), wherein -A H When present, it is pyrazolyl and is optionally substituted by one or more -R X replace.

[0360] (51) The compound according to any one of (1) to (21), wherein -AH When present, it is independently 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl or pyrazol-1-yl, and is optionally substituted by one or more substituents -R X replace.

[0361] (52) The compound according to any one of (1) to (21), wherein -A H When present, it is 1H-pyrazol-3-yl and is optionally substituted by one or more -R X replace.

[0362]

[0363] (53) The compound according to any one of (1) to (21), wherein -A H When present, it is imidazolyl and is optionally substituted by one or more -R X replace.

[0364] (54) The compound according to any one of (1) to (21), wherein -A H When present, it is independently 1H-imidazol-2-yl, 1H-imidazol-5-yl, 1H-imidazol-4-yl or imidazol-1-yl, and is optionally substituted by one or more substituents -R X replace.

[0365]

[0366]

[0367] (55) The compound according to any one of (1) to (21), wherein -A H When present, it is pyridyl and is optionally substituted by one or more -R X replace.

[0368] (56) The compound according to any one of (1) to (21), wherein -A H When present, it is pyridin-2-yl and is optionally substituted by one or more -R X replace.

[0369] (57) The compound according to any one of (1) to (21), wherein -A H When present, it is pyridin-3-yl and is optionally substituted by one or more -R X replace.

[0370] (58) The compound according to any one of (1) to (21), wherein -A HWhen present, it is pyridin-4-yl and is optionally substituted by one or more -R X replace.

[0371]

[0372] Fused bicyclic groups:

[0373] (59) The compound according to any one of (1) to (21), wherein -A H When present, it is indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, thienylpyridinyl, thienylthienyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl or benzopyranyl, and is optionally substituted by one or more substituents -R X replace.

[0374] (60) The compound according to any one of (1) to (21), wherein -A H When present, it is indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl or benzopyranyl, and is optionally substituted by one or more substituents -R X replace.

[0375] (61) The compound according to any one of (1) to (21), wherein -A H When present, it is indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl, quinazolinyl or quinoxalinyl, and is optionally substituted by one or more substituents -R X replace.

[0376] (62) The compound according to any one of (1) to (21), wherein -A H When present, benzofuranyl, benzothienyl, quinolinyl or isoquinolinyl, and is optionally substituted by one or more substituents -R X replace.

[0377] (63) The compound according to any one of (1) to (21), wherein -A H When present, it is benzofuranyl or benzothienyl, and is optionally substituted by one or more substituents -R X replace.

[0378] (64) The compound according to any one of (1) to (21), wherein -A H When present, it is benzothienyl and is optionally substituted by one or more substituents -RX replace.

[0379] (65) The compound according to any one of (1) to (21), wherein -A H When present, it is benzothiophen-2-yl and is optionally substituted by one or more substituents -R X replace.

[0380] (66) The compound according to any one of (1) to (21), wherein -A H When present, it is benzothiophen-3-yl and is optionally substituted by one or more substituents -R X replace.

[0381]

[0382] (67) The compound according to any one of (1) to (21), wherein -A H When present, it is benzothiazolyl and is optionally substituted by one or more substituents -R X replace.

[0383] (68) The compound according to any one of (1) to (21), wherein -A H When present, it is 1,2-benzothiazol-3-yl and is optionally substituted by one or more -R X replace.

[0384] (69) The compound according to any one of (1) to (21), wherein -A H When present is 1,3-benzothiazol-2-yl, and is optionally substituted by one or more -R X replace.

[0385]

[0386] (70) The compound according to any one of (1) to (21), wherein -A H When present, it is thienopyridinyl and is optionally substituted by one or more -R X replace.

[0387] (71) The compound according to any one of (1) to (21), wherein -A H When present, it is thieno[3,2-b]pyridinyl and is optionally substituted by one or more -R X replace.

[0388] (72) The compound according to any one of (1) to (21), wherein -A HWhen present, it is thieno[3,2-b]pyridin-2-yl and is optionally substituted by one or more -R X replace.

[0389] (73) The compound according to any one of (1) to (21), wherein -A H When present, it is thieno[3,2-b]pyridin-3-yl and is optionally substituted by one or more -R X replace.

[0390]

[0391] (74) The compound according to any one of (1) to (21), wherein -A H When present, it is thienothiphenyl and is optionally substituted by one or more -R X replace.

[0392] (75) The compound according to any one of (1) to (21), wherein -A H When present, it is thieno[3,2-b]thienyl and is optionally substituted by one or more -R X replace.

[0393] (76) The compound according to any one of (1) to (21), wherein -A H When present, it is thieno[3,2-b]thiophen-5-yl, and is optionally substituted by one or more substituents -R X replace.

[0394] (77) The compound according to any one of (1) to (21), wherein -A H When present, it is thieno[3,2-b]thiophen-6-yl, and is optionally substituted by one or more substituents -R X replace.

[0395]

[0396] (78) The compound according to any one of (1) to (21), wherein -A H When present, it is quinolinyl or isoquinolinyl, and is optionally substituted by one or more substituents -R X replace.

[0397] (79) The compound according to any one of (1) to (21), wherein -A H When present, it is quinolinyl and is optionally substituted by one or more substituents -R X replace.

[0398] (80) The compound according to any one of (1) to (21), wherein -A H When present, it is quinolin-7-yl and is optionally substituted by one or more substituents -R X replace.

[0399] Group -R X

[0400] (81) The compound according to any one of (1) to (80), wherein each -R X When present, independently selected from:

[0401] -R XX ,

[0402] -F, -Cl, -Br, -I,

[0403] -OH, -OR XX ,

[0404] -L XX -OH, -L XX -OR XX ,

[0405] -CF3, -CHF2, -OCF3, -OCHF2,

[0406] -NH2, -NHR XX 、-NR XX 2. -R XM ,

[0407] -L XX -NH2、-L XX -NHR XX 、-L XX -NR XX 2. -L XX -R XM ,

[0408] -C(=O)OH, -C(=O)OR XX 、-OC(=O)R XX ,

[0409] -C(=O)NH2, -C(=O)NHR XX 、-C(=O)NR XX 2. -C(=O)R XM ,

[0410] -NHC(=O)R XX 、-NR XN C(=O)R XX ,

[0411] -NHC(=O)NH2、-NHC(=O)NHR XX 、-NHC(=O)NR XX 2、-NHC(=O)R XM ,

[0412] -NR XN C(=O)NH2、-NR XN C(=O)NHR XX 、-NR XN C(=O)NR XX 2、-NR XN C(=O)R XM ,

[0413] -NHC(=O)OR XX 、-NR XN C(=O)OR XX ,

[0414] -OC(=O)NH2、-OC(=O)NHR XX 、-OC(=O)NR XX 2、-OC(=O)R XM ,

[0415] -NHC(=NH)NH2,

[0416] -C(=O)R XX ,

[0417] -S(=O)NH2、-S(=O)NHR XX 、-S(=O)NR XX 2、-S(=O)R XM ,

[0418] -S(=O)2NH2、-S(=O)2NHR XX 、-S(=O)2NR XX 2、-S(=O)2R XM ,

[0419] -NHS(=O)R XX 、-NR XN S(=O)R XX ,

[0420] -NHS(=O)2R XX 、-NR XN S(=O)2R XX ,

[0421] -S(=O)R XX 、-S(=O)2R XX ,

[0422] -SH, -SR XX , -CN and -NO2;

[0423] And additionally, two adjacent groups -R X When present, they may together form:

[0424] -O-CH2-O-, -O-CH2CH2-O-, -CH2-CH2-O-, -CH2-CH2CH2-O-,

[0425] -CH2-O-CH2- or -CH2-CH2-O-CH2-.

[0426] (82) The compound according to any one of (1) to (80), wherein each -R X When present, independently selected from:

[0427] -R XX 、-R XXU 、-R XXV ,

[0428] -F, -Cl, -Br, -I,

[0429] -OH, -OR XX ,

[0430] -CF3, -CHF2, -OCF3, -OCHF2,

[0431] -NH2, -NHR XX 、-NR XX 2. -R XM ,

[0432] -C(=O)OH, -C(=O)OR XX 、-OC(=O)R XX ,

[0433] -C(=O)NH2, -C(=O)NHR XX 、-C(=O)NR XX 2. -C(=O)R XM ,

[0434] -NHC(=O)R XX 、-NR XN C(=O)R XX ,

[0435] -C(=O)R XX ,

[0436] -S(=O)NH2, -S(=O)NHR XX 、-S(=O)NR XX2. -S(=O)R XM ,

[0437] -S(=O)2NH2, -S(=O)2NHR XX 、-S(=O)2NR XX 2. -S(=O)2R XM ,

[0438] -NHS(=O)R XX 、-NR XN S(=O)R XX ,

[0439] -NHS(=O)2R XX 、-NR XN S(=O)2R XX ,

[0440] -S(=O)R XX 、-S(=O)2R XX ,

[0441] -SR XX , -CN and -NO2.

[0442] (83) The compound according to any one of (1) to (80), wherein each -R X When present, independently selected from:

[0443] -R XX ,

[0444] -F, -Cl, -Br, -I,

[0445] -OH, -OR XX ,

[0446] -CF3, -CHF2, -OCF3, -OCHF2,

[0447] -NH2, -NHR XX 、-NR XX 2. -R XM ,

[0448] -C(=O)OH, -C(=O)OR XX 、-OC(=O)R XX ,

[0449] -C(=O)NH2, -C(=O)NHR XX 、-C(=O)NR XX 2. -C(=O)R XM ,

[0450] -NHC(=O)R XX 、-NRXN C(=O)R XX ,

[0451] -C(=O)R XX ,

[0452] -S(=O)NH2, -S(=O)NHR XX 、-S(=O)NR XX 2. -S(=O)R XM ,

[0453] -S(=O)2NH2, -S(=O)2NHR XX 、-S(=O)2NR XX 2. -S(=O)2R XM ,

[0454] -NHS(=O)R XX 、-NR XN S(=O)R XX ,

[0455] -NHS(=O)2R XX 、-NR XN S(=O)2R XX ,

[0456] -S(=O)R XX 、-S(=O)2R XX ,

[0457] -SR XX , -CN and -NO2.

[0458] (84) The compound according to any one of (1) to (80), wherein each -R X When present, independently selected from:

[0459] -R XX 、-R XXU 、-R XXV ,

[0460] -F, -Cl, -Br, -I,

[0461] -OH, -OR XX ,

[0462] -CF3, -CHF2, -OCF3, -OCHF2,

[0463] -NH2, -NHR XX 、-NR XX 2. -R XM ,

[0464] -C(=O)OH, -C(=O)ORXX 、-OC(=O)R XX ,

[0465] -SR XX , -CN and -NO2.

[0466] (85) The compound according to any one of (1) to (80), wherein each -R X When present, independently selected from:

[0467] -R XX 、-R XXU ,

[0468] -F, -Cl, -Br,

[0469] -OH, -OR XX ,

[0470] -CF3, -CHF2, -OCF3, -OCHF2,

[0471] -C(=O)NH2, -C(=O)NHR XX 、-C(=O)NR XX 2. -C(=O)R XM ,

[0472] -C(=O)R XX and

[0473] -CN;

[0474] And additionally, two adjacent groups -R X When present, they may together form:

[0475] -O-CH2-O- or -CH2-CH2-O-.

[0476] (86) The compound according to any one of (1) to (80), wherein each -R X When present, independently selected from:

[0477] -R XX ,

[0478] -F, -Cl, -Br, -I,

[0479] -OH, -OR XX ,

[0480] -CF3, -CHF2, -OCF3, -OCHF2,

[0481] -NH2, -NHR XX 、-NR XX 2. -R XM and

[0482] -CN.

[0483] (87) The compound according to any one of (1) to (80), wherein each -R X When present, independently selected from:

[0484] -R XX ,

[0485] -F, -Cl, -Br, -I,

[0486] -OH, -OR XX ,

[0487] -CF3, -CHF2, -OCF3 and -OCHF2.

[0488] (88) The compound according to any one of (1) to (80), wherein each -R X When present, independently selected from:

[0489] -R XX ,

[0490] -F, -Cl, -Br, and -I.

[0491] (89) The compound according to any one of (1) to (80), wherein each -R X When present, independently selected from:

[0492] -R XX , -F and -Cl.

[0493] Group-L XX -

[0494] (90) The compound according to any one of (1) to (89), wherein each -L XX -, when present, is independently -CH2CH2CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH(CH3)- or -CH2-.

[0495] (91) The compound according to any one of (1) to (89), wherein each -L XX -, when present, is independently -CH2CH2- or -CH2-.

[0496] (92) The compound according to any one of (1) to (89), wherein each -L XX -, when present, is -CH2-.

[0497] Group -R XX

[0498] (93) The compound according to any one of (1) to (92), wherein each -R XX When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0499] (94) The compound according to any one of (1) to (92), wherein each -R XX When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0500] (95) The compound according to any one of (1) to (92), wherein each -R XX When present it is -Me.

[0501] Group -R XXU

[0502] (96) The compound according to any one of (1) to (95), wherein each -R XXU When present, it is independently -CH=CH2 or -CH2-CH=CH2.

[0503] (97) The compound according to any one of (1) to (95), wherein each -R XXU When present it is -CH=CH2.

[0504] Group -R XXV

[0505] (98) The compound according to any one of (1) to (97), wherein each -R XXV When present, it is independently -CH≡CH or -CH2-C≡CH.

[0506] (99) The compound according to any one of (1) to (97), wherein each -R XXV When present, it is -CH≡CH.

[0507] Group -R XN

[0508] (100) The compound according to any one of (1) to (99), wherein each -R XN When present is independently -Me, -Et, -nPr or -iPr.

[0509] (101) The compound according to any one of (1) to (99), wherein each -R XN When present it is -Me.

[0510] Group -R XM

[0511] (102) The compound according to any one of (1) to (101), wherein each -R XM When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, and:

[0512] Optionally substituted with one or more groups selected from:

[0513] -R XMM 、-C(=O)R XMM 、-C(=O)OR XMM and -S(=O)2R XMM .

[0514] (103) The compound according to any one of (1) to (101), wherein each -R XM When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.

[0515] Group -R XMM

[0516] (104) The compound according to any one of (1) to (103), wherein each -R XMM When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0517] (105) The compound according to any one of (1) to (103), wherein each -R XMM When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0518] (106) The compound according to any one of (1) to (103), wherein each -R XMM When present it is -Me.

[0519] Group -R 1

[0520] (107) The compound according to any one of (1) to (106), wherein -R 1 Yes-R 11 .

[0521] (108) The compound according to any one of (1) to (106), wherein -R 1 Yes -H.

[0522] Group -R 11

[0523] (109) The compound according to any one of (1) to (108), wherein -R 11 When present, it is -R 11A .

[0524] (110) The compound according to any one of (1) to (108), wherein -R 11 When present, it is -R 11B .

[0525] Group -R 11A

[0526] (111) The compound according to any one of (1) to (110), wherein -R 11A When present, independently -R A1 、-R A4 、-L A -R A2 、-L A -R A4 or -L A -R A5 .

[0527] (112) The compound according to any one of (1) to (110), wherein -R 11A When present, independently -R A1 、-L A -R A2 、-L A -R A4 or -L A -R A5 .

[0528] (113) The compound according to any one of (1) to (110), wherein -R 11A When present, independently -R A1 or -L A -R A2 .

[0529] (114) The compound according to any one of (1) to (110), wherein -R 11A When present, it is -R A1 .

[0530] (115) The compound according to any one of (1) to (110), wherein -R 11A When present it is -L A -R A2 .

[0531] (116) The compound according to any one of (1) to (110), wherein -R 11A When present it is -L A -R A4 .

[0532] (117) The compound according to any one of (1) to (110), wherein -R 11A When present it is -L A -R A5 .

[0533] Group -R A1

[0534] (118) The compound according to any one of (1) to (117), wherein each -R A1 When present, is independently -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu or -tBu; and optionally replaced by one or more groups -R AA2 replace.

[0535] (119) The compound according to any one of (1) to (117), wherein each -R A1 When present, it is -iBu; and optionally replaced by one or more groups -R AA2 replace.

[0536] (120) The compound according to any one of (1) to (117), wherein each -R A1 When present, it is -sBu; and optionally replaced by one or more groups -R AA2 replace.

[0537] (121) The compound according to any one of (1) to (117), wherein each -R A1 When present, it is -iPr; and optionally replaced by one or more groups -R AA2 replace.

[0538] (122) The compound according to any one of (1) to (117), wherein each -R A1 When present, it is -Me; and optionally replaced by one or more groups -R AA2 replace.

[0539] (123) The compound according to any one of (1) to (117), wherein each -R A1 When present is independently -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu or -tBu.

[0540] (124) The compound according to any one of (1) to (117), wherein each -R A1 When present is independently -iPr, -iBu or -sBu.

[0541] (125) The compound according to any one of (1) to (117), wherein each -RA1 When present, it is -iBu.

[0542] (126) The compound according to any one of (1) to (117), wherein each -R A1 When present it is -sBu.

[0543] (127) The compound according to any one of (1) to (117), wherein each -R A1 When present, it is -iPr.

[0544] (128) The compound according to any one of (1) to (117), wherein each -R A1 When present it is -Me.

[0545] Group -R A2

[0546] (129) The compound according to any one of (1) to (128), wherein each -R A2 When present, is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0547] (1304) A compound according to any one of (1) to (128), wherein each -R A2 When present is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0548] (131) The compound according to any one of (1) to (128), wherein each -R A2 When present is independently cyclopropyl.

[0549] Group -R A3

[0550] (132) The compound according to any one of (1) to (131), wherein each -R A3 When present, is independently oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl or diazepanyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0551] (133) The compound according to any one of (1) to (131), wherein each -R A3 When present, is independently tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, and is optionally substituted by one or more groups -RAA1 and one or more groups -R AA2 replace.

[0552] (134) The compound according to any one of (1) to (131), wherein each -R A3 When present, is independently tetrahydrofuranyl, tetrahydropyranyl or dioxanyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0553] (135) The compound according to any one of (1) to (131), wherein each -R A3 When present, is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0554] (136) The compound according to any one of (1) to (131), wherein each -R A3 When present is independently tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.

[0555] (137) The compound according to any one of (1) to (131), wherein each -R A3 When present is independently tetrahydrofuranyl, tetrahydropyranyl or dioxanyl.

[0556] (138) The compound according to any one of (1) to (131), wherein each -R A3 When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.

[0557] Group -R A4

[0558] (139) The compound according to any one of (1) to (138), wherein each -R A4 When present, phenyl is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0559] (140) The compound according to any one of (1) to (138), wherein each -R A4 When present it is phenyl.

[0560] Group -R A5

[0561] (141) The compound according to any one of (1) to (140), wherein each -RA5 When present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, quinazolinyl or phthalazinyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0562] (142) The compound according to any one of (1) to (140), wherein each -R A5 When present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0563] (143) The compound according to any one of (1) to (140), wherein each -R A5 When present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl or isothiazolyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0564] (144) The compound according to any one of (1) to (140), wherein each -R A5 When present, is independently pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0565] (145) The compound according to any one of (1) to (140), wherein each -R A5 When present, it is independently imidazolyl or indolyl, and is optionally substituted by one or more groups -R AA1 and one or more groups -R AA2 replace.

[0566] (146) The compound according to any one of (1) to (140), wherein each -R A5 When present is independently furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl.

[0567] (147) The compound according to any one of (1) to (140), wherein each -R A5 When present is independently furyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl or isothiazolyl.

[0568] (148) The compound according to any one of (1) to (140), wherein each -R A5 When present is independently pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl.

[0569] (149) The compound according to any one of (1) to (140), wherein each -R A5 When present is independently imidazolyl or indolyl.

[0570] Group-L A -

[0571] (150) The compound according to any one of (1) to (149), wherein each -L A -, when present, is independently -CH2CH2CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH(CH3)- or -CH2-.

[0572] (151) The compound according to any one of (1) to (149), wherein each -L A -, when present, is independently -CH2CH2 or -CH2-.

[0573] (152) The compound according to any one of (1) to (149), wherein each -L A -, when present, is -CH2-.

[0574] Group -R AA1

[0575] (153) The compound according to any one of (1) to (152), wherein each -R AA1 When present, it is -R AA .

[0576] Group -R AA2

[0577] (154) The compound according to any one of (1) to (153), wherein each -R AA2 When present, independently selected from:

[0578] -F, -Cl, -Br, -I,

[0579] -OH, -OR AA ,

[0580] -OCF3,

[0581] -NH2, -NHR AA 、-N(R AA )2. -R AM ,

[0582] -C(=O)OH, -C(=O)OR AA 、-OC(=O)R AA ,

[0583] -C(=O)NH2, -C(=O)NHR AA 、-C(=O)N(R AA )2, -C(=O)R AM ,

[0584] -NHC(=O)R AA 、-NR AN C(=O)R AA ,

[0585] -C(=O)R AA ,

[0586] -S(=O)NH2, -S(=O)NHR AA 、-S(=O)N(R AA )2、-S(=O)R AM ,

[0587] -S(=O)2NH2, -S(=O)2NHR AA 、-S(=O)2N(R AA )2、-S(=O)2R AM ,

[0588] -NHS(=O)R AA 、-NR AN S(=O)R AA ,

[0589] -NHS(=O)2R AA 、-NR AN S(=O)2R AA ,

[0590] -S(=O)R AA 、-S(=O)2R AA ,

[0591] -SH, -SR AA , -CN and -NO2.

[0592] (155) The compound according to any one of (1) to (153), wherein each -R AA2When present, independently selected from:

[0593] -F, -Cl, -Br, -I,

[0594] -OH, -OR AA ,

[0595] -OCF3,

[0596] -NH2, -NHR AA 、-N(R AA )2. -R AM and

[0597] -CN.

[0598] (156) The compound according to any one of (1) to (153), wherein each -R AA2 When present, independently selected from:

[0599] -F, -Cl, -Br, -I,

[0600] -OH, -OR AA and

[0601] -OCF3.

[0602] (157) The compound according to any one of (1) to (153), wherein each -R AA2 When present, independently selected from:

[0603] -OH, -OR AA ,

[0604] -NH2, -NHR AA 、-N(R AA )2. -R AM ,

[0605] -C(=O)OH, -C(=O)OR AA ,

[0606] -C(=O)NH2, -C(=O)NHR AA 、-C(=O)N(R AA )2, -C(=O)R AM ,

[0607] -NHC(=NH)NH2,

[0608] -SH and -SR AA .

[0609] (158) The compound according to any one of (1) to (153), wherein each -R AA2 When present, independently selected from:

[0610] -OH,

[0611] -NH2,

[0612] -C(=O)OH,

[0613] -C(=O)NH2,

[0614] -NHC(=NH)NH2,

[0615] -SH and -SMe.

[0616] Group-L AA -

[0617] (159) The compound according to any one of (1) to (158), wherein each -L AA -, when present, is independently -CH2CH2CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH(CH3)- or -CH2-.

[0618] (160) The compound according to any one of (1) to (158), wherein each -L AA -, when present, is independently -CH2CH2 or -CH2-.

[0619] Group -R AA

[0620] (161) The compound according to any one of (1) to (160), wherein each -R AA When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0621] (162) The compound according to any one of (1) to (160), wherein each -R AA When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0622] (163) The compound according to any one of (1) to (160), wherein each -R AA When present it is -Me.

[0623] Group -R AN

[0624] (164) The compound according to any one of (1) to (163), wherein each -R AN When present is independently -Me, -Et, -nPr or -iPr.

[0625] (165) The compound according to any one of (1) to (163), wherein each -RAN When present it is -Me.

[0626] Group -R AM

[0627] (166) The compound according to any one of (1) to (165), wherein each -R AM When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, and:

[0628] Optionally substituted with one or more groups selected from:

[0629] -R AMM 、-C(=O)R AMM 、-C(=O)OR AMM and -S(=O)2R AMM .

[0630] (167) The compound according to any one of (1) to (165), wherein each -R AM When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.

[0631] Group -R AMM

[0632] (168) The compound according to any one of (1) to (167), wherein each -R AMM When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0633] (169) The compound according to any one of (1) to (167), wherein each -R AMM When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0634] (170) The compound according to any one of (1) to (167), wherein each -R AMM When present it is -Me.

[0635] Group -R 11A :Some specific groups

[0636] (171) The compound according to any one of (1) to (110), wherein -R 11A When present, independently selected from:

[0637] -CH3 (e.g., as in alanine),

[0638] -CH2CH(CH3)2 (e.g., as in leucine),

[0639] -CH(CH3)CH2CH3 (e.g., as in isoleucine),

[0640] -CH2CH2-S-CH3 (e.g., as in methionine),

[0641] -CH2-(phenyl) (e.g., as in phenylalanine),

[0642] -CH2-(1H-indol-3-yl) (e.g. as in tryptophan),

[0643] -CH(CH3)2 (e.g., as in valine),

[0644] -CH2-C(=O)NH2 (e.g. as in asparagine),

[0645] -CH2-SH (e.g., as in cysteine),

[0646] -CH2CH2-C(=O)NH2 (e.g. as in glutamine),

[0647] -CH2-OH (e.g., as in serine),

[0648] -CH(OH)CH3 (e.g., as in threonine),

[0649] -CH2-(4-hydroxy-phenyl) (e.g. as in tyrosine),

[0650] -CH2CH2CH2-NH-C(=NH)-NH2 (e.g. as in arginine),

[0651] -CH2-(1H-imidazol-4-yl) (e.g. as in histidine),

[0652] -CH2CH2CH2CH2-NH2 (e.g., as in lysine),

[0653] -CH2-C(=O)OH (e.g., as in aspartic acid) and

[0654] -CH2CH2-C(=O)OH (eg, as in glutamic acid).

[0655] (172) The compound according to any one of (1) to (110), wherein -R 11A When present, independently selected from:

[0656] -CH2CH(CH3)2 (e.g., as in leucine),

[0657] -CH(CH3)CH2CH3 (e.g., as in isoleucine),

[0658] -CH(CH3)2 (e.g., as in valine).

[0659] (173) The compound according to any one of (1) to (110), wherein -R 11A When present it is -CH2CH(CH3)2 (eg as in leucine).

[0660] (174) The compound according to any one of (1) to (110), wherein -R 11A When present it is -CH(CH3)CH2CH3 (eg as in isoleucine).

[0661] (175) The compound according to any one of (1) to (110), wherein -R 11A When present it is -CH(CH3)2 (eg as in valine).

[0662] Group -R 11B

[0663] (176) The compound according to any one of (1) to (175), wherein -R 11B When present, independently selected from:

[0664] -F, -Cl, -Br, -I,

[0665] -OH, -OR BB ,

[0666] -OCF3,

[0667] -NH2, -NHR BB 、-NR BB 2. -R BM ,

[0668] -C(=O)OH, -C(=O)OR BB 、-OC(=O)R BB ,

[0669] -C(=O)NH2, -C(=O)NHR BB 、-C(=O)NR BB 2. -C(=O)R BM ,

[0670] -NHC(=O)R BB 、-NR BN C(=O)R BB ,

[0671] -C(=O)R BB ,

[0672] -S(=O)NH2, -S(=O)NHR BB 、-S(=O)NR BB 2. -S(=O)R BM ,

[0673] -S(=O)2NH2, -S(=O)2NHR BB 、-S(=O)2NR BB 2. -S(=O)2R BM ,

[0674] -NHS(=O)R BB 、-NR BN S(=O)R BB ,

[0675] -NHS(=O)2R BB 、-NR BN S(=O)2R BB ,

[0676] -S(=O)R BB 、-S(=O)2R BB ,

[0677] -SR BB , -CN and -NO2.

[0678] (177) The compound according to any one of (1) to (175), wherein each -R 11B When present, independently selected from:

[0679] -F, -Cl, -Br, -I,

[0680] -OH, -OR BB ,

[0681] -OCF3,

[0682] -NH2, -NHR BB 、-NR BB 2. -R BM ,

[0683] -SR BB and -CN.

[0684] (178) The compound according to any one of (1) to (175), wherein each -R 11B When present, independently selected from:

[0685] -F, -Cl, -Br, -I,

[0686] -OH, -OR BB ,

[0687] -OCF3 and

[0688] -SR BB .

[0689] (179) The compound according to any one of (1) to (175), wherein each -R 11B When present, independently selected from:

[0690] -F, -Cl, -Br, -I,

[0691] -OH, -OR BB and

[0692] -OCF3.

[0693] Group -R BB

[0694] (180) The compound according to any one of (1) to (179), wherein each -R BB When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0695] (181) The compound according to any one of (1) to (179), wherein each -R BB When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0696] (182) The compound according to any one of (1) to (179), wherein each -R BB When present it is -Me.

[0697] Group -R BN

[0698] (183) The compound according to any one of (1) to (182), wherein each -R BN When present is independently -Me, -Et, -nPr or -iPr.

[0699] (184) The compound according to any one of (1) to (182), wherein each -R BN When present it is -Me.

[0700] Group -R BM

[0701] (185) The compound according to any one of (1) to (184), wherein each -R BM When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, and:

[0702] Optionally substituted with one or more groups selected from:

[0703] -R BMM 、-C(=O)R BMM 、-C(=O)OR BMM and -S(=O)2R BMM .

[0704] (186) The compound according to any one of (1) to (184), wherein each -R BM When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.

[0705] Group -R BMM

[0706] (187) The compound according to any one of (1) to (186), wherein each -R BMM When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0707] (188) The compound according to any one of (1) to (186), wherein each -R BMM When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0708] (189) The compound according to any one of (1) to (186), wherein each -R BMM When present it is -Me.

[0709] Group -R 2

[0710] (190) The compound according to any one of (1) to (189), wherein -R 2 Yes -H.

[0711] (191) The compound according to any one of (1) to (189), wherein -R 2 Yes-R 22 .

[0712] Group -R 22

[0713] (192) The compound according to any one of (1) to (191), wherein -R 22 When present, it is -R 22C .

[0714] (193) The compound according to any one of (1) to (191), wherein -R 22 When present, it is -R 22D .

[0715] Group -R 22C

[0716] (194) The compound according to any one of (1) to (193), wherein -R 22C When present, independently -R C1 、-R C4 、-L C -R C4 or -L C -R C5 .

[0717] (195) The compound according to any one of (1) to (193), wherein -R 22C When present, independently -R C1 、-L C -R C4 or -L C -R C5 .

[0718] (196) The compound according to any one of (1) to (193), wherein -R 22C When present, independently -R C1 or -L C -R C4 .

[0719] (197) The compound according to any one of (1) to (193), wherein -R 22C When present, it is -R C1 .

[0720] (198) The compound according to any one of (1) to (193), wherein -R 22C When present it is -L C -R C4 .

[0721] (199) The compound according to any one of (1) to (193), wherein -R 22C When present it is -L C -R C5 .

[0722] Group -R C1

[0723] (200) The compound according to any one of (1) to (199), wherein each -R C1 When present, is independently -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu or -tBu; and optionally replaced by one or more groups -R CC2 replace.

[0724] (201) The compound according to any one of (1) to (199), wherein each -R C1When present, it is independently -Me; and optionally replaced by one or more groups -R CC2 replace.

[0725] (202) The compound according to any one of (1) to (199), wherein each -R C1 When present, it is independently -iPr; and optionally replaced by one or more groups -R CC2 replace.

[0726] (203) The compound according to any one of (1) to (199), wherein each -R C1 When present, it is independently -iBu; and optionally replaced by one or more groups -R CC2 replace.

[0727] (204) The compound according to any one of (1) to (199), wherein each -R C1 When present is independently -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu or -tBu.

[0728] (205) The compound according to any one of (1) to (199), wherein each -R C1 When present, independently is -Me.

[0729] (206) The compound according to any one of (1) to (199), wherein each -R C1 When present, independently -iPr.

[0730] (207) The compound according to any one of (1) to (199), wherein each -R C1 When present, independently -iBu.

[0731] Group -R C2

[0732] (208) The compound according to any one of (1) to (207), wherein each -R C2 When present, is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0733] (209) The compound according to any one of (1) to (207), wherein each -R C2 When present is independently cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0734] Group -R C3

[0735] (210) The compound according to any one of (1) to (209), wherein each -R C3 When present, is independently oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, azepanyl or diazepanyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0736] (211) The compound according to any one of (1) to (209), wherein each -R C3 When present, is independently tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0737] (212) The compound according to any one of (1) to (209), wherein each -R C3 When present, is independently tetrahydrofuranyl, tetrahydropyranyl or dioxanyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0738] (213) The compound according to any one of (1) to (209), wherein each -R C3 When present, is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0739] (214) The compound according to any one of (1) to (209), wherein each -R C3 When present is independently tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.

[0740] (215) The compound according to any one of (1) to (209), wherein each -R C3 When present is independently tetrahydrofuranyl, tetrahydropyranyl or dioxanyl.

[0741] (216) The compound according to any one of (1) to (209), wherein each -R C3 When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.

[0742] Group -R C4

[0743] (217) The compound according to any one of (1) to (216), wherein each -R C4 When present, phenyl is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0744] (218) The compound according to any one of (1) to (216), wherein each -R C4 When present it is phenyl.

[0745] Group -R C5

[0746] (219) The compound according to any one of (1) to (218), wherein each -R C5 When present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, indazolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, quinazolinyl or phthalazinyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0747] (220) The compound according to any one of (1) to (218), wherein each -R C5 When present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0748] (221) The compound according to any one of (1) to (218), wherein each -R C5 When present, is independently furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl or isothiazolyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0749] (222) The compound according to any one of (1) to (218), wherein each -R C5 When present, is independently pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -RCC2 replace.

[0750] (223) The compound according to any one of (1) to (218), wherein each -R C5 When present, it is independently imidazolyl or indolyl, and is optionally substituted by one or more groups -R CC1 and one or more groups -R CC2 replace.

[0751] (224) The compound according to any one of (1) to (218), wherein each -R C5 When present is independently furanyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl.

[0752] (225) The compound according to any one of (1) to (218), wherein each -R C5 When present is independently furyl, thienyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl or isothiazolyl.

[0753] (226) The compound according to any one of (1) to (218), wherein each -R C5 When present is independently pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl.

[0754] (227) The compound according to any one of (1) to (218), wherein each -R C5 When present is independently imidazolyl or indolyl.

[0755] Group-L C -

[0756] (228) The compound according to any one of (1) to (227), wherein each -L C -, when present, is independently -CH2CH2CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH(CH3)- or -CH2-.

[0757] (229) The compound according to any one of (1) to (227), wherein each -L C -, when present, is independently -CH2CH2 or -CH2-.

[0758] (230) The compound according to any one of (1) to (227), wherein each -L C -, when present, is -CH2-.

[0759] Group -R CC1

[0760] (231) The compound according to any one of (1) to (230), wherein each -R CC1 When present, it is -R CC .

[0761] Group -R CC2

[0762] (232) The compound according to any one of (1) to (231), wherein each -R CC2 When present, independently selected from:

[0763] -F, -Cl, -Br, -I,

[0764] -OH, -OR CC ,

[0765] -OCF3,

[0766] -NH2, -NHR CC 、-N(R CC )2. -R CM ,

[0767] -C(=O)OH, -C(=O)OR CC 、-OC(=O)R CC ,

[0768] -C(=O)NH2, -C(=O)NHR CC 、-C(=O)N(R CC )2, -C(=O)R CM ,

[0769] -NHC(=O)R CC 、-NR CN C(=O)R CC ,

[0770] -C(=O)R CC ,

[0771] -S(=O)NH2, -S(=O)NHR CC 、-S(=O)N(R CC )2、-S(=O)R CM ,

[0772] -S(=O)2NH2, -S(=O)2NHR CC 、-S(=O)2N(R CC )2、-S(=O)2R CM ,

[0773] -NHS(=O)R CC 、-NR CN S(=O)RCC ,

[0774] -NHS(=O)2R CC 、-NR CN S(=O)2R CC ,

[0775] -S(=O)R CC 、-S(=O)2R CC ,

[0776] -SH, -SR CC , -CN and -NO2.

[0777] (233) A compound according to any one of (1) to (231), wherein each -R CC2 When present, independently selected from:

[0778] -F, -Cl, -Br, -I,

[0779] -OH, -OR CC ,

[0780] -OCF3,

[0781] -NH2, -NHR CC 、-N(R CC )2. -R CM and

[0782] -CN.

[0783] (234) A compound according to any one of (1) to (231), wherein each -R CC2 When present, independently selected from:

[0784] -F, -Cl, -Br, -I,

[0785] -OH, -OR CC and

[0786] -OCF3.

[0787] (235) A compound according to any one of (1) to (231), wherein each -R CC2 When present, independently selected from:

[0788] -OH, -OR CC ,

[0789] -NH2, -NHR CC 、-N(R CC )2. -R CM ,

[0790] -C(=O)OH, -C(=O)ORCC ,

[0791] -C(=O)NH2, -C(=O)NHR CC 、-C(=O)N(R CC )2, -C(=O)R CM ,

[0792] -NHC(=NH)NH2,

[0793] -SH and -SR CC .

[0794] (236) A compound according to any one of (1) to (231), wherein each -R CC2 When present, independently selected from:

[0795] -OH,

[0796] -NH2,

[0797] -C(=O)OH,

[0798] -C(=O)NH2,

[0799] -NHC(=NH)NH2,

[0800] -SH and -SMe.

[0801] Group-L CC -

[0802] (237) The compound according to any one of (1) to (236), wherein each -L CC -, when present, is independently -CH2CH2CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH(CH3)- or -CH2-.

[0803] (238) The compound according to any one of (1) to (236), wherein each -L CC -, when present, is independently -CH2CH2 or -CH2-.

[0804] (239) The compound according to any one of (1) to (236), wherein each -L CC -, when present, is -CH2-.

[0805] Group -R CC

[0806] (240) The compound according to any one of (1) to (239), wherein each -R CC When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0807] (241) The compound according to any one of (1) to (239), wherein each -R CC When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0808] (242) The compound according to any one of (1) to (239), wherein each -R CC When present it is -Me.

[0809] Group -R CN

[0810] (243) The compound according to any one of (1) to (242), wherein each -R CN When present is independently -Me, -Et, -nPr or -iPr.

[0811] (244) The compound according to any one of (1) to (242), wherein each -R CN When present it is -Me.

[0812] Group -R CM

[0813] (245) The compound according to any one of (1) to (244), wherein each -R CM When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, and:

[0814] Optionally substituted with one or more groups selected from:

[0815] -R CMM 、-C(=O)R CMM 、-C(=O)OR CMM and -S(=O)2R CMM .

[0816] (246) The compound according to any one of (1) to (244), wherein each -R CM When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.

[0817] Group -R CMM

[0818] (247) The compound according to any one of (1) to (246), wherein each -R CMM When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0819] (248) The compound according to any one of (1) to (246), wherein each -RCMM When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0820] (249) The compound according to any one of (1) to (246), wherein each -R CMM When present it is -Me.

[0821] Group -R 22C :Some specific groups

[0822] (250) The compound according to any one of (1) to (193), wherein -R 22C When present, independently selected from:

[0823] -CH3 (e.g., as in alanine),

[0824] -CH2CH(CH3)2 (e.g., as in leucine),

[0825] -CH(CH3)CH2CH3 (e.g., as in isoleucine),

[0826] -CH2CH2-S-CH3 (e.g., as in methionine),

[0827] -CH2-(phenyl) (e.g., as in phenylalanine),

[0828] -CH2-(1H-indol-3-yl) (e.g. as in tryptophan),

[0829] -CH(CH3)2 (e.g., as in valine),

[0830] -CH2-C(=O)NH2 (e.g. as in asparagine),

[0831] -CH2-SH (e.g., as in cysteine),

[0832] -CH2CH2-C(=O)NH2 (e.g. as in glutamine),

[0833] -CH2-OH (e.g., as in serine),

[0834] -CH(OH)CH3 (e.g., as in threonine),

[0835] -CH2-(4-hydroxy-phenyl) (e.g. as in tyrosine),

[0836] -CH2CH2CH2-NH-C(=NH)-NH2 (e.g. as in arginine),

[0837] -CH2-(1H-imidazol-4-yl) (e.g. as in histidine),

[0838] -CH2CH2CH2CH2-NH2 (e.g., as in lysine),

[0839] -CH2-C(=O)OH (e.g., as in aspartic acid) and

[0840] -CH2CH2-C(=O)OH (eg, as in glutamic acid).

[0841] Group -R 22D

[0842] (251) The compound according to any one of (1) to (250), wherein -R 22D When present, independently selected from:

[0843] -F, -Cl, -Br, -I,

[0844] -OH, -OR DD ,

[0845] -OCF3,

[0846] -NH2, -NHR DD 、-NR DD 2. -R DM ,

[0847] -C(=O)OH, -C(=O)OR DD 、-OC(=O)R DD ,

[0848] -C(=O)NH2, -C(=O)NHR DD 、-C(=O)NR DD 2. -C(=O)R DM ,

[0849] -NHC(=O)R DD 、-NR DN C(=O)R DD ,

[0850] -C(=O)R DD ,

[0851] -S(=O)NH2, -S(=O)NHR DD 、-S(=O)NR DD 2. -S(=O)R DM ,

[0852] -S(=O)2NH2, -S(=O)2NHR DD 、-S(=O)2NR DD 2. -S(=O)2R DM,

[0853] -NHS(=O)R DD 、-NR DN S(=O)R DD ,

[0854] -NHS(=O)2R DD 、-NR DN S(=O)2R DD ,

[0855] -S(=O)R DD 、-S(=O)2R DD ,

[0856] -SR DD , -CN and -NO2.

[0857] (252) The compound according to any one of (1) to (250), wherein each -R 22D When present, independently selected from:

[0858] -F, -Cl, -Br, -I,

[0859] -OH, -OR DD ,

[0860] -OCF3,

[0861] -NH2, -NHR DD 、-NR DD 2. -R DM ,

[0862] -SR DD and -CN.

[0863] (253) The compound according to any one of (1) to (250), wherein each -R 22D When present, independently selected from:

[0864] -F, -Cl, -Br, -I,

[0865] -OH, -OR DD ,

[0866] -OCF3 and

[0867] -SR DD .

[0868] (254) The compound according to any one of (1) to (250), wherein each -R 22D When present, independently selected from:

[0869] -F, -Cl, -Br, -I,

[0870] -OH, -OR DD and

[0871] -OCF3.

[0872] Group -R DD

[0873] (255) The compound according to any one of (1) to (254), wherein each -R DD When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0874] (256) The compound according to any one of (1) to (254), wherein each -R DD When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0875] (257) The compound according to any one of (1) to (254), wherein each -R DD When present it is -Me.

[0876] Group -R DN

[0877] (258) The compound according to any one of (1) to (257), wherein each -R DN When present is independently -Me, -Et, -nPr or -iPr.

[0878] (259) The compound according to any one of (1) to (257), wherein each -R DN When present it is -Me.

[0879] Group -R DM

[0880] (260) The compound according to any one of (1) to (259), wherein each -R DM When present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl, and:

[0881] Optionally substituted with one or more groups selected from:

[0882] -R DMM 、-C(=O)R DMM 、-C(=O)OR DMM and -S(=O)2R DMM .

[0883] (261) A compound according to any one of (1) to (259), wherein each -R DMWhen present is independently pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.

[0884] Group -R DMM

[0885] (262) The compound according to any one of (1) to (261), wherein each -R DMM When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0886] (263) A compound according to any one of (1) to (261), wherein each -R DMM When present, it is a straight or branched chain saturated C 1-4 alkyl.

[0887] (264) A compound according to any one of (1) to (261), wherein each -R DMM When present it is -Me.

[0888] Linked groups R 1 and R 2

[0889] (265) The compound according to any one of (1) to (106), wherein -R 1 and -R 2 Together with the carbon atom to which it is attached, it forms a saturated C 3-6 Cycloalkyl or non-aromatic C 3-7 heterocyclyl, and optionally substituted by one or more groups -R CC2 replace.

[0890] (266) The compound according to any one of (1) to (106), wherein -R 1 and -R 2 Together with the carbon atom to which it is attached, it forms a saturated C 3-6 Cycloalkyl, and optionally substituted by one or more groups -R CC2 replace.

[0891] (267) The compound according to any one of (1) to (106), wherein -R 1 and -R 2 Together with the carbon atom to which it is attached, it forms a saturated C5 cycloalkyl group, and is optionally substituted by one or more groups -R CC2 replace.

[0892] Optional substituents -R C22 It may be, for example, as defined above.

[0893] R 1 and R 2 Some preferred combinations of

[0894] (268) The compound according to any one of (1) to (106), wherein:

[0895] -R 1 are independently -CH(CH3)CH2CH3, -CH2CH(CH3)2 or -CH(CH3)2; and

[0896] -R 2 Yes -H.

[0897] (269) The compound according to any one of (1) to (106), wherein:

[0898] -R 1 are independently -CH(CH3)CH2CH3 or -CH2CH(CH3)2; and

[0899] -R 2 Yes -H.

[0900] (270) The compound according to any one of (1) to (106), wherein:

[0901] -R 1 is -CH2CH(CH3)2; and

[0902] -R 2 Yes -H.

[0903] Group -R N1

[0904] (271) The compound according to any one of (1) to (270), wherein -R N1 Yes -H.

[0905] (272) The compound according to any one of (1) to (270), wherein -R N1 Yes-R N .

[0906] Group -R N2

[0907] (273) The compound according to any one of (1) to (272), wherein -R N2 Yes -H.

[0908] (274) The compound according to any one of (1) to (272), wherein -R N2 Yes-R N .

[0909] Group -R N

[0910] (275) The compound according to any one of (1) to (274), wherein each -RN When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl, wherein each phenyl group is optionally substituted with one or more groups selected from the group consisting of -F, -Cl, -Br, -Me, -OH, -OMe, -CF3 and -OCF3.

[0911] (276) A compound according to any one of (1) to (274), wherein each -R N When present, independently a straight or branched chain saturated C 1-4 Alkyl, phenyl or -CH2-phenyl.

[0912] (277) The compound according to any one of (1) to (274), wherein each -R N When present, independently a straight or branched chain saturated C 1-4 alkyl.

[0913] (278) The compound according to any one of (1) to (274), wherein each -R N When present it is -Me.

[0914] Group -R N1 and -R N2

[0915] (279) The compound according to any one of (1) to (278), wherein -R N1 and -R N2 Connect together to form C 2-6 Alkylene.

[0916] (280) The compound according to any one of (1) to (278), wherein -R N1 and -R N2 Connected together to form -(CH2)2-, -(CH2)3-, -(CH2)4- or -(CH2)5-.

[0917] Chiral center

[0918] (281) A compound according to any one of (1) to (280), wherein the sulfur atom forming part of the sulfonyl imide amide group (i.e., marked with an asterisk (*) in the following formula) is in the (R) configuration.

[0919]

[0920] (282) A compound according to any one of (1) to (280), wherein the sulfur atom forming part of the sulfonyl imide amide group (i.e., marked with an asterisk (*) in the preceding formula) is in the (S) configuration.

[0921] (283) The compound according to any one of (1) to (282), wherein -R 1 and -R 2 The carbon atom to which it is attached (ie, designated by a pound sign (#) in the formula below) is in the (R) configuration.

[0922]

[0923] (284) The compound according to any one of (1) to (282), wherein -R 1 and -R 2 The carbon atom to which it is attached (ie, designated by a pound sign (#) in the preceding formula) is in the (S) configuration.

[0924] (285) The compound according to any one of (1) to (282), wherein R 2 is -H, and the compound is selected from the following formulae, and pharmaceutically acceptable salts, hydrates and solvates thereof:

[0925]

[0926] (286) The compound according to any one of (1) to (280), wherein:

[0927] the sulfur atom forming part of the sulfonyl imide amide group (ie, indicated by an asterisk (*) in the formula below) is in the (R) configuration; and

[0928] -R 1 and -R 2 The carbon atom to which it is attached (ie, designated by a pound sign (#) in the formula below) is in the (R) configuration.

[0929]

[0930] (287) The compound according to any one of (1) to (280), wherein:

[0931] the sulfur atom forming part of the sulfonyl imide amide group (i.e., indicated by an asterisk (*) in the above formula) is in the (R) configuration; and

[0932] -R 1 and -R 2 The attached carbon atom (ie, designated by a pound sign (#) in the above formula) is in the (S) configuration.

[0933] (288) The compound according to any one of (1) to (280), wherein:

[0934] the sulfur atom forming part of the sulfonyl imide amide group (i.e., indicated by an asterisk (*) in the above formula) is in the (S) configuration; and

[0935] -R 1 and -R 2 The carbon atom to which it is attached (ie, designated by a pound sign (#) in the above formula) is in the (R) configuration.

[0936] (289) The compound according to any one of (1) to (280), wherein:

[0937] the sulfur atom forming part of the sulfonyl imide amide group (i.e., indicated by an asterisk (*) in the above formula) is in the (S) configuration; and

[0938] -R 1 and -R 2 The attached carbon atom (ie, designated by a pound sign (#) in the above formula) is in the (S) configuration.

[0939] Some preferred combinations

[0940] (290) The compound according to any one of (1) to (280), wherein:

[0941] -R 1 are independently -CH(CH3)CH2CH3, -CH2CH(CH3)2 or -CH(CH3)2;

[0942] -R 2 is -H; and

[0943] -R 1 and -R 2 The attached carbon atom is in the (S) configuration.

[0944] (291) The compound according to any one of (1) to (280), wherein:

[0945] -R 1 are independently -CH(CH3)CH2CH3 or -CH2CH(CH3)2;

[0946] -R 2 is -H; and

[0947] -R 1 and -R 2 The attached carbon atom is in the (S) configuration.

[0948] (292) The compound according to any one of (1) to (280), wherein:

[0949] -R 1 is -CH2CH(CH3)2;

[0950] -R 2 is -H; and

[0951] -R 1 and -R 2 The attached carbon atom is in the (S) configuration.

[0952] Some specific compounds

[0953] (293) The compound according to (1), which is selected from the compound of the following formula, and pharmaceutically acceptable salts, hydrates and solvates thereof:

[0954]

[0955]

[0956]

[0957]

[0958]

[0959]

[0960]

[0961]

[0962]

[0963]

[0964]

[0965]

[0966]

[0967]

[0968]

[0969]

[0970]

[0971]

[0972] combination

[0973] It will be appreciated that certain features of the invention that, for the sake of clarity, are described in the context of separate embodiments may also be provided in combination in a single embodiment. Conversely, various features of the invention that, for the sake of brevity, are described in the context of a single embodiment may also be provided independently or in any suitable subcombination. N1 、-R N2 、-R 1 、-R 2 All combinations of embodiments of chemical groups represented by the formula (e.g., SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57

[0974] substantially purified form

[0975] One aspect of the present invention pertains to ANASIA compounds in purified form.

[0976] In one embodiment, the compound is in a substantially purified form and / or is in a form that is substantially free of contaminants.

[0977] In one embodiment, the compound is in a substantially purified form having a purity of at least 50% by weight, such as at least 60% by weight, such as at least 70% by weight, such as at least 80% by weight, such as at least 90% by weight, such as at least 95% by weight, such as at least 97% by weight, such as at least 98% by weight, such as at least 99% by weight.

[0978] Unless otherwise specified, the substantially purified form refers to a compound in any stereoisomer or enantiomeric form. For example, in one embodiment, the substantially purified form refers to a mixture of stereoisomers, i.e., purified relative to other compounds. In one embodiment, the substantially purified form refers to one stereoisomer, e.g., an optically pure stereoisomer. In one embodiment, the substantially purified form refers to a mixture of enantiomers. In one embodiment, the substantially purified form refers to an equimolar mixture of enantiomers (i.e., a racemic mixture, a racemate). In one embodiment, the substantially purified form refers to one enantiomer, e.g., an optically pure enantiomer.

[0979] In one embodiment, the compound is in a form that is substantially free of contaminants, wherein the contaminants constitute no more than 50% by weight, such as no more than 40% by weight, such as no more than 30% by weight, such as no more than 20% by weight, such as no more than 10% by weight, such as no more than 5% by weight, such as no more than 3% by weight, such as no more than 2% by weight, such as no more than 1% by weight.

[0980] Unless otherwise specified, the contaminants refer to other compounds, i.e., compounds other than stereoisomers or enantiomers. In one embodiment, the contaminants refer to other compounds and other stereoisomers. In one embodiment, the contaminants refer to other compounds and another enantiomer.

[0981] In one embodiment, the compound is in a substantially purified form having an optical purity of at least 60% (i.e., 60% of the compound on a molar basis is the desired stereoisomer or enantiomer and 40% is the undesired stereoisomer or enantiomer), such as at least 70%, such as at least 80%, such as at least 90%, such as at least 95%, such as at least 97%, such as at least 98%, such as at least 99%.

[0982] Isomers

[0983] Certain compounds may exist in one or more specific geometric isomers, optical isomers, enantiomers, diastereomers, epimers, atropisomers, stereoisomers, tautomers, conformers, or anomeric forms, including, but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r-forms; meso- and racemic-forms; R-, S-, and meta-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; syn- and anti-forms; α- and β-forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and semi-chair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms").

[0984] It should be noted that, except as discussed below with respect to tautomeric forms, specifically excluded from the term "isomer" as used herein are structural (or constitutional) isomers (i.e., isomers that differ in the connectivity between the atoms rather than merely the position of the atoms in space). For example, a reference to a methoxy group, i.e., -OCH3, should not be construed as a reference to its structural isomer, hydroxymethyl, i.e., -CH2OH. Similarly, a reference to an o-chlorophenyl group should not be construed as a reference to its structural isomer, m-chlorophenyl. However, a reference to a class of structures fully encompasses structural isomeric forms within that class (e.g., C 1-3The alkyl group includes n-propyl and isopropyl; the butyl group includes n-butyl, isobutyl, sec-butyl and tert-butyl; and the methoxyphenyl group includes o-methoxyphenyl, m-methoxyphenyl and p-methoxyphenyl).

[0985] The above exclusions do not relate to tautomeric forms, such as keto-, enol- and enolate-forms, as, for example, in the following tautomeric pairs: keto / enol (shown below), imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thione / enethiol, N-nitroso / hydroxyazo, and nitro / acid nitro.

[0986]

[0987] It should be noted that the term "isomer" specifically includes compounds having one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H. 2 H(D) and 3 H(T); C can be in any isotopic form, including 12 C. 13 C and 14 C; O can be in any isotopic form, including 16 O and 18 O; S can be in any isotopic form, including 32 S. 33 S. 34 S. 35 S and 36 S et al.

[0988] Unless otherwise specifically stated, reference to a particular compound includes all such isotopic forms, including mixtures thereof (e.g., racemic mixtures). Methods for preparing (e.g., asymmetric synthesis) and separating (e.g., fractional crystallization and chromatographic separation means) such isomeric forms are known in the art or are readily obtained in a known manner by employing the methods taught herein or known methods.

[0989] Salt

[0990] It may be appropriate or desirable to prepare, purify and / or handle the corresponding salts of the compounds, for example pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts are discussed in Berge et al., 1977, “Pharmaceutically Acceptable Salts,” J.Pharm.Sci. , Volume 66, Pages 1-19.

[0991] For example, if the compound is anionic, or has a functional group that can be anionic (e.g., -COOH can be -COO -), then a suitable cation may be used to form a salt. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + ; Alkaline earth metal cations, such as Ca 2+ and Mg 2+ ; and other cations such as Al 3+ Examples of suitable organic cations include, but are not limited to, ammonium ions (i.e., NH4 + ) and substituted ammonium ions (e.g. NH3R + NH2R2 + 、NHR3 + NR4 + Some examples of suitable substituted ammonium ions are those derived from ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids such as lysine and arginine. Examples of common quaternary ammonium ions are N(CH3)4 + .

[0992] If the compound is cationic, or has a functional group that can be cationic (e.g., -NH2 can be -NH3 + ), then a suitable anion can be used to form a salt. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfurous acid, nitric acid, nitrous acid, phosphoric acid, and phosphorous acid.

[0993] Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetoxybenzoic acid, acetic acid, ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, glucoheptanoic acid, gluconic acid, glutamic acid, glycolic acid, hydroxymaleic acid, hydroxynaphthoic acid, isethionic acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, methanesulfonic acid, mucic acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pantothenic acid, phenylacetic acid, benzenesulfonic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, toluenesulfonic acid, and valeric acid. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethylcellulose.

[0994] Unless specifically stated otherwise, a reference to a particular compound also includes its salt forms.

[0995] Hydrates and solvates

[0996] It may be appropriate or desirable to prepare, purify and / or process the corresponding solvates of the compounds. The term "solvate" is used herein in its conventional sense to refer to a complex of a solute (e.g., a compound, a salt of a compound) and a solvent. If the solvent is water, the solvate is generally referred to as a hydrate, such as a hemihydrate, monohydrate, sesquihydrate, dihydrate, trihydrate, etc.

[0997] Unless otherwise specifically stated, a reference to a particular compound also includes its solvate and hydrate forms.

[0998] Chemically protected form

[0999] It may be appropriate or desirable to prepare, purify and / or process the compound in a chemically protected form. The term "chemically protected form" is used herein in its conventional chemical sense and refers to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions under specific conditions (e.g., pH, temperature, radiation, solvents, etc.). In practice, well-known chemical methods are employed to reversibly render a functional group unreactive under specific conditions that would otherwise be reactive under those conditions. In a chemically protected form, one or more reactive functional groups are in the form of a protected group or protecting group (also known as a masked group or masking group or a blocked group or blocking group). By protecting the reactive functional group, reactions involving other unprotected reactive functional groups can be performed without affecting the protected group; the protecting group can typically be removed in a subsequent step without substantially affecting the rest of the molecule. See, for example, Protective Groups in Organic Synthesis (T. Greene and P. Wuts; 4th ed.; John Wiley and Sons, 2006).

[1000] A variety of such "protection," "blocking," or "masking" methods are widely available and well-known in organic synthesis. For example, a compound having two non-equivalent reactive functional groups that are reactive under specific conditions can be derivatized so that one of the functional groups is "protected" under the specific conditions and is therefore unreactive; in the protected state, the compound can be used as a reactant that effectively has only one reactive functional group. After the desired reaction (involving the other functional group) is completed, the protected group can be "deprotected" to restore its original functionality.

[1001] For example, a hydroxy group can be protected as an ether (-OR) or ester (-OC(=O)R), such as tert-butyl ether; anisole, diphenylmethyl ether (diphenylmethyl ether), or trityl ether (triphenylmethyl ether); trimethylsilyl or tert-butyldimethylsilyl ether; or an acetyl ester (-OC(=O)CH3, -OAc).

[1002] For example, amine groups can be protected as amides (-NRCO-R) or carbamates (-NRCO-OR), such as: methylamide (-NHCO-CH3); benzyloxyamide (-NHCO-OCH2C6H5, -NH-Cbz); tert-butoxyamide (-NHCO-OC(CH3)3, -NH-Boc); 2-biphenyl-2-propoxyamide (-NHCO-OC(CH3)2C6H4C6H5, -NH-B 9-fluorenylmethoxyamide (-NH-Fmoc); 6-nitrobenzylmethoxyamide (-NH-Nvoc); 2-trimethylsilylethoxyamide (-NH-Teoc); 2,2,2-trichloroethoxyamide (-NH-Troc); allyloxyamide (-NH-Alloc); 2(-phenylsulfonyl)ethoxyamide (-NH-Psec); or where appropriate (e.g., cyclic amines), in the form of a nitroxide radical (>NO●).

[1003] Prodrug

[1004] It may be appropriate or desirable to prepare, purify and / or process a compound in a prodrug form. As used herein, the term "prodrug" refers to a compound that, when metabolized (e.g., in vivo), produces a desired active compound. Typically, a prodrug is inactive or has less activity than the desired active compound, but may provide advantageous handling, administration, or metabolic characteristics.

[1005] For example, some prodrugs are esters of the active compound (e.g., physiologically acceptable, readily metabolizable esters). During metabolism, the ester group (-C(=O)OR) is cleaved to produce the active drug. Such esters can be formed by esterifying any carboxylic acid group (-C(=O)OH) in the parent compound, and, where appropriate, the esterification is performed before protecting any other reactive groups present in the parent compound, followed by deprotection as necessary.

[1006] Additionally, some prodrugs undergo enzymatic activation to produce the active compound, or a compound that undergoes additional chemical reaction to produce the active compound (e.g., in ADEPT, GDEPT, LIDEPT, etc.). For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.

[1007] Chemical synthesis

[1008] Methods for chemically synthesizing ANASIA compounds are described herein. These and / or other well-known methods can be modified and / or adapted in a known manner to provide alternative or improved methods for synthesizing ANASIA compounds.

[1009] Composition

[1010] One aspect of the present invention relates to a composition (eg, a pharmaceutical composition) comprising an ANASIA compound as described herein and a pharmaceutically acceptable carrier, diluent, or excipient.

[1011] Another aspect of the present invention relates to a method of preparing a composition (eg, a pharmaceutical composition) comprising mixing an ANASIA compound as described herein and a pharmaceutically acceptable carrier, diluent, or excipient.

[1012] use

[1013] The ANASIA compounds described herein are useful, for example, for treating conditions (e.g., diseases) that are ameliorated by inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetases (aaRSs) (e.g., bacterial leucyl-tRNA synthetase, LeuRS, etc.) as described herein.

[1014] Selectivity

[1015] In one embodiment, the inhibition of a bacterial aminoacyl-tRNA synthetase (aaRS) is selective inhibition, eg, relative to a mammalian aminoacyl-tRNA synthetase (aaRS), eg, a corresponding mammalian aminoacyl-tRNA synthetase.

[1016] In one embodiment, the inhibition of a bacterial aminoacyl-tRNA synthetase (aaRS) is selective inhibition, eg, relative to a human aminoacyl-tRNA synthetase (aaRS), eg, a corresponding human aminoacyl-tRNA synthetase.

[1017] For example, in one embodiment, the ANASIA compound selectively inhibits bacterial leucyl-tRNA synthetase (LeuRS) compared to human leucyl-tRNA synthetase (LeuRS).

[1018] Use in methods of inhibiting bacterial aminoacyl-tRNA synthetases

[1019] One aspect of the present invention relates to a method of inhibiting (e.g., selectively inhibiting) a bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS, etc.) in vitro or in vivo, comprising contacting the synthetase with an effective amount of an ANASIA compound as described herein.

[1020] One aspect of the present invention relates to a method of inhibiting (e.g., selectively inhibiting) the function of a bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS, etc.) in a cell (e.g., a bacterial cell) in vitro or in vivo, comprising contacting the cell with an effective amount of an ANASIA compound as described herein.

[1021] One of ordinary skill in the art can readily determine whether a candidate compound inhibits a bacterial aminoacyl-tRNA synthetase (e.g., bacterial leucyl-tRNA synthetase, etc.). For example, suitable assays are described herein or are known in the art.

[1022] In one embodiment, the method is performed in vitro.

[1023] In one embodiment, the method is performed in vivo.

[1024] In one embodiment, the ANASIA compound is provided in the form of a pharmaceutically acceptable composition.

[1025] One aspect of the present invention relates to a method of inhibiting a bacterial aminoacyl-tRNA synthetase (e.g., bacterial leucyl-tRNA synthetase, etc.) in a cell (e.g., a bacterial cell) in vitro or in vivo, comprising contacting the cell with an effective amount of an ANASIA compound as described herein.

[1026] For example, a cell sample can be grown in vitro and a compound can be contacted with the cells to observe the effect of the compound on these cells. As an example of "effect", the morphological state of the cells (e.g., alive or dead, etc.) can be determined. When a compound is found to have an effect on a cell, this can be used as a prognostic or diagnostic marker for the efficacy of the compound in a method of treating a patient carrying cells of the same cell type.

[1027] Use in therapeutic methods

[1028] Another aspect of the invention relates to an ANASIA compound as described herein for use in a method of treating the human or animal body by therapy, such as for use in a method of treating a condition (eg, a disease) as described herein.

[1029] Use in pharmaceutical manufacturing

[1030] Another aspect of the invention relates to the use of an ANASIA compound as described herein in the manufacture of a medicament, eg, for use in a method of treatment, eg, for use in a method of treating a condition (eg, a disease) as described herein.

[1031] In one embodiment, the pharmaceutical agent comprises an ANASIA compound.

[1032] Treatment

[1033] Another aspect of the invention relates to a method of treatment, e.g., a method of treating a condition (e.g., a disease) as described herein, comprising administering to a subject in need of treatment a therapeutically effective amount of an ANASIA compound as described herein, preferably in the form of a pharmaceutical composition.

[1034] Conditions Treated—Conditions Ameliorated by Inhibition of Bacterial Aminoacyl-tRNA Synthetases

[1035] In one embodiment (e.g., use in a method of treatment, use in the manufacture of a medicament, an embodiment of a method of treatment), the treatment is the treatment of a condition (e.g., a disease) that is improved by inhibiting (e.g., selectively inhibiting) a bacterial aminoacyl-tRNA synthetase (e.g., a bacterial leucyl-tRNA synthetase, etc.).

[1036] Conditions treated – bacterial infections

[1037] In one embodiment (eg, use in a method of treatment, use in the manufacture of a medicament, an embodiment of a method of treatment), the treatment is treatment of a bacterial infection.

[1038] In one embodiment, the bacterium is a Gram-positive bacterium (ie, the bacterial infection is an infection with a Gram-positive bacterium; the bacterial infection is an infection with a Gram-positive bacterium, etc.).

[1039] In one embodiment, the bacteria is a Gram-negative bacteria.

[1040] In one embodiment, the bacteria are aerobic bacteria.

[1041] In one embodiment, the bacteria is an anaerobic bacteria.

[1042] In one embodiment, the bacterium is an intracellular bacterium.

[1043] In one embodiment, the bacterium is:

[1044] Staphylococci, such as Staphylococcus aureus;

[1045] Enterococci, such as Enterococcus faecalis;

[1046] Streptococci, such as Streptococcus pneumoniae;

[1047] Haemophilus species, such as Haemophilus influenzae (H. influenzae);

[1048] Moraxella, such as M. catarrhalis;

[1049] Klebsiella species, such as K. pneumoniae;

[1050] Acinetobacter species, such as A. baumanii;

[1051] Pseudomonas, such as Pseudomonas aeruginosa;

[1052] Proteus, such as Proteus mirabilis;

[1053] Neisseria species, such as Neisseria gonorrhoeae;

[1054] Clostridioides, such as Clostridioides difficile;

[1055] Campylobacter species, such as C. jejuni;

[1056] Salmonella, such as S. typhi;

[1057] Shigella, such as Shigella flexneri;

[1058] Enterobacter species, such as E. cloacae;

[1059] Citrobacter species, such as Citrobacter freundii;

[1060] Serratia, such as Serratia marcescens; or

[1061] Escherichia, for example, Escherichia coli.

[1062] In one embodiment, the bacterium is:

[1063] Mycobacteria, for example, Mycobacterium tuberculosis.

[1064] In one embodiment, the bacterium is:

[1065] Chlamydia, such as C. trachomatis;

[1066] Rickettsiae, such as Rickettsia prowazekii; or

[1067] Mycoplasma, such as M. pneumoniae.

[1068] Type / location of infection

[1069] Infections can be associated with specific locations, organs, etc.

[1070] In one embodiment, the infection is:

[1071] Central nervous system infections;

[1072] Outer ear infection;

[1073] Middle ear infections, including acute otitis media;

[1074] Cranial sinus infection;

[1075] Eye infections;

[1076] Oral infections, including infections of the teeth, gums, or mucous membranes;

[1077] Upper respiratory tract infection;

[1078] Lower respiratory tract infection;

[1079] Urogenital tract infections;

[1080] Urinary tract infection;

[1081] Intra-abdominal infection;

[1082] Gastrointestinal infections;

[1083] Gynecological infections;

[1084] Septicemia;

[1085] bone or joint infection;

[1086] Skin or skin structure infection;

[1087] Bacterial endocarditis;

[1088] wound infection; or

[1089] Burn infection.

[1090] prevention

[1091] The treatment may be as prophylactic treatment, for example: antimicrobial prophylaxis during surgery; and antimicrobial prophylaxis in immunosuppressed patients, including patients receiving cancer chemotherapy or organ transplant patients.

[1092] treat

[1093] In the context of treating a condition, the term "treatment" as used herein generally refers to treatment in humans or animals (e.g., in veterinary applications) in which some desired therapeutic effect is achieved, such as inhibiting the progression of the condition, and includes slowing of the rate of progression, cessation of the rate of progression, alleviation of symptoms of the condition, improvement of the condition, and cure of the condition. Treatment as a preventative measure (i.e., prophylaxis) is also included. For example, treatment for patients who have not yet developed a condition but are at risk of developing the condition is encompassed within the scope of the term "treatment."

[1094] For example, the treatment of bacterial infection includes preventing bacterial infection, reducing the incidence of bacterial infection, alleviating the symptoms of bacterial infection, etc.

[1095] As used herein, the term "therapeutically effective amount" refers to that amount of a compound, or material, composition, or dosage form containing the compound, effective to produce some desired therapeutic effect when administered according to the desired treatment regimen and commensurate with a reasonable benefit / risk ratio.

[1096] Combination therapy

[1097] The term "treatment" includes combination treatments and therapies in which two or more treatments or therapies are combined, for example, sequentially or simultaneously. For example, the compounds described herein can also be used in combination therapies, for example, in combination with other agents.

[1098] One aspect of the invention pertains to combinations of compounds as described herein with one or more (eg, 1, 2, 3, 4, etc.) additional therapeutic agents, such as other antibacterial agents.

[1099] The specific combination will be determined at the discretion of the physician selecting the dosage using his or her normal knowledge and dosing regimens known to skilled practitioners.

[1100] The agents (i.e., ANASIA described herein, plus one or more other agents) can be administered simultaneously or sequentially and can be administered by different routes at individually variable dosing schedules. For example, when administered sequentially, the agents can be administered at closely spaced intervals (e.g., over a period of 5-10 minutes) or at longer intervals (e.g., 1, 2, 3, 4 hours or longer, or even longer periods of time, if desired), the precise dosage regimen being commensurate with the characteristics of the therapeutic agents.

[1101] The agents (ie, ANASIA described herein, plus one or more other agents) can be formulated together in a single dosage form, or the individual agents can be formulated separately and provided together in a kit, optionally with instructions for their use.

[1102] Other Uses

[1103] The ANASIA compounds described herein can also be used as cell culture additives to inhibit bacterial aminoacyl-tRNA synthetases (eg, bacterial leucyl-tRNA synthetase, etc.).

[1104] The ANASIA compounds described herein can also be used as part of an in vitro assay, for example, to determine whether a candidate host would benefit from treatment with the compound in question.

[1105] The ANASIA compounds described herein can also be used, for example, as standards in assays to identify other active compounds, other bacterial aminoacyl-tRNA synthetase inhibitors, and the like.

[1106] Reagent test kit

[1107] One aspect of the invention relates to a kit comprising (a) an ANASIA compound as described herein, or a composition comprising an ANASIA compound as described herein, e.g., preferably provided in a suitable container and / or with suitable packaging; and (b) instructions, e.g., written instructions, on how to administer the compound or composition.

[1108] The written instructions may also include a list of indications for which the active ingredient is suitable for treatment.

[1109] Route of administration

[1110] An ANASIA compound or a pharmaceutical composition comprising an ANASIA compound can be administered to a subject by any convenient route of administration, such as systemically / peripherally or topically (ie, at the desired site of action).

[1111] Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, for example, by patches, plasters, etc.); transmucosal (including, for example, patches, plasters, etc.); intranasal (e.g., by nasal sprays); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy, e.g., through the use of an aerosol, e.g., via oral or nasal administration); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, e.g., by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcutaneous, intraarticular, subarachnoid, and intrasternal; by implantation of a depot or reservoir, e.g., subcutaneous or intramuscular.

[1112] Subjects / patients

[1113] The subject / patient can be a chordate, a vertebrate, a mammal, a placental mammal, a marsupial (e.g., a kangaroo, a koala), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), a murine (e.g., a mouse), a lagomorph (e.g., a rabbit), an avian (e.g., a bird), a canine (e.g., a dog), a feline (e.g., a cat), an equine (e.g., a horse), a porcine (e.g., a pig), an ovine (e.g., a sheep), a bovine (e.g., a cow), a primate, an anthropoid (e.g., a monkey or ape), a monkey (e.g., a marmoset, a baboon), an ape (e.g., a gorilla, a chimpanzee, an orangutan, a gibbon), or a human.

[1114] Furthermore, the subject / patient may be in any developmental form thereof, such as a fetus.

[1115] In a preferred embodiment, the subject / patient is a human.

[1116] formulations

[1117] Although the ANASIA compound can be administered independently, it is preferred that the compound be provided in the form of a pharmaceutical formulation (e.g., composition, preparation, medicament) comprising at least one ANASIA compound as described herein and one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including but not limited to pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, antioxidants, lubricants, stabilizers, solubilizers, surfactants (e.g., wetting agents), masking agents, colorants, flavorings, and sweeteners. The formulation may further comprise other active agents, such as other therapeutic or prophylactic agents.

[1118] Thus, the present invention further provides pharmaceutical compositions as defined above, and methods for preparing pharmaceutical compositions, comprising mixing at least one ANASIA compound as described herein with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, such as carriers, diluents, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dose) of the compound.

[1119] As used herein, the term "pharmaceutically acceptable" refers to compounds, ingredients, materials, compositions, dosage forms, etc. that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., humans) without excessive toxicity, irritation, allergic response, or other problems or complications, and commensurate with a reasonable benefit / risk ratio. Each carrier, diluent, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients in the formulation.

[1120] Suitable carriers, diluents, excipients etc. can be found in standard pharmaceutical texts, e.g. Remington's Pharmaceutical Sciences , 18th ed., Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients ,5th edition,2005.

[1121] The formulation can be prepared by any method well known in the pharmaceutical field. Such methods include the step of combining the compound with a carrier that constitutes one or more auxiliary ingredients. Generally speaking, the formulation is prepared by uniformly and closely combining the compound with a carrier (e.g., a liquid carrier, a finely powdered solid carrier, etc.), and then shaping the product if necessary.

[1122] The formulations may be prepared to provide fast or slow release; immediate, delayed, timed, or sustained release; or a combination thereof.

[1123] The formulation may suitably be in the form of a liquid, solution (e.g., aqueous, non-aqueous solution), suspension (e.g., aqueous, non-aqueous suspension), emulsion (e.g., oil-in-water, water-in-oil emulsion), elixir, syrup, lick, mouthwash, drops, tablet (including, e.g., coated tablet), granules, powder, lozenge, pastille, capsule (including, e.g., hard and soft gelatin capsules), cachet, pill, ampoule, bolus, suppository, pessary, tincture, gel, paste, ointment, unguent, lotion, oil, foam, spray, mist or aerosol.

[1124] The formulation may be suitably provided in the form of a patch, adhesive plaster, bandage, dressing, etc., which is filled with one or more compounds and optionally one or more other pharmaceutically acceptable ingredients, including, for example, permeation, penetration and absorption enhancers. The formulation may also be suitably provided in the form of a reservoir or storage container.

[1125] The compound can be dissolved in one or more other pharmaceutically acceptable ingredients, suspended in one or more other pharmaceutically acceptable ingredients, or mixed with one or more other pharmaceutically acceptable ingredients. The compound can be provided in liposomes or other microparticles designed to target the compound, for example, to blood components or one or more organs.

[1126] Formulations suitable for oral administration (e.g., by ingestion) include liquids, solutions (e.g., aqueous, non-aqueous solutions), suspensions (e.g., aqueous, non-aqueous suspensions), emulsions (e.g., oil-in-water, water-in-oil emulsions), elixirs, syrups, elixirs, tablets, granules, powders, capsules, cachets, pills, ampoules, boluses.

[1127] Formulations suitable for buccal administration include mouthwashes, lozenges, pastilles, and patches, plasters, reservoirs, and reservoirs. Lozenges typically contain the compound in a flavoring matrix, usually sucrose and gum arabic or tragacanth. Pastilles typically contain the compound in an inert matrix, such as gelatin and glycerol, or sucrose and gum arabic. Mouthwashes typically contain the compound in a suitable liquid carrier.

[1128] Formulations suitable for sublingual administration include tablets, lozenges, pastilles, capsules, and pills.

[1129] Formulations suitable for oral mucosal administration include liquids, solutions (e.g., aqueous, non-aqueous solutions), suspensions (e.g., aqueous, non-aqueous suspensions), emulsions (e.g., oil-in-water, water-in-oil emulsions), mouthwashes, lozenges, pastilles, as well as patches, plasters, reservoirs, and reservoirs.

[1130] Formulations suitable for non-oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous solutions), suspensions (e.g., aqueous, non-aqueous suspensions), emulsions (e.g., oil-in-water, water-in-oil emulsions), suppositories, pessaries, gels, pastes, ointments, salves, lotions, oils, as well as patches, bandages, reservoirs, and depots.

[1131] Formulations suitable for transdermal administration include gels, pastes, salves, ointments, lotions, and oils, as well as patches, bandages, bandages, dressings, reservoirs, and depots.

[1132] Tablets can be made by conventional means, such as compression or molding, optionally with one or more auxiliary ingredients. Compressed tablets can be prepared by compressing a compound in a free-flowing form (such as a powder or granules) in a suitable machine, optionally mixed with one or more binders (e.g., povidone, gelatin, gum arabic, sorbitol, tragacanth, hydroxypropyl methylcellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silicon dioxide); disintegrants (e.g., sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethylcellulose); surfactants or dispersants or wetting agents (e.g., sodium lauryl sulfate); preservatives (e.g., methylparaben, propylparaben, sorbic acid); flavorings, flavor enhancers, and sweeteners. Molded tablets can be made by molding a mixture of powdered compounds moistened with an inert liquid diluent in a suitable machine. The tablets may optionally be coated or scored and may be formulated to provide slow or controlled release of the compound therein using, for example, hydroxypropylmethylcellulose in varying proportions to provide the desired release profile. The tablets may optionally have a coating, for example to affect release, such as an enteric coating to provide release in parts of the intestinal tract other than the stomach.

[1133] Ointments are typically prepared from the compound and a paraffinic or water-miscible ointment base.

[1134] Ointments are typically prepared from the compound and an oil-in-water ointment base. If desired, the aqueous phase of the ointment base may include, for example, at least about 30% w / w of a polyhydroxy alcohol, i.e., an alcohol having two or more hydroxyl groups, such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, and polyethylene glycol, and mixtures thereof. Topical formulations may desirably include compounds that enhance absorption or penetration of the compound into the skin or other affected area. Examples of such skin penetration enhancers include dimethyl sulfoxide and related analogs.

[1135] Emulsions are typically prepared from a compound and an oil phase, which may optionally contain only an emulsifier (emulsifier) ​​(also known as an emulgent), or it may contain at least one emulsifier and a fat or oil or a mixture of a fat and an oil. Preferably, a hydrophilic emulsifier and a lipophilic emulsifier are included simultaneously, with the lipophilic emulsifier acting as a stabilizer. It is also preferred to include both oil and fat simultaneously. Generally speaking, an emulsifier with or without a stabilizer constitutes a so-called emulsifying wax, and the wax, together with the oil and / or fat, constitutes a so-called emulsifying ointment base, which forms the oily dispersed phase of the ointment formulation.

[1136] Suitable emulsifiers and emulsion stabilizers include Tween 60, Span 80, cetearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate. The selection of the oil or fat that is suitable for the formulation is based on obtaining desired cosmetic properties, because the solubility of compound in most of the oil used in the pharmaceutical emulsion formulation may be extremely low. Therefore, ointment should preferably be a grease-free, non-dyed and washable product with a suitable consistency, to avoid leaking pipe or other containers. Straight or branched chain, monobasic or dibasic alkyl esters can be used, such as diisoadipate, stearic acid isocetyl ester, propylene glycol coconut oil fatty acid diester, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or the blend of the branched chain ester called Crodamol CAP, and the latter three are preferred esters. Depending on required characteristics, these esters can be used alone or in combination. Alternatively, high melting point lipids such as white petrolatum and / or liquid paraffin or other mineral oils may be used.

[1137] When the carrier is a liquid, suitable formulations for intranasal administration include, for example, nasal spray, nasal drops, or aerosol administration by nebulizer include aqueous or oily solutions of the compound.

[1138] When the carrier is a solid, formulations suitable for intranasal administration include, for example, those in the form of a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns, which is administered as a snuff, i.e., by rapid inhalation through the nostrils from a powder-containing container held close to the nose.

[1139] Formulations suitable for pulmonary administration (eg, by inhalation or insufflation therapy) include those in the form of an aerosol spray from a pressurized pack with the use of a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.

[1140] Suitable formulations for ophthalmic administration include eye drops wherein the compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the compound.

[1141] Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, a neutral or hardened oil, wax, fat, semi-liquid or liquid polyol, such as cocoa butter or a salicylate, or as a solution or suspension for treatment by enema.

[1142] Formulations suitable for vaginal administration may be presented as pessaries, tampons, ointments, gels, pastes, foams or spray formulations containing in addition to the compound such carriers as are known in the art to be appropriate.

[1143] Preparations suitable for parenteral administration (e.g., administration by injection) include aqueous or non-aqueous, isotonic, pyrogen-free sterile liquids (e.g., solutions, suspensions) in which the compound is dissolved, suspended, or otherwise provided (e.g., in liposomes or other microparticles). Such liquids may additionally contain other pharmaceutically acceptable ingredients, such as antioxidants, buffers, preservatives, stabilizers, antibacterial agents, suspending agents, thickening agents, and solutes that make the preparation isotonic with the blood (or other relevant body fluids) of the intended recipient. Examples of excipients include, for example, water, alcohol, polyols, glycerol, vegetable oils, etc. Examples of isotonic carriers suitable for use in such preparations include sodium chloride injection, Ringer's solution, or lactated Ringer's injection. Typically, the concentration of the compound in the liquid is from about 1 ng / mL to about 10 μg / mL, for example, from about 10 ng / mL to about 1 μg / mL. The formulations can be provided in unit dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition, requiring only the addition of a sterile liquid carrier, such as water for injection, immediately before use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules and tablets.

[1144] dose

[1145] Those skilled in the art will appreciate that the appropriate dosage of ANASIA compounds and compositions comprising ANASIA compounds may vary from patient to patient. Determining the optimal dosage will generally involve balancing the level of therapeutic benefit with any risks or adverse side effects. The selected dosage level will depend on a variety of factors, including but not limited to the activity of the specific ANASIA compound, the route of administration, the time of administration, the rate of excretion of the ANASIA compound, the duration of treatment, other drugs, compounds and / or materials used in combination, the severity of the condition, and the patient's species, sex, age, weight, illness, general health, and previous medical history. The amount and route of administration of the ANASIA compound will ultimately be at the discretion of the physician, veterinarian, or clinician, but the selected dosage should generally achieve a local concentration at the site of action that achieves the desired effect without causing significant adverse or adverse side effects.

[1146] Administration can be achieved by a single dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods for determining the most effective means and dosages for administration are well known to those skilled in the art and will vary with the formulation used for therapy, the purpose of therapy, the target cells being treated, and the subject being treated. Single or multiple administrations can be performed at the dosage level and pattern selected by the treating physician, veterinarian, or clinician.

[1147] Generally, suitable dosages of ANASIA compounds are in the range of about 0.1 mg to about 5000 mg (more typically about 10 mg to about 3000 mg) per kilogram of subject body weight per day. Where the compound is a salt, ester, amide, prodrug, etc., the dosage is calculated based on the parent compound and therefore, the actual weight used is proportionally increased.

[1148] General chemical synthesis

[1149] Methods for chemically synthesizing ANASIA compounds are described herein and can be prepared by techniques known in the art. These and / or other well-known methods may be modified and / or adapted to facilitate the synthesis of additional compounds described herein.

[1150] In the following general schemes, when specific reaction conditions, such as temperatures, reaction durations, acids, bases, reagents, solvents, coupling agents, etc., are mentioned, it is understood that other reaction conditions, such as temperatures, reaction durations, acids, bases, reagents, solvents, coupling agents, etc., may also be used and are therefore included within the scope of this disclosure.

[1151] General plan 1

[1152]

[1153] The scheme shown above illustrates one of several possible methods for synthesizing sulfonyl imide amide derivatives of formula (G). Using this method, an appropriate arylsulfonyl chloride of formula (A) is reacted with sodium sulfite and sodium carbonate in water to obtain a sodium sulfinate of formula (B1). This can then be converted to an arylsulfenamide of formula (C) by reacting it with oxalyl chloride or thionyl chloride, followed by ammonia. Alternatively, a sulfonyl chloride of formula (A) is reacted with an alcohol in the presence of a base such as TEA and triphenylphosphine to obtain an active ester of formula (B2), which, upon reaction with LiHMDS / ammonium chloride, yields a compound of formula (C).

[1154] The product of formula (C) can be acylated with an activated amino acid of formula (D) in the presence of a suitable base to obtain the corresponding acylsulfenamide of formula (E). The product of formula (E) can be converted into a sulfonyl imide amide intermediate of formula (F) by reaction with tert-butyl hypochlorite and then with an appropriate amine or ammonia. The product (F) can be deprotected to obtain the target sulfonyl imide amide derivative of formula (G). Then, if necessary, the individual stereoisomers (enantiomers, diastereomers) of (G) or its precursor (F) can be separated by applying an appropriate separation method.

[1155] General Scheme 2

[1156]

[1157] Another possible method for synthesizing the sulfonyl imide amide derivative of formula (G) is shown in the scheme shown above. By using this method, the corresponding sulfonyl chloride of formula (A) can be obtained from commercial sources or can be prepared by methods known in the art. For example, the corresponding sulfhydryl compound can be converted into sulfonyl chloride when reacting with sodium hypochlorite and concentrated hydrochloric acid, thus obtaining the sulfonyl chloride of formula (A). The sulfonyl chloride of formula (A) can be converted into the sulfonamide of formula (H) when reacting with ammonia. The sulfonamide of formula (H) forms the TBDMS-protected sulfonamide of formula (I) after processing with TBDMS chloride and alkali such as sodium hydride or TEA. The TBDMS-protected sulfonamide of formula (I) is reacted with freshly prepared PPh Cl and DIPEA, and then reacted with ammonia to obtain the TBDMS-protected sulfonyl imide amide intermediate of formula (J). The sulfonyl imide amide intermediate of formula (J) can be converted into the key intermediate of formula (K) after being treated with HCl in dioxane or TFA. The intermediate of formula (K) can be acylated with an activated amino acid ester of formula (D) in the presence of a suitable base such as DBU or sodium hydride to obtain a compound of formula (L) in the form of a diastereoisomer mixture. The isomers can also be separated by analytical techniques such as chiral chromatography or reversed-phase HPLC. Finally, the Boc group of the intermediate of formula (L) can be cleaved with HCl or TFA to obtain a compound of formula (G).

[1158] General Scheme 3

[1159]

[1160] Another possible method for synthesizing sulfonyl imide amide derivatives of formula (G) is shown in the scheme shown above. By using this method, the intermediate of formula (J) can be acylated with an activated amino acid of formula (D) in the presence of a suitable base to obtain a compound of formula (M), which, after deprotection using HCl or TFA, gives the final compound of formula (G).

[1161] Synthesis of (tert-Butyloxycarbonyl)-L-leucine 2,5-dioxopyrrolidin-1-yl ester (Int-X1)

[1162]

[1163] To a stirred solution of N-Boc-L-leucine (2 g, 8.64 mmol) in DMF (20 mL) was added EDC.HCl (2.48 g, 12.9 mmol), followed by N-hydroxysuccinimide (1.19 g, 1.03 mmol) and stirred at room temperature for 16 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum to give the title compound Int-X1 (1.7 g, 29.82%) as an off-white solid. MS-ESI: 229.1 (M+H-Boc).

[1164] The following intermediates were prepared according to the procedure described for Int-X1.

[1165]

[1166]

[1167] Synthesis of 2,5-dioxopyrrolidin-1-yl 1-((tert-Butyloxycarbonyl)amino)-3-methylcyclopentane-1-carboxylate (Int-X5)

[1168]

[1169] Step-1: At 0 ° C, to a stirred solution of titanium tetraisopropoxide (6.96 g, 24.48 mmol) and 7M methanolic ammonia (3.36 g, 197.95 mmol) was added 3-methylcyclopentan-1-one (2 g, 20.40 mmol) and the reaction mixture was stirred at room temperature for 4 hours. Then, the reaction was cooled to -10 ° C and TMS-CN (2.09 g, 21.02 mmol) was slowly added and the reaction mixture was stirred at room temperature for 12 hours. After TLC indicated that the reaction was complete, the reaction mixture was filtered through a bed of celite, then poured into water and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give 1-amino-3-methylcyclopentane-1-carbonitrile (2.6 g, quantitative) as a yellow oil. LCMS ESI (m / z): 125.21 (M + 1)

[1170] Step-2: To a stirred solution of 1-amino-3-methylcyclopentane-1-carbonitrile (0.7 g, 5.64 mmol) in dioxane (3.5 mL) was added concentrated hydrochloric acid (7 mL) and stirred at 75° C. for 16 hours. After TLC indicated the reaction was complete, the reaction mixture was evaporated under vacuum to give 1-amino-3-methylcyclopentane-1-carboxylic acid (0.75 g, 92.9%) as a brown solid. LCMS ESI (m / z): 144.22 (M+1).

[1171] Step-3: Under a nitrogen atmosphere, 2M NaOH aqueous solution (3.36 g, 83.91 mmol) and Boc anhydride (5.49 g, 25.17 mmol) were added to a stirred solution of 1-amino-3-methylcyclopentane-1-carboxylic acid (3 g, 20.97 mmol) in dioxane (60 mL) at 0°C and stirred at room temperature for 3 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into cold water and extracted with DCM to remove impurities. The pH value of the aqueous layer was adjusted to slightly acidic (about pH 6) using dilute hydrochloric acid and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give 1-((tert-butoxycarbonyl)amino)-3-methylcyclopentane-1-carboxylic acid (1.73 g, 33.93%) as a yellow oil.

[1172] Step-4: To a stirred solution of 1-((tert-butoxycarbonyl)amino)-3-methylcyclopentane-1-carboxylic acid (1.73 g, 7.1193 mmol) in DMF (17.3 mL) was added EDC.HCl (1.63 g, 8.5432 mmol), followed by N-hydroxysuccinimide (1.29 g, 8.5432 mmol) and stirred at room temperature for 3 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product, which was further purified by column chromatography (40% ethyl acetate / hexane) to give 2,5-dioxopyrrolidin-1-yl 1-((tert-butoxycarbonyl)amino)-3-methylcyclopentane-1-carboxylate (Int-X5) (0.9 g, 37.19%) as a white solid. LCMS ESI (m / z): 341.3 (M+1).

[1173] Synthesis of 5-(difluoromethyl)thiophene-2-sulfonyl chloride (Int-Y1)

[1174]

[1175] Step-1: To a cooled solution of 5-bromothiophene-2-carbaldehyde (10 g, 52.9 mmol) in DCM (20 mL) was added DAST (12.7 g, 78 mmol) and the mixture was stirred at room temperature overnight. The reaction mixture was quenched with ice water and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography to give Int-Y1-A1 (5.1 g, 46.36%).

[1176] Step-2: To a degassed solution of 2-bromo-5-(difluoromethyl)thiophene (1.5 g, 7 mmol) and DIPEA (1.8 g, 14 mmol) in dioxane (15 mL) was added Xantphos (0.40 g, 0.7 mmol), Pd2dba3 (0.32 g, 0.35 mmol) and benzylmercaptan (0.87 g, 7 mmol) and the reaction mixture was heated at 100°C for 4 hours. After completion of the reaction as indicated by TLC, the reaction mixture was filtered through celite and the filtrate was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. This reaction was repeated twice and the crude products of all three batches were combined and subjected to silica gel column chromatography to obtain Int-Y1-A2 (5 g, 92%).

[1177] Step-3: To a stirred solution of 2-(phenylmethylthio)-5-(difluoromethyl)thiophene (4 g, 15.4 mmol) in acetic acid (65 mL) and water (8 mL) was added N-chlorosuccinimide (8.3 g, 6.2 mmol) in portions at room temperature and stirred for 2 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude mixture was purified by silica gel column chromatography (ethyl acetate / hexane: 1:10) to give the title compound Int-Y1 (3.1 g, 85%). The compound was used immediately in the next step without analysis.

[1178] Synthesis of Thieno[3,2-b]thiophene-2-sulfonyl chloride (Int-Y2)

[1179]

[1180] Step-1: To a solution of thieno[3,2-b]thiophene (1 g, 7.13 mmol) in DMF (8 mL) was added portionwise N-bromosuccinimide (1.27 g, 7.13 mmol) at 0°C, and the reaction mixture was stirred at 0°C for 4 hours. After completion of the reaction, the reaction mixture was poured into ice-cold water and extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with ice-cold water (4 × 100 mL), dried over Na2SO4 and evaporated in vacuo to give Int-Y2-A1 (1.2 g, 76%). 1 H NMR (400MHz, DMSO-d6) δ7.74 (d, J = 5.2 Hz, 1H), 7.66 (s, 1H), 7.41 (d, J = 5.2 Hz, 1H).

[1181] Step-2-3: Follow the procedure described for Int-Y1 (Step-2-3).

[1182] Synthesis of 5-chlorothiophene-3-sulfonyl chloride (Int-Y3)

[1183]

[1184] Step-1: To a solution of 2,3-dibromothiophene (10 g, 41.33 mmol) in acetic acid (100 mL) was added N-chlorosuccinimide (5.84 g, 43.81 mmol) portionwise and the reaction mixture was refluxed for 3 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (500 mL) and extracted with ethyl acetate (500 mL). The organic layer was washed with dilute NaOH solution (3 × 500 mL), brine (500 mL), dried over Na2SO4, and evaporated in vacuo to give Int-Y3-A1 (10.1 g, 88%). 1 HNMR (400MHz, CDCl3) δ6.80 (s, 1H).

[1185] Step-2: To a suspension of 2,3-dibromo-5-chlorothiophene (7.2 g, 26.05 mmol) in acetic acid (80 mL) was added zinc powder (17 g, 260.51 mmol) and the reaction mixture was heated at 100°C for 16 hours. After heating for 16 hours, the reaction mixture was filtered through celite and the filtrate was partitioned between water (300 mL) and ethyl acetate (300 mL). The organic layer was washed with saturated sodium bicarbonate solution (5 x 300 mL), dried over Na2SO4 and evaporated in vacuo to give Int-Y3-A2 (4.5 g, 82%). 1 HNMR (400MHz, CDCl3) δ7.05 (d, J = 1.6 Hz, 1H) 6.88 (d, J = 1.6 Hz, 1H).

[1186] Step-3: To a degassed solution of 4-bromo-2-chlorothiophene (2 g, 10.12 mmol) and DIPEA (2.61 g, 20.25 mmol) in dioxane (20 mL) was added Xantphos (0.586 g, 1.01 mmol), Pd2dba3 (0.463 g, 0.5 mmol) and benzylmercaptan (1.25 g, 10.12 mmol) and the reaction mixture was heated at 100°C overnight. After TLC indicated the completion of the reaction, the reaction mixture was filtered through celite and the filtrate was poured into water and extracted with ethyl acetate (2 x 70 mL). The combined organic layers were washed with brine (2 x 150 mL), dried over Na2SO4 and evaporated in vacuo to afford Int-Y3-A3. (1.5 g, 62%). LCMSESI (m / z): 240.6 (M+H) (yield 32.44% over 3 steps).

[1187] Step-4: To a stirred solution of 4-(phenylmethylthio)-2-chlorothiophene (1.13 g, 4.70 mmol) in acetic acid (22.6 mL) and water (2.26 mL) was added N-chlorosuccinimide (1.88 g, 14.12 mmol) in portions at room temperature and stirred for 3 hours. After TLC indicated the completion of the reaction, the reaction mixture was evaporated under vacuum to remove acetic acid and then partitioned between water (50 mL) and ethyl acetate (50 mL). The organic layer was washed with water (50 mL), dried over Na2SO4 and evaporated under vacuum. The crude product was subjected to silica gel column chromatography to obtain the title compound Int-Y3 (0.79 g, 77.8%).

[1188] Synthesis of Thieno[3,2-b]thiophene-3-sulfonyl chloride (Int-Y4)

[1189]

[1190] Step-1: To a solution of 3,4-dibromothiophene (15 g, 62.00 mmol) in THF (150 mL) was added lithium diisopropylamide (2 M in THF) (62 mL, 123.96 mmol) at -78 ° C and the reaction mixture was stirred at -78 ° C for 2 hours. DMF (5.77 mL, 74.38 mmol) was added dropwise to the reaction mixture, which was then stirred at room temperature for another 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into NH4Cl solution (500 mL) and extracted with ethyl acetate (500 mL). The organic layer was dried over Na2SO4 and evaporated under vacuum. The crude product was subjected to silica gel column chromatography to obtain 3,4-dibromothiophene-2-carbaldehyde (11 g, 65%). 1 H NMR (400MHz, DMSO-d6) δ9.85 (s, 1H), 8.46 (s, 1H).

[1191] Step-2: To a solution of 3,4-dibromothiophene-2-carboxaldehyde (11 g, 40.74 mmol) in DMF (110 mL) was added ethyl thioglycolate (6 g, 48.88 mmol), potassium carbonate (17 g, 123.9 mmol) and 18-crown-6 (1 g, 4.03 mmol). The reaction mixture was stirred at 70 ° C for 2 hours. After LCMS indicated that the reaction was complete, the reaction mixture was poured into ice-cold water (200 mL). The solid was filtered and washed with water. The residue was dried in vacuo to give 6-bromothieno[3,2-b]thiophene-2-carboxylate (12.5 g, quantitative). 1H NMR (400MHz, DMSO-d6) δ8.31 (s, 1H), 8.12 (s, 1H), 4.33 (q, J = 7.1Hz, 1H), 1.32 (t, J = 6.8Hz, 3H).

[1192] Step-3: To a solution of ethyl 6-bromothieno[3,2-b]thiophene-2-carboxylate (12.5 g, 42.94 mmol) in THF:water (1:1) (120 mL) was added lithium hydroxide monohydrate (5.4 g, 129.26 mmol) and the reaction mixture was heated at 70°C for 3 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (200 mL) and acidified with 1N HCl (about pH 4) to obtain a white precipitate, which was filtered and dried in vacuo to give 6-bromothieno[3,2-b]thiophene-2-carboxylic acid (8.6, 76%). 1 H NMR (400MHz, DMSO-d6) δ13.54(s,1H),8.21(s,1H),8.08(s,1H).

[1193] Step-4: To a degassed solution of 6-bromothieno[3,2-b]thiophene-2-carboxylic acid (4.3 g, 16.34 mmol) in N-methyl-2-pyrrolidone (45 mL) was added potassium carbonate (0.33 g, 2.45 mmol) and silver acetate (0.27 g, 1.63 mmol). The reaction mixture was heated at 120°C for 3 hours. After TLC indicated the reaction was complete, the reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layers were washed with brine (4 x 200 mL), dried over Na2SO4, and evaporated under vacuum. The crude product was subjected to silica gel column chromatography to obtain 3-bromothieno[3,2-b]thiophene (3 g, 41.89%). 1 HNMR (400MHz, DMSO-d6) δ7.82 (s, 1H), 7.79 (d, J = 5.1 Hz, 1H), 7.56 (d, J = 5.1 Hz, 1H).

[1194] Step-5: To a degassed solution of 3-bromothieno[3,2-b]thiophene (3.6 g, 16.43 mmol) and DIPEA (4.25 g, 32.86 mmol) in dioxane (36 mL) was added Xantphos (0.95 g, 1.64 mmol), Pd2dba3 (0.75 g, 0.82 mmol) and benzylmercaptan (2.04 g, 16.43 mmol). The reaction mixture was heated at 100 ° C for 3 hours. After TLC indicated that the reaction was complete, the reaction mixture was filtered through celite and the filtrate was poured into water (100 mL) and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine (2×200 mL), dried over Na2SO4 and evaporated under vacuum. The crude product was subjected to silica gel column chromatography to obtain Int-Y4-A5 (3.4 g, 78.86%). 1 H NMR (400MHz, DMSO-d6) δ7.71 (d, J = 5.2, 1H), 7.53 (s, 1H), 7.46 (d, J = 5.2Hz, 1H), 7.29-7.21 (m, 5H), 4.23 (s, 2H).

[1195] Step-6: To a stirred solution of 3-(phenylmethylthio)thieno[3,2-b]thiophene (3.4 g, 12.95 mmol) in acetic acid (68 mL) and water (6.8 mL) was added N-chlorosuccinimide (5.18 g, 38.87 mmol) in portions at room temperature. The reaction mixture was stirred for 2 hours. After TLC indicated the completion of the reaction, the reaction mixture was evaporated under vacuum and then partitioned between water (150 mL) and ethyl acetate (150 mL). The organic layer was washed with water (150 mL), dried over Na2SO4 and evaporated under vacuum. The crude product was subjected to silica gel column chromatography to obtain the title compound Int-Y4 (2.9 g, 93.75%).

[1196] Synthesis of Benzo[d][1,3]dioxolane-5-sulfonyl Chloride (Int-Y5)

[1197]

[1198] Step-1: To a solution of benzo[d][1,3]dioxolane (5 g) in DCM (50 mL) was added sulfuryl chloride (3 mL) at 0°C and stirred for 5 minutes. After TLC indicated the reaction was complete, the reaction mixture was poured into ice water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, and evaporated in vacuo to give the title compound Int-Y5 (3 g, 33.2%) as a liquid.

[1199] Synthesis of 4,5-dichlorothiophene-3-sulfonyl chloride (Int-Y6)

[1200]

[1201] Step-1: To a solution of 2,3-dichlorothiophene (10 g, 65.34 mmol) in CHCl (100 mL) was added bromine (10.10 mL, 196.0 mmol) at 0°C and the reaction mixture was stirred overnight at room temperature. After TLC indicated the completion of the reaction, the reaction mixture was poured into a saturated sodium thiosulfate solution (200 mL) and extracted with DCM (2×200 mL). The combined organic layers were washed with sodium thiosulfate solution (200 mL), brine (200 mL), dried over NaSO, and evaporated in vacuo to afford Int-Y6-A1 (15 g, 98.98%).

[1202] Step-2: At 0 ° C, bromine (10.0 mL, 194.0 mmol) was added to a solution of 5-bromo-2,3-dichlorothiophene (15 g, 64.67 mmol) in CH2Cl2 (150 mL) and the reaction mixture was stirred at room temperature for 72 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into a saturated sodium thiosulfate solution (250 mL) and extracted with DCM (2 × 300 mL). The combined organic layers were dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography to give Int-Y6-A2 (15.5 g, 75.20%).

[1203] Step-3: To a suspension of 4,5-dibromo-2,3-dichlorothiophene (10 g, 26.23 mmol) in acetic acid (50 mL) was added zinc powder (8.56 g, 131.11 mmol) and the reaction mixture was heated at 100 ° C overnight. The reaction mixture was filtered through celite and the filtrate was partitioned between water (300 mL) and ethyl acetate (500 mL). The organic layer was washed with saturated sodium bicarbonate solution (5×300 mL), dried over Na 2 SO 4 and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography to give Int-Y6-A3 (5.76 g, 77.19%).

[1204] Step-4: To a degassed solution of 4-bromo-2,3-dichlorothiophene (3 g, 12.93 mmol) and DIPEA (5.53 g, 32.33 mmol) in dioxane (30 mL) was added Xantphos (1.49 g, 2.58 mmol), Pd2dba3 (1.18 g, 12.93 mmol) and benzyl mercaptan (2.4 g, 19.40 mmol) and the reaction mixture was heated at 100 ° C overnight. After TLC indicated that the reaction was complete, the reaction mixture was filtered through celite and the filtrate was poured into water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude mixture was purified by silica gel column chromatography to give Int-Y6-A4 (2.5 g, 70.23%).

[1205] Step-5: To a stirred solution of 4-(phenylmethylthio)-2,3-dichlorothiophene (3 g, 10.90 mmol) in acetic acid (27 mL) and water (3 mL) was added N-chlorosuccinimide (4.36 g, 32.70 mmol) in portions at room temperature and stirred for 1 hour. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give the title compound Int-Y6, (3.81 g, quantitative). The compound was used immediately in the next step without analysis.

[1206] Synthesis of 2,5-dichlorothiophene-3-sulfonyl chloride (Int-Y7)

[1207]

[1208] Step-1: To a solution of 3-bromo-2-chlorothiophene (5.0 g, 25.3 mmol) in AcOH (5 mL) was added N-chlorosuccinimide (3.58 g, 26.8 mmol) and the mixture was heated at 100 ° C for 4 hours. After TLC indicated the completion of the reaction, the reaction mixture was quenched with ice water and extracted with ethyl acetate (3×50 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography to give Int-Y7-A1 (5.2 g, 97.96%). 1 H NMR (400MHz, DMSO) δ7.36 (s, 1H).

[1209] Step-2: To a degassed solution of 3-bromo-2,5-dichlorothiophene (5.0 g, 21.5 mmol) and DIPEA (2.55 mL, 32.3 mmol) in dioxane (20 mL) was added Xantphos (2.49 g, 4.31 mmol), Pd2(dba3) (1.97 g, 2.15 mmol) and benzylmercaptan (2.55 mL, 32.3 mmol). The reaction mixture was heated at 100 ° C for 16 hours. After TLC indicated that the reaction was complete, the reaction mixture was filtered through celite and the filtrate was poured into water (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give Int-Y7-A2 (5 g, 84.75%). 1 H NMR (400MHz, DMSO): δ7.32-7.23 (m, 6H), 4.21 (s, 2H).

[1210] Step-3: To a stirred solution of 3-(phenylmethylthio)-2,5-dichlorothiophene (3.86 g, 14.0 mmol) in acetic acid (25 mL) and water (5 mL) was added N-chlorosuccinimide (5.61 g, 42.0 mmol) in portions at room temperature and stirred for 1 hour. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (25 mL) and extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give Int-Y7. The crude mixture was used directly in the next step without analysis.

[1211] The following intermediates were prepared according to the procedure described for Int-Y1.

[1212]

[1213] Synthesis of benzenesulfenamide (Int-A-2.1)

[1214]

[1215] Step-1: A mixture of benzenesulfonyl chloride (15 g, 84 mmol), sodium sulfite (21.4 g, 160 mmol) and sodium bicarbonate (14.1 g, 16 mmol) in water (60 mL) was heated at 100 ° C for 1 hour. After the reaction was completed, water was removed under vacuum. The solid was refluxed in ethanol (150 mL) for 30 minutes and filtered. The filtrate was concentrated in vacuo to give Int-A-1.1 (13 g, 94%) as a white solid. MS-ESI (-ve): 140.9 (M-Na).

[1216] Step-2: At 0 ° C, oxalyl chloride (6 mL, 66 mmol) was added dropwise to a stirred suspension of sodium benzenesulfinate (10 g, 60 mmol) in toluene (100 mL) and stirred at room temperature for 2 hours. A mixture of 30% ammonia solution (60 mL) and ethyl acetate (60 mL) was added to the reaction mixture and stirred for another hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give the title compound Int-A-2.1 (5.5 g, 65%) as an off-white solid. MS-ESI: 142.04 (M+H).

[1217] Synthesis of sodium thiophene-2-sulfinate (Int-A-2.20)

[1218]

[1219] At 100 ° C, a mixture of thiophene-2-sulfonyl chloride (5g, 27mmol), sodium sulfite (6.9g, 54mmol) and sodium bicarbonate (5.8g, 54mmol) in water (30mL) was heated for 1 hour. After the reaction was completed, water was removed under vacuum. The solid was refluxed in ethanol (50mL) for 30 minutes and filtered. The filtrate was concentrated in vacuo to obtain Int-A1-2.20 (5g, 100%) as a white solid. The substance was further used in the next step.

[1220] At 0 ° C, oxalyl chloride (4.48 mL, 35 mmol) was added dropwise to a stirred suspension of sodium thiophene-2-sulfinate (5 g, 29 mmol) in toluene (20 mL) and the mixture was stirred at room temperature for 1 hour. A mixture of 30% aqueous ammonia solution (20 mL) and ethyl acetate (20 mL) was added to the reaction mixture and stirred for another hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give the title compound Int-A-2.20 (3 g, 69%) as an off-white solid. LCMS ESI (m / z): 148.1 (M + H).

[1221] The following intermediates were prepared according to the procedure described for Int-A-2.1.

[1222]

[1223]

[1224]

[1225]

[1226]

[1227]

[1228] Synthesis of 3-chloro-2-fluorobenzenesulfenamide (Int-A-2.2)

[1229]

[1230] Step-1: To a stirred solution of 3-chloro-2-fluorobenzenesulfonyl chloride (5 g, 21.8 mmol) in DCM (50 mL) was added TEA (30.41 mL, 218.2 mmol), L-menthol (3.4 g, 21.8 mmol) and triphenylphosphine (5.72 g, 21.8 mmol) at 0 ° C. and stirred at room temperature for 16 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with DCM. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 1: 9) to give Int-A1-2.2 (4 g, 55.09%) as a solid. LCMS ESI (m / z): 349.8 (M + 18).

[1231] Step-2: To a stirred solution of Int-A1-2.2 (4 g, 12.01 mmol) in THF (40 mL) was added 1 M LiHMDS in THF (3.50 mL, 18.02 mmol) at 0 ° C and stirred at 0 ° C for 1.5 hours. At 0 ° C, saturated NH4Cl solution (32 mL) was added to the reaction mixture and stirred at room temperature for another 5 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give the title compound Int-A-2.2 (1.5 g, 65.21%) as an off-white solid. LCMS ESI (m / z): 193.9 and 195.9 (M + H).

[1232] The following intermediates were prepared according to the procedure described for Int-A-2.2.

[1233]

[1234] Synthesis of 3-phenoxybenzenesulfenamide (Int-A-2.44)

[1235]

[1236] Step-1: To a stirred solution of 1-bromo-3-phenoxybenzene (3 g, 12.0 mmol) in THF (20 mL) was added n-BuLi (8 mL, 12.0 mmol, 1.6 M in THF) at -78 ° C and stirred at the same temperature for another hour. SO 2 was purged into the reaction mixture at the same temperature for 1 hour. After completion of the reaction, the reaction mixture was filtered and the residue was triturated with ether / pentane and dried under vacuum to give 3-phenoxybenzenesulfinate (1.9 g, 84.92%). The isolated lithium salt was readily used in the next step.

[1237] Step-2: To a suspension of 3-phenoxybenzenesulfinate lithium (1.97 g, 8.2 mmol) in toluene (20 mL) was added oxalyl chloride (1.4 mL, 16.4 mmol) at 0 ° C. and the reaction mixture was stirred at room temperature for 1 hour. A mixture of 30% ammonia solution (30 mL) and ethyl acetate (30 mL) was added to the reaction mixture and stirred for another hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 1: 1) to give 3-phenoxybenzenesulfenamide (1.1 g, 57.50%) as an off-white solid. LCMS ESI (m / z): 234.3 (M+1).

[1238] Synthesis of 4-fluorothiophene-2-sulfenamide (Int-F-3.0)

[1239]

[1240] Step-1: A mixture of Int-F-1.0 (450 mg, 2.5 mmol), methyl 3-mercaptopropionate (0.269 mL, 2.5 mmol), Pd2(dba)3 (57 mg, 0.062 mmol), Xanthphos (72 mg, 0.12 mmol) and DIPEA (0.86 mL, 5.0 mmol) was heated in dioxane (6 mL) for 2 hours. The mixture was cooled to room temperature and filtered through a short celite column. The solvent was evaporated and the residue was purified by column chromatography on a silica gel column using a mixture of light petroleum ether and EtOAc (10: 1) as eluent to give Int-F-2.0 (483 mg, 82%), which was used in step-2.

[1241] Step-2: m-CPBA (1.12 g, 6.5 mmol) was added portionwise to a stirred solution of Int-F-2.0 (1.12 g, 6.5 mmol) in DCM (17 mL) at 0 ° C. The mixture was gradually warmed to room temperature and stirred overnight, and then quenched with an aqueous Na2S2O3 solution (5 M) at 0 ° C. The organic phase was washed with water, dried over Na2SO4 and evaporated. The residue was purified by column chromatography on a silica gel column eluting with a mixture of light petroleum ether and EtOAc (2: 1–1: 1) to give Int-F1-2.0 (518 mg, 95%), which was used in step-3.

[1242] Step-3: Int-F1-2.0 (513 mg, 2.03 mmol) was dissolved in refluxing methanol (20 mL). 21% sodium ethoxide solution in ethanol (0.76 mL, 2.03 mmol) was added and the resulting solution was cooled to room temperature. The reaction mixture was concentrated and the residual solid was dried in vacuo. The residue was suspended in toluene (+2 drops of DMF) and at room temperature, oxalyl chloride was added thereto. The resulting mixture was stirred for 1 hour, then cooled to -78 ° C and NH3 was passed through. The mixture was evaporated and the residue was purified by column chromatography to give Int-F-3.0 (272 mg, 81%). 1 H NMR (300 MHz, CHLOROFORM-d) δ 7.23 (dd, J = 1.9, 1.2 Hz, 1H), 7.01 (dd, J = 1.9, 0.6 Hz, 1H), 4.54 (s, 2H).

[1243] The following intermediates were prepared according to the procedure described for Int-F-3.0.

[1244]

[1245] Synthesis of tert-butyl ((2S)-4-methyl-1-oxo-1-((phenylsulfinyl)amino)pentan-2-yl)carbamate (Int-A-3.1)

[1246]

[1247] At room temperature, to a stirred solution of benzenesulfenamide (5.3 g, 37 mmol) in DCM (50 mL) was added DBU (11.2 g, 74 mmol), followed by Int-X1 (14.8 g, 45 mmol) and stirred for 3 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 1: 1) to give the title compound Int-A-3.1 (7.8 g, 59%) as a solid. LCMS ESI (m / z): 377.2 (M+Na).

[1248] The following intermediates were prepared according to the procedure described for Int-A-3.1.

[1249]

[1250]

[1251]

[1252] Synthesis of tert-((2S)-4-methyl-1-oxo-1-((thiophen-2-ylsulfinyl)amino)pentan-2-yl)carbamic acid Butyl ester (Int-A-3.20)

[1253]

[1254] To a stirred solution of thiophene-2-sulfenamide (1.0 g, 6.8 mmol) in DMF (5 mL) was added 60% NaH (0.16 g, 6.8 mmol) at 0 ° C and stirred for another 1 hour at the same temperature. Int-X1 (2.23 g, 6.8 mmol) was added to the reaction mixture and stirred for another 4 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 1: 1) to give the title compound Int-A-3.20 (2 g, 81.63%) as a solid. LCMS ESI (m / z): 361.3 (M+1).

[1255] The following intermediates were prepared according to the procedures described for Int-A-3.20.

[1256]

[1257]

[1258]

[1259]

[1260]

[1261]

[1262]

[1263]

[1264]

[1265]

[1266] Synthesis of ((2S)-1-((amino(oxo)(phenyl)-λ6-sulfanylidene)amino)-4-methyl-1-oxopentan-2-yl)- tert-butyl ((S)-1-(((R)-amino(oxo)(phenyl)-λ6-sulfanylidene)amino)-4-methyl-1- tert-Butyl 2-oxopentan-2-yl)carbamate (Int-A-4.1, Int-A-4.1-Fr-1 and Int-A-4.1-Fr-2)

[1267]

[1268] To a stirred solution of (Int-A-3.1) (1 g, 2.8 mmol) in THF (10 mL) was added tert-butyl hypochlorite (0.40 mL, 3.6 mmol) at 0 ° C. and stirred for another 1 hour at the same temperature. 30% ammonia solution (15 mL) was added to the reaction mixture and stirred at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give the title compound Int-A-4.1 (0.40 g, 28%) as a mixture of diastereomers. LCMS ESI (m / z): 270.0 (M+H-Boc).

[1269] The diastereomers were separated by chiral preparative HPLC (column: YMC CHIRALART CELLULOSE_SC, mobile phase: A = 0.1% DEA in heptane, B = IPA:ACN (70:30), A:B = 75:25) to give Isomer-1 and Isomer-2. These isomers eluted at retention times of 8.73 minutes (Isomer-1) and 13.68 minutes (Isomer-2).

[1270] Synthesis of ((2S)-1-((amino(oxo)(thiophen-2-yl)-λ6-sulfanylidene)amino)-4-methyl-1-oxo tert-Butyl (pentan-2-yl)carbamate (Int-A-4.20-Fr-1 and Int-A-4.20-Fr-2)

[1271]

[1272] To a stirred solution of (Int-A-3.20) (1 g, 2.7 mmol) in THF (5 mL) was added tert-butyl hypochlorite (0.39 mL, 3.6 mmol) at 0 ° C. and stirred at the same temperature for 1 hour. 30% ammonia solution (15 mL) was added to the reaction mixture and ammonia gas was blown in at 0 ° C. The reaction mixture was stirred for 2 hours at the same temperature. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography to give the title compound Int-A-4.20 (0.180 g, 17%) as a mixture of diastereomers. LCMS ESI (m / z): 376.3 (M + H).

[1273] The diastereomers were separated by chiral preparative HPLC (DIACEL Chiral PAK_IG, mobile phase: A = 0.1% DEA in heptane, B = IPA:ACN (75:30), A:B = 85:15) to give Isomer-1 and Isomer-2. These isomers eluted at retention times of 10.25 minutes (Isomer-1) and 15.27 minutes (Isomer-2).

[1274] The following intermediates were prepared according to the procedure described for Int-A-4.1.

[1275]

[1276]

[1277]

[1278]

[1279]

[1280]

[1281]

[1282]

[1283]

[1284]

[1285]

[1286]

[1287]

[1288]

[1289]

[1290]

[1291]

[1292]

[1293]

[1294]

[1295]

[1296]

[1297]

[1298]

[1299]

[1300]

[1301]

[1302]

[1303]

[1304]

[1305]

[1306]

[1307]

[1308]

[1309]

[1310]

[1311]

[1312]

[1313]

[1314]

[1315]

[1316]

[1317]

[1318]

[1319]

[1320]

[1321]

[1322]

[1323]

[1324]

[1325] Synthesis of (S)-2-amino-N-((S)-amino(oxo)(phenyl)-λ6-sulfanylidene)-4-methylpentanamide hydrochloride Salt and (S)-2-amino-N-((R)-amino(oxo)(phenyl)-λ6-sulfanylidene)-4-methylpentanamide hydrochloride (ANASIA-003-1 / 2)

[1326]

[1327] At 0 ° C, to a solution of Int-A-4.1-Fr-1 (isomer-1) (90 mg, 0.24 mmol) in 1,4-dioxane (2 mL) was added 4M HCl in 1,4-dioxane (2 mL). The reaction mixture was stirred for 1 hour at room temperature. After TLC indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure and then triturated with n-pentane and diethyl ether to give the title compound ANASIA-003-1 (59 mg, 91%) as a hydrochloride salt. 1 H-NMR (400 MHz, DMSO-d6) δ: 7.95 (brs, 5H), 7.91-7.81 (m, 2H), 7.65-7.59 (m, 3H), 3.69-3.67 (m, 1H); 1.73-1.53 ​​(m, 2H); 1.44-1.38 (m, 1H), 0.87-0.86 (d, J=4.4 Hz, 3H), 0.86-0.85 (d, J=6.4 Hz, 3H). LCMS ESI (m / z): 269.9 (M+1), purity 100% at 210 nm.

[1328] At 0 ° C, to a solution of Int-A-4.1-Fr-2 (isomer-2) (77 mg, 0.21 mmol) in 1,4-dioxane (2 mL) was added 4M HCl in 1,4-dioxane (2 mL). The reaction mixture was stirred for 1 hour at room temperature. After TLC indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure. The product was triturated with n-pentane: ether to give the title compound ANASIA-003-2 (54 mg, 100%) as a hydrochloride salt. 1 H-NMR (400 MHz, DMSO-d6) δ: 7.97-7.91 (m, 6H), 7.91-7.81 (m, 3H), 3.70-3.60 (m, 1H); 1.73-1.65 (m, 2H), 1.58-1.55 (m, 1H), 0.91-0.90 (d, J = 6.4 Hz, 3H), 0.89-0.87 (d, J = 6.4 Hz, 3H). LCMS ESI (m / z): 270.0 (M+1), purity 100% at 210 nm.

[1329] Synthesis of (S)-2-amino-N-((S)-amino(oxo)(thiophen-2-yl)-λ6-sulfanylidene)-4-methylpentanamide Hydrochloride and (S)-2-amino-N-((R)-amino(oxo)(thiophen-2-yl)-λ6-sulfanylidene)-4-methylpentanamide hydrochloride Salt

[1330] (ANASIA-007-1 / 2)

[1331]

[1332] To a solution of Int-A-4.20-Fr-1 (isomer-1) (48 mg, 0.12 mmol) in 1,4-dioxane was added 4M HCl in 1,4-dioxane (0.65 mL) at 0°C. The reaction mixture was stirred for 1 hour at room temperature. After TLC indicated the reaction was complete, the reaction mixture was concentrated under reduced pressure and subsequently triturated with n-pentane. The compound was then purified by preparative HPLC (column: REPACK C 18 , mobile phase: A = 0.05% HCl in water, B = ACN) to afford the title compound ANASIA-007-1 (16 mg, 45%) as a hydrochloride salt. 1H-NMR (400 MHz, DMSO-d6) δ: 8.23 ​​(brs, 2H), 8.16 (brs, 3H), 7.99 (dd, J = 1.2 Hz, 1H), 7.73 (dd, J = 1.2 Hz, 1H), 7.19 (dd, J = 4.8 Hz, 1H), 3.68 (dd, J = 5.6, 1H), 1.78-1.75 (m, 1H), 1.65-1.60 (m, 1H), 1.52-1.48 (m, 1H), 0.89-0.87 (two d, 6H). LCMSE SI (m / z): 276.2 (M+1), purity at 210 nm: 99+%.

[1333] At 0 ° C, 4M HCl in 1,4-dioxane solution (0.65 mL) was added to a solution in Int-A-4.20-Fr-2 (isomer-2) (40 mg, 0.10 mmol). The reaction mixture was stirred for 1 hour at room temperature. After TLC indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure. The product was triturated with n-pentane: ether to give the title compound ANASIA-007-2 (18 mg, 51%) as a hydrochloride salt. 1 H-NMR (400 MHz, DMSO-d6) δ: 8.30 (brs, 2H), 8.04 (brs, 3H), 8.00 (dd, J = 1.4 Hz, 1H), 7.75 (dd, J = 1.4 Hz, 1H), 7.21 (dd, J = 3.8, 1H), 3.66-3.65 (m, 1H), 1.08-1.78 (m, 1H), 1.69-1.67 (m, 1H), 1.60-1.57 (m, 1H), 0.91-0.89 (two d, 6H). LCMS ESI (m / z): 276.3 (M+1), purity at 210 nm: 99+%.

[1334] Synthesis of (2S)-2-amino-N-(amino(3-chloro-2-fluorophenyl)(oxo)-λ6-sulfanylidene)-4-methylvaleryl Amine 2,2,2-trifluoroacetate (ANASIA-001)

[1335]

[1336] To a stirred solution of Int-A-4.2 (50 mg, 0.11 mmol) in DCM (0.5 mL) was added TFA (0.1 mL) and stirred at room temperature for 1 hour. After TLC indicated the reaction was complete, the reaction mixture was concentrated under reduced pressure and then triturated with n-pentane and diethyl ether to give the title compound ANASIA-001 (25 mg, 65.78%) as a TFA salt. 1H-NMR (400 MHz, DMSO-d6) δ: 8.04 (brs, 5H), 7.94-7.86 (m, 2H), 7.48-7.44 (m, 1H), 3.74-3.68 (m, 1H), 1.76-1.55 (m, 3H), 0.91-0.86 (m, 6H). LCMS ESI (m / z): 322.1 & 324.1 (M+H); purity at 210 nm: 94.11%.

[1337] The following compounds were prepared according to the procedures described for ANASIA-003 and ANASIA-001 using HCl or TFA.

[1338]

[1339]

[1340]

[1341]

[1342]

[1343]

[1344]

[1345]

[1346]

[1347]

[1348]

[1349]

[1350]

[1351]

[1352]

[1353]

[1354]

[1355]

[1356]

[1357]

[1358]

[1359]

[1360]

[1361]

[1362]

[1363]

[1364]

[1365]

[1366]

[1367]

[1368]

[1369]

[1370]

[1371]

[1372]

[1373]

[1374]

[1375]

[1376]

[1377]

[1378]

[1379]

[1380]

[1381]

[1382]

[1383]

[1384]

[1385]

[1386]

[1387] Synthesis of (S)-2-amino-N-((S)-amino(3'-fluoro-[1,1'-biphenyl]-3-yl)(oxo)-λ6-sulfinane (S)-2-amino-N-((R)-amino(3'-fluoro-[1,1'-biphenyl]-3-yl)(oxo)- λ6-sulfanylidene)-4-methylpentanamide hydrochloride

[1388] (ANASIA-051-1 / 2)

[1389] Step-1: Synthesis of Int-A-4.51, Int-A-51-Fr-1 and Int-A-51-Fr-2

[1390]

[1391] A solution of Int-A-4.23 (0.2 g, 0.44 mmol), (3-fluorophenyl)boronic acid (0.06 g, 0.44 mmol) and K2CO3 (0.12 g, 0.89 mmol) in DMF (2 mL) was purged with nitrogen for 30 minutes. PdCl2(dtbpf) (0.03 g, 0.04 mmol) was added to the reaction mixture and heated in a microwave at 110 ° C for 2 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give the title compound Int-A-4.51 (114 mg, 55%) as a mixture of diastereomers. LCMS ESI (m / z): 464.2 (M + H).

[1392] The diastereomers were separated by chiral preparative HPLC (column: YMC CHIRALART CELLULOSE-SC, mobile phase: A = n-heptane, B = IPA:ACN (70:30), A:B = 90:10) to give Isomer-1 and Isomer-2. These isomers eluted at retention times of 12.08 minutes (Isomer-1) and 18.01 minutes (Isomer-2).

[1393] Step-2: Synthesis of ANASIA-051-1 and ANASIA-051-2

[1394]

[1395] To a solution of Int-A-4.51-Fr-1 (isomer-1) (29 mg, 0.06 mmol) was added 4M HCl in 1,4-dioxane (1 mL) at 0 ° C. The reaction mixture was stirred at room temperature for 1 hour. After TLC indicated the reaction was complete, the reaction mixture was concentrated in vacuo and then triturated with n-pentane: ether to give the title compound ANASIA-051-1 (16 mg, 70%) as a hydrochloride salt. 1 H NMR (400 MHz, DMSO-d6) δ 8.19 (s, 1H), 8.12–7.89 (m, 7H), 7.73 (t, J = 7.9 Hz, 1H), 7.68–7.51 (m, 3H), 7.34–7.26 (m, 1H), 3.73 (brs, 1H), 1.80–1.34 (m, 3H), 0.85 (d, J = 6.1 Hz, 6H); LCMS ESI (m / z): 364.2 (M+1); purity at 220 nm: 96.14%.

[1396] At 0 ° C, 4M HCl in 1,4-dioxane solution (1 mL) was added to a solution of Int-A-4.51-Fr-2 (isomer-2) (23 mg, 0.04 mmol). The reaction mixture was stirred for 1 hour at room temperature. After TLC indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure. The product was triturated with n-pentane: ether to give the title compound ANASIA-051-2 (17 mg, 88%) as a hydrochloride salt. 1 H NMR (400 MHz, DMSO-d6) δ 8.20 (s, 1H), 8.04–8.00 (m, 3H), 7.95–7.90 (m, 4H), 7.73 (t, J=7.9 Hz, 1H), 7.65–7.55 (m, 3H), 7.35–7.25 (m, 1H), 3.73 (brs, 1H), 1.78–1.54 (m, 3H), 0.91–0.85 (m, 6H); LCMS ESI (m / z): 364.2 (M+1); purity at 220 nm: 91.50%.

[1397] Synthesis of (2S)-N-((3-allylphenyl)(amino)(oxo)-λ6-sulfanylidene)-2-amino-4-methylvaleryl Amine hydrochloride (ANASIA-085)

[1398]

[1399] Step-1: A solution of tert-butyl ((2S)-1-((amino(3-bromophenyl)(oxo)-λ6-sulfanylidene)amino)-4-methyl-1-oxopentan-2-yl)carbamate (0.3 g, 0.66 mmol) and allyltributyltin (0.24 g, 0.74 mmol) in DMF (2 mL) was purged with nitrogen for 30 minutes. PdCl2(dtbpf).DCM complex (0.04 g, 0.06 mmol) was added to the reaction mixture and heated at 120 ° C. under microwave for 2 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane-28:72) to give Int-A-4.75 (75 mg, 27.37%) as a mixture of diastereomers. LCMS ESI (m / z): 310.2 (M+H).

[1400] Step-2: Boc deprotection of Int-A-4.75 was carried out as described for ANASIA-051 using 4M HCl in dioxane to afford ANASIA-085.

[1401] 1 H NMR (400 MHz, MeOD) δ 7.85-7.80 (m, 2H), 7.55-7.49 (m, 2H), 6.03-5.96 (m, 1H), 5.16-5.10 (m, 2H), 3.79-3.74 (m, 1H), 3.50 (d, 2H), 1.85-1.54 (m, 3H), 1.00-0.86 (m, 6H). LCMS ESI (m / z): 310.2 (M+H). Purity at 230 nm: 100%.

[1402] Synthesis of (S)-2-amino-4-methyl-N-((S)-(methylamino)(oxo)(phenyl)-λ6-sulfanylidene)pentanoyl Amine and (S)-2-amino-4-methyl-N-((R)-(methylamino)(oxo)(phenyl)-λ6-sulfanylidene)pentanamide (ANASIA-010-1 / 2)

[1403]

[1404] Step-1: To a stirred solution of Int-A-3.1 (1 g, 2.8 mmol) in THF (10 mL) was added tert-butyl hypochlorite (0.40 mL, 3.6 mmol) at 0 ° C and stirred for another 1 hour. Methylamine solution (5 mL) was added to the reaction mixture and stirred at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give Int-A-4.54 (0.292 g, 27%) as a mixture of diastereomers. The diastereomers were separated by chiral preparative HPLC (column: DIACEL Chiral PAK_IG, mobile phase: A = heptane, B = IPA: MeOH (70: 30), A: B = 70: 30) to give Isomer-1 and Isomer-2. These isomers eluted at retention times of 15.66 minutes (Isomer-1) and 21.41 minutes (Isomer-2).

[1405] Step-2: Boc deprotection of Int-A-4.52-Fr-1 and Int-A-4.52-Fr-2 was carried out as described for ANASIA-003 using 4M HCl in dioxane.

[1406] Isomer-1: 1 H NMR (400 MHz, DMSO-d6) δ 8.08 (brs, 5H), 7.90–7.84 (m, 2H), 7.75–7.61 (m, 3H), 3.75–3.65 (m, 1H), 2.42 (s, 3H), 1.84–1.40 (m, 3H), 0.88 (d, J=6.4 Hz, 6H). LCM SESI (m / z): 284.0 (M+H), purity at 210 nm: 100%.

[1407] Isomer-2: 1 H NMR (400 MHz, DMSO-d6) δ 8.15-7.99 (m, 5H), 7.75–7.61 (m, 2H), 7.88–7.74 (m, 3H), 3.72 (brs, 1H), 2.42 (d, 3H), 1.84–1.40 (m, 3H), 0.88 (two d, 6H). LCMS ESI (m / z): 284.1 (M+H), purity at 210 nm: 96.13%.

[1408] Synthesis of pyridine-4-sulfonyl chloride (Int-B-2.1)

[1409]

[1410] Step-1: At -5 ° C, a mixture of 4-mercaptopyridine (1.5 g, 13.51 mmol), concentrated hydrochloric acid (18 mL) and dichloromethane (18 mL) was stirred and 5% NaOCl solution (3.33 g, 44.93 mmol) was added dropwise to the reaction mixture. After the addition was completed, the reaction mixture was slowly stirred at -5 ° C for 1 hour. After the reaction was completed, the reaction mixture was diluted with water and extracted with dichloromethane (3×25 mL). The combined organic layer was used in the next step without evaporation.

[1411] Step-2: At -78 ° C, ammonia gas was purged into THF (30 mL) and a freshly prepared solution of pyridine-4-sulfonyl chloride (100 mL) in dichloromethane was added at -78 ° C. The reaction mixture was stirred for another hour. After TLC indicated the completion of the reaction, the reaction mixture was evaporated under vacuum to give the title compound Int-B-2.1 (0.7 g, 33% over 2 steps) as a light yellow solid. LCMS ESI (m / z): 159.06 (M + 1).

[1412] Synthesis of 4-methylthiazole-2-sulfonamide (Int-B-2.2)

[1413]

[1414] At 0 ° C, 5% NaOCl (150 mL, 75.4 mmol) was added dropwise to a stirred solution of 4-methylthiazole-2-thiol (3 g, 22.8 mmol) in H2SO4 (75 mL) and stirred at room temperature for 30 minutes. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with DCM. At 0 ° C, the combined organic layer was immediately added dropwise to a stirred mixture of a pre-cooled saturated NH3 solution in MeOH (60 mL) and DCM (135 mL), and stirred at room temperature for 3 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with DCM. The combined organic layer was washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 4: 6) to give the title compound Int-B-2.2 (300 mg, 7.5%) as a white solid.

[1415] Synthesis of quinoline-7-sulfonamide (Int-B-2.3)

[1416]

[1417] Step-1: To a stirred solution of 7-bromoquinoline (5 g, 24 mmol) in dioxane (50 mL) was added DIPEA (8.21 mL, 48 mmol) and purged with nitrogen for 30 minutes, followed by the addition of Xantphos (1.38 g, 2.4 mmol), Pd2dba3 (1.09 g, 1.2 mmol) and benzylmercaptan (2.98 mL, 24 mmol). The reaction mixture was heated at 100 ° C for 4 hours. After TLC indicated that the reaction was complete, the reaction mixture was filtered through celite. The filtrate was poured into water and extracted with ethyl acetate (3×25 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give Int-B-2.3-A1 (4 g, 66%). LCMS ESI (m / z): 252.0 [M+H] +.

[1418] Step-2: To a stirred solution of Int-B-2.3-A1 (4 g, 15.9 mmol) in acetic acid (60 mL) / water (8 mL) was added N-chlorosuccinimide (8.4 g, 63.6 mmol) and stirred at room temperature for 6 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give Int-B-2.3-A2 (3 g, 82%).

[1419] Step-3: A solution of Int-B-2.3-A2 (3 g, 13 mmol) in THF (20 mL) was added to a stirred solution of saturated ammonia in THF (100 mL) at 0°C. A solid precipitated. The solid was evaporated to dryness and triturated with diethyl ether to afford the title compound Int-B-2.3 (2 g, 73%). LCMS ESI (m / z): 209.0 (M+H).

[1420] Synthesis of 4-chlorothiazole-2-sulfonamide (Int-B-2.4)

[1421]

[1422] Procedure: To a stirred solution of 2,4-dichlorothiazole (5 g, 32 mmol) in DMF (50 mL) was added 60% NaH (2.3 g, 96 mmol) at 0 ° C and stirred for 1 hour. Benzyl mercaptan (10 mL, 32 mmol) was added to the reaction mixture and the reaction mixture was heated at 60 ° C for 4 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give Int-B-2.4-A1 (1.5 g, 19%). LCMS ESI (m / z): 242.2 & 244.2 (M + H).

[1423] Step-2: To a stirred solution of Int-B-2.4-A1 (1.5 g, 6.2 mmol) in acetic acid (36 mL) / water (4 mL) was added N-chlorosuccinimide (3.3 g, 24.8 mmol) and stirred at room temperature for 6 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give Int-B-2.4-A2 (1 g, 73%). The substance was used immediately after separation.

[1424] Step-3: Int-B-2.4 was prepared by a procedure similar to that described for Int-B-2.3 (Step-3). LCMS ESI (m / z): 197.0 (MH).

[1425] Synthesis of 5-methylthiazole-2-sulfonamide (Int-B-2.5)

[1426]

[1427] Step-1: At -78 ° C, n-BuLi (13 mL, 20 mmol, 1.6 M) was added to a stirred solution of 5-methylthiazole (2 g, 20 mmol) in MTBE (20 mL) and stirred for another 1 hour at the same temperature. Gaseous SO2 was passed through the reaction mixture and kept at the same temperature for 1 hour. NCS (4 g, 30 mmol) was added to the reaction mixture and stirred at room temperature for 2 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 1: 1) to give Int-B-2.5-A1 (1.5 g, 38%). 1H-NMR (400MHz, DMSO-d6) δ: 7.76 (s, 1H), 2.66 (s, 3H).

[1428] Step-2: Int-B-2.5 was prepared by a procedure similar to that described for Int-B-2.3 (Step-3). LCMS ESI (m / z): 178.9 (M+H).

[1429] Synthesis of 2,6-difluorobenzenesulfonamide (Int-B-2.6)

[1430]

[1431] Ammonia gas was passed through a solution of 2,6-difluorobenzenesulfonyl chloride (2 g, 9.4 mmol) in THF (100 mL) at 0°C, and the mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo to give the title compound Int-B-2.6 (1.8 g, 99%). LCMS ESI (m / z): 211.4 (M+18).

[1432] Synthesis of 2,4-dichlorothiazole-5-sulfonamide (Int-B-2.7)

[1433]

[1434] Step-1: 2,4-dichlorothiazole (0.5 g, 3.2 mmol) was added to chlorosulfonic acid (3 mL) at 0 ° C with stirring and the resulting reaction mixture was stirred at 154 ° C for 8 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into cold water (50 mL) and extracted with diethyl ether (3×20 mL). The combined organic layer was washed with brine, dried over Na2SO4 and evaporated in vacuo to give 2,4-dichlorothiazole-5-sulfonyl chloride (0.550 g, 68.51%). The crude material was used in the next step without purification.

[1435] Step-2: To a freshly prepared saturated solution of ammonia in THF (10 mL) was added a solution of 2,4-dichlorothiazole-5-sulfonyl chloride in THF (10 mL) at -78 ° C. The reaction mixture was stirred for 1 hour at -78 ° C. After TLC indicated the completion of the reaction, the reaction mixture was allowed to reach room temperature and evaporated in vacuo to give a crude product, which was purified by silica gel column chromatography (ethyl acetate / hexane) to give 2,4-dichlorothiazole-5-sulfonamide (0.275 g, 56.18%). LCMS ESI (-ve) (m / z): 232.1 & 234.1 (M & M-2).

[1436] Synthesis of 3,4-dichlorothiophene-2-sulfonamide (Int-B-2.8)

[1437]

[1438] Step-1: To a stirred solution of 3,4-dibromothiophene (3 g, 12.4 mmol) in DMF (20 mL) was added CuCl2 (5.0 g, 37.2 mmol) and the reaction mixture was stirred at 180 ° C for 8 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (150 mL) and extracted with diethyl ether (3×150 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give 3,4-dichlorothiophene (1.6 g, 84.92%). 1 H NMR (400MHz, DMSO) δ7.27(s,1H),7.22(s,1H).

[1439] Step-2: At -78 ° C, to a stirred solution of 3,4-dichlorothiophene (1.6 g, 10 mmol) in THF (20 mL), n-BuLi (8 mL, 12.6 mmol, 2 M in THF) was added and stirred for 1 hour. Then, SO2 gas was purged through the reaction mixture at -78 ° C for 1 hour. NCS (1.3 g, 10 mmol) was added to the reaction mixture and stirred at room temperature for 2 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (3×150 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give 3,4-dichlorothiophene-2-sulfonyl chloride (1.5 g, 60%). The crude material was used directly in the next step without any purification.

[1440] Step-3: To a freshly prepared solution of saturated ammonia in THF (20 mL) was added freshly prepared 3,4-dichlorothiophene-2-sulfonyl chloride in THF at -78 ° C and the reaction mixture was stirred for 1 hour. After TLC indicated the completion of the reaction, the reaction mixture was evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give 3,4-dichlorothiophene-2-sulfonamide (0.159 g, 8.36% over 2 steps) as a light yellow solid. LCMS ESI (-ve) (m / z): 230.1 & 232.1 (M & M-2).

[1441] Synthesis of 2-methylthiophene-3-sulfonamide (Int-B-2.9)

[1442]

[1443] Step-1: 2-bromo-5-methylthiophene (5 g, 28.4 mmol) was added to a solution of chlorosulfonic acid (12.1 mL, 181.8 mmol) in DCM at -78 ° C. The reaction mixture was stirred for 15 minutes at -78 ° C., and then stirred at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into water (200 mL) and extracted with DCM (3 × 100 mL). The combined organic layers were dried over Na2SO4 and evaporated under vacuum. The crude product was used directly in the next step.

[1444] Step-2: Ammonia gas was purged into THF (40 mL) at -78°C. A solution of 5-bromo-2-methylthiophene-3-sulfonyl chloride (7.7 g, 28.2 mmol) in THF (10 mL) was added to freshly prepared ammonia in THF at -78°C. The reaction mixture was stirred for an additional 30 minutes. After TLC indicated the reaction was complete, the reaction mixture was evaporated under vacuum to give 5-bromo-2-methylthiophene-3-sulfonamide (5 g, 70%). LCMS ESI (m / z): 254.12 & 256.13 (M & M+2).

[1445] Step-3: To a suspension of 10% Pd / C (2 g) in methanol (20 mL) was added a solution of Int-B-2.9-A2 (2 g, 7.81 mmol, 1 eq) in methanol (10 mL) at room temperature. Hydrogen was purged through the reaction mixture for 2 hours. After completion of the reaction, it was monitored by TLC (mobile phase: 30% ethyl acetate in hexane). The reaction mixture was filtered using celite and the filtrate was concentrated under reduced pressure. The crude product was purified using a silica column (60 × 120 mesh silica-eluted with 15% ethyl acetate / hexane) to give Int-B-2.9 (1.2 g, 92%) as a yellow solid. LCMS ESI (-ve) (m / z): 176.01 (MH).

[1446] Synthesis of 2-chlorothiophene-3-sulfonamide (Int-B-2.10)

[1447]

[1448] Step-1: At -78 ℃, to a stirred solution of 3-bromo-2-chlorothiophene (1g, 5mmol) in THF (10mL), n-BuLi (4.1mL, 6.5mmol, 1.6M) was added and stirred at the same temperature for 45 minutes. At the same temperature, SO2 gas was passed through the reaction mixture for 1 hour. NCS (0.67g, 5mmol) was added to the reaction mixture and stirred at 0 ℃ for 2 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product (1.31g, 100%). The compound was used immediately in the next step without analysis.

[1449] Step-2: To a solution of 2-chlorothiophene-3-sulfonyl chloride (1.31 g, 6 mmol) in THF (10 mL) was added a freshly prepared saturated ammonia solution in THF (13 mL) at -78°C. A solid precipitated and was evaporated to dryness, and the crude product was purified by reverse phase column chromatography (ACN / water) to give the title compound Int-B-2.10 (0.302 g, 25.32%). 1 H-NMR (400MHz, DMSO-d6) δ: 7.83 (bs, 2H), 7.43 (d, J = 4.0, 1H), 7.22 (d, J = 4.0, 1H).

[1450] Synthesis of 4-cyanothiophene-3-sulfonamide (Int-B-2.11)

[1451]

[1452] Step-1: To a solution of 4-bromothiophene-3-carboxylic acid (5 g, 24.1 mmol) in THF (50 mL) was added SOCl2 (3.5 mL, 48.2 mmol) and a catalytic amount of DMF at 0 ° C and stirred for 1 hour. Then, the reaction mixture was poured into a liquid ammonia solution (50 mL) at 10 ° C. The reaction mixture was stirred at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were dried over Na2SO4 and evaporated in vacuo to give 4-bromothiophene-3-carboxamide (2.6 g, 53%). LCMS ESI (m / z): 206.1 & 208.0 (M & M+2).

[1453] Step-2: To a solution of 4-bromothiophene-3-carboxamide (0.4 g, 1.94 mmol) in DMF (5 mL) was added SOCl (0.28 mL, 3.88 mmol) at 0°C and stirred at the same temperature for 4 hours. After TLC indicated completion of the reaction, the reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (3×30 mL). The combined organic layers were dried over NaSO and evaporated in vacuo to give 4-bromothiophene-3-carbonitrile (0.25 g, 68%). 1 H NMR (400MHz, DMSO) δ 8.72 (d, J = 3.2 Hz, 1H), 8.00 (d, J = 3.2 Hz, 1H).

[1454] Step-3: To a degassed solution of 4-bromothiophene-3-carbonitrile (0.25 g, 1.32 mmol) in dioxane (25 mL) was added benzylthiol (0.19 mL, 1.59 mmol), DIPEA (0.46 mL, 2.65 mmol), Xantphos (0.077 g, 0.13 mmol), and Pd2(dba)3 (0.12 g, 0.13 mmol). The reaction mixture was heated at 100°C for 16 hours. After TLC indicated the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate (3×30 mL). The combined organic layers were dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give 4-(phenylmethylthio)thiophene-3-carbonitrile (0.15 g, 48.8%). LCMS ESI (m / z): 249.2 (M+18).

[1455] Step-4: To a stirred solution of 4-(phenylmethylthio)thiophene-3-carbonitrile (0.1 g, 0.43 mmol) in acetic acid (0.9 mL) and water (0.1 mL) was added N-chlorosuccinimide (0.23 g, 1.72 mmol) and stirred at room temperature for 1 hour. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4 and evaporated under vacuum. The crude product was used directly in the next step.

[1456] Step-5: To a freshly prepared saturated ammonia solution in THF (30 mL) was added a solution of 4-cyanothiophene-3-sulfonyl chloride (1.2 g, 5.78 mmol) in THF (20 mL) at -78 ° C. The reaction mixture was stirred for another 30 minutes. After TLC indicated the completion of the reaction, the reaction mixture was evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give 5-cyanothiophene-3-sulfonamide (0.54 g, 54%).

[1457] Synthesis of 5-chlorothiophene-3-sulfonamide (Int-B-2.12)

[1458]

[1459] Step-1: To a solution of 2,3-dibromothiophene (10 g, 41.33 mmol) in acetic acid (100 mL) was added N-chlorosuccinimide (5.84 g, 43.81 mmol) portionwise and the reaction mixture was refluxed for 3 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (500 mL) and extracted with ethyl acetate (500 mL). The organic layer was washed with dilute NaOH solution (3 × 500 mL), brine (500 mL), dried over Na2SO4, and evaporated in vacuo to afford Int-B-2.12-A1 (10.1 g, 88%). 1 H NMR (400MHz, CDCl3) δ6.80 (s, 1H).

[1460] Step-2: To a suspension of 2,3-dibromo-5-chlorothiophene (7.2 g, 26.05 mmol) in acetic acid (80 mL) was added zinc powder (17 g, 260.51 mmol) and the reaction mixture was heated at 100°C for 16 hours. After 16 hours, the reaction mixture was filtered through celite and the filtrate was partitioned between water (300 mL) and ethyl acetate (300 mL). The organic layer was washed with saturated sodium bicarbonate solution (5 x 300 mL), dried over Na2SO4, and evaporated in vacuo to give Int-B-2.12-A2 (4.5 g, 82%). 1 HNMR (400MHz, CDCl3) δ7.05 (d, J = 1.6 Hz, 1H) 6.88 (d, J = 1.6 Hz, 1H).

[1461] Step-3: React using similar reaction procedure described for Int-B-2.4 to give 5-chlorothiophene-3-sulfonamide Int-B-2.12. LCMS ESI (m / z): 198.1 (M+H).

[1462] Synthesis of 3,4-difluorothiophene-2-sulfonamide (Int-B-2.13)

[1463]

[1464] Step-1: Tosyl chloride (70.5 g, 370 mmol) was added to a solution of 2,2,3,3-tetrafluorobutane-1,4-diol (20 g, 123 mmol) in pyridine (120 mL) at 0 ° C. The reaction mixture was heated at 55 ° C for 16 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into cold water (1000 mL) and a solid precipitated. It was dissolved in DCM (1000 mL) and washed with 5% H2SO4 solution (2×200 mL). The organic layer was dried over Na2SO4 and evaporated in vacuo to give bis(4-methylbenzenesulfonic acid) 2,2,3,3-tetrafluorobutane-1,4-diyl ester (56 g, 96%). LCMS ESI (m / z): 471.5 (M+H).

[1465] Step-2: To a solution of 2,2,3,3-tetrafluorobutane-1,4-diyl bis(4-methylbenzenesulfonate) (56 g, 119 mmol) in N,N-dimethylacetamide (260 mL) was added NaS.H0 (56 g, 718 mmol) and the reaction mixture was heated at 70°C for 8 hours. After completion of the reaction, the reaction mixture was distilled at 70°C under 20-25 mbar and the product (6 g, 31.4%) was collected at -78°C. The isolated material was used directly in the next step.

[1466] Step-3: To a solution of 3,3,4,4-tetrafluorotetrahydrothiophene (6 g, 38 mmol) in DMSO (60 mL) was added KOH (10.5 g, 187 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 hours. After 16 hours, the reaction mixture was directly distilled (bath temperature: 70°C, vacuum: 24 mbar) and the product was collected in a receiver under vacuum at -78°C to give 3,4-difluorothiophene (3.5 g, 78.7%). The isolated material was used directly in the next step.

[1467] Step-4: At -78 ° C, to a stirred solution of 3,4-difluorothiophene (3.5 g, 29.1 mmol) in THF (35 mL) was added n-BuLi (36 mL, 58 mmol, 1.6 M in THF) and stirred for 1 hour. At -78 ° C, SO2 gas was purged through the reaction mixture for 1 hour. Then, NCS (5.8 g, 43 mmol) was added to the reaction mixture and stirred at room temperature for 2 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (3 × 150 mL). The combined organic layer was washed with brine, dried over Na2SO4 and evaporated in vacuo to give 3,4-difluorothiophene-2-sulfonyl chloride (6.8 g, quantitative). The crude material was used directly in the next step without any purification.

[1468] Step-5: To a freshly prepared solution of saturated ammonia in THF (20 mL) was added a solution of 3,4-difluorothiophene-2-sulfonyl chloride (6.8 g) in THF (20 mL) at -78 ° C and the reaction mixture was stirred for 1 hour. After TLC indicated the completion of the reaction, the reaction mixture was evaporated under vacuum. The crude product was purified by silica gel column chromatography (22%, ethyl acetate / hexane) to give 3,4-difluorothiophene-2-sulfonamide (1.6 g, 27.5% over 2 steps) as a white solid. LCMS ESI (-ve) (m / z): 198.3 (M-1).

[1469] Synthesis of 3,4-dimethylthiophene-2-sulfonamide (Int-B-2.14)

[1470]

[1471] Step-1: To a stirred solution of 3,4-dibromothiophene (5 g, 20.66 mmol) in THF (10 mL) was added NiCl2(dppf) (0.112 g, 20.66 mmol) at room temperature. MeMgBr (20 mL, 61.98 mmol) was added to the reaction mixture and stirred at 50 ° C for 12 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (200 mL) and extracted with diethyl ether (3×100 mL). The combined organic layers were dried over Na2SO4 and evaporated in vacuo to give crude 3,4-dimethylthiophene (2.1 g, 90.75%) as a brown liquid. The isolated material was used in the next step without purification.

[1472] Step-2: To a stirred solution of 3,4-dimethylthiophene (1.8 g, 16.07 mmol) in THF (10 mL) was added 1.6 M n-BuLi (21 mL, 32.14 mmol) at -78 ° C and stirred for 1 hour. NCS (3.5 g, 24.10 mmol) was added to the reaction mixture and stirred for 30 minutes. After TLC indicated that the reaction was complete, the reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were dried over Na2SO4 and evaporated in vacuo to give 3,4-dimethylthiophene-2-sulfonyl chloride (1.9 g, 56.03%) as a yellow liquid. The isolated material was used in the next step without purification.

[1473] Step-3: To a freshly prepared saturated ammonia solution in THF (20 mL) was added a solution of 3,4-dimethylthiophene-2-sulfonyl chloride (1.9 g, 16.07 mmol) in THF (10 mL) at -78 ° C. The reaction mixture was stirred for 1 hour. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over Na2SO4 and evaporated under vacuum. The crude product was purified by column chromatography (22% EtOAc: hexane) to give 3,4-dimethylthiophene-2-sulfonamide (0.2 g, 11.57%) as a white solid. LCMS ESI (m / z): 192.21 (M + 1).

[1474] Synthesis of 5-bromothiophene-2-sulfonamide (Int-B-2.15)

[1475]

[1476] Step-1: To a solution of 2-bromothiophene (5.0 g, 30.566 mmol) in DCM (50 mL) was added chlorosulfuric acid (17.86 g, 153.34 mmol) at -78 ° C and stirred at room temperature for 1 hour. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (200 mL) and extracted with DCM (2×200 mL). The combined organic layers were dried over Na 2 SO 4 and evaporated in vacuo to give Int-B-2.15-A1 (6.2 g, 77.30%). The compound was used immediately in the next step without analysis.

[1477] Step-2: To a solution of 3,5-dichlorothiophene-2-sulfonyl chloride (6.2 g, 23.70 mmol) in THF (10 mL) was added a saturated ammonia solution in THF (60 mL) at -78°C. A solid precipitated and was evaporated to dryness. The crude product was triturated with pentane to give the title compound Int-B-2.15 (4.4 g, 76.66%). LCMS ESI (-ve) (m / z): 240.0 (M-2).

[1478] Synthesis of 3-isopropylthiophene-2-sulfonamide (Int-B-2.16)

[1479]

[1480] Step-1: At -78 ° C, to a stirred solution of ClSO3H (10.7 g, 92.00 mmol) in DCM (20 mL), a solution of 3-bromothiophene (3 g, 18.40 mmol) in DCM (10 mL) was added and stirred at -78 ° C for 15 minutes, followed by stirring at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into cold water and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was used directly in the next step.

[1481] Step-2: 3-bromothiophene-2-sulfonyl chloride (10 mL) in THF (10 mL) was added to a freshly prepared saturated ammonia solution in THF (30 mL) at -78 ° C. The reaction mixture was stirred for another hour at the same temperature. After TLC indicated the completion of the reaction, the reaction mixture was evaporated under vacuum to give a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 5:5) to give 3-bromothiophene-2-sulfonamide (1.5 g, 54.01%) as a white solid. (1.5 g, 33.66% over 2 steps). 1 H NMR (400MHz, DMSO) δ7.90 (s, 2H), 7.86 (d, J = 5.2 Hz, 1H), 7.24 (d, J = 5.2 Hz, 1H).

[1482] Step-3: To a degassed solution of 3-bromothiophene-2-sulfonamide (2.0 g, 8.26 mmol) in THF:H2O (56 mL:10.4 mL) was added potassium trifluoro(prop-1-en-2-yl)borate (1.83 g, 12.39 mmol), Cs2CO3 (8.07 g, 24.79 mmol) and Pd2(dppf)Cl2.DCM complex (1.01 g, 1.23 mmol) and stirred at 80 ° C for 2 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into cold water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography (25% ethyl acetate / hexane) to give 3-(prop-1-en-2-yl)thiophene-2-sulfonamide (1.4 g, 83.40%) as a white solid. LCMS ESI (m / z): 204.24 (M+H). 1 H NMR (400MHz, DMSO d6) δ: 7.71 (d, J = 5.2 Hz, 1H), 7.61 (s, 2H), 7.08 (d, J = 5.2 Hz, 1H), 5.24 (d, J = 20 Hz, 2H), 2.05 (s, 3H).

[1483] Step-4: To a stirred solution of 3-(prop-1-en-2-yl)thiophene-2-sulfonamide (1.2 g, 5.90 mmol) in MeOH (30 mL) was added 10% Pd-C (2.4 gm) and purged with hydrogen for 2 hours. The reaction mixture was filtered through a bed of celite and the filtrate was evaporated under vacuum to give a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 1.8:8.2) to give 3-isopropylthiophene-2-sulfonamide (0.5 g, 41.26%) as a white solid. LCMS ESI (-ve) (m / z): 204.1 (M-1).

[1484] Synthesis of 2-((2,4-dimethoxybenzyl)oxy)benzenesulfonamide (Int-B-2.17)

[1485]

[1486] To a suspension of NaH (0.456 g, 1.14 mmol) in DMF (5 mL) was added 2-fluorobenzenesulfonamide (0.5 g, 2.85 mmol) and (2,4-dimethoxyphenyl)methanol (0.480 g, 2.85 mmol) and the reaction mixture was heated at 120 ° C for 16 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layer was washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was subjected to silica gel column chromatography to obtain the title compound Int-B-2.17 (0.4 g, 43.34%). 1 H NMR (400MHz, DMSO) δ7.74(d,J=7.6Hz,1H),7.57-7.52(m,1H),7.41(d,J=8.4Hz,1H),7.27(d,J=8.4Hz,1H),7.08-7. 04(m,1H),6.84(s,2H),6.64(s,1H),6.55-6.53(dd,J=8.2Hz,J=1.8Hz,1H),5.21(s,2H),3.82(s,3H),3.77(s,3H).

[1487] Synthesis of 3-ethylthiophene-2-sulfonamide (Int-B-2.21)

[1488]

[1489] To a stirred solution of 3-ethylthiophene (3 g, 26.7 mmol) in acetonitrile (4 mL) was added sulfur trioxide pyridine complex (5.5 g, 34.7 mmol) at room temperature. The reaction mixture was stirred at 50 ° C for 12 hours. The reaction mixture was cooled to 0 ° C and ethyl acetate was added to the reaction mixture and stirred for 2 hours. The solid was filtered.

[1490] The solid was suspended in DME (20 mL) and DMF (2.1 mL), followed by addition of (COCl) (4.93 g, 38.8 mmol) at 0 ° C. The reaction mixture was stirred for 1.5 hours at 0 ° C. Ammonia solution (15 mL) was added to the reaction mixture and stirred for 20 minutes at 0 ° C. After TLC indicated that the reaction was complete, the reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude product was purified by silica gel column chromatography (20% ethyl acetate / hexane) to give 3-ethylthiophene-2-sulfonamide (1.4 g, 28.27%) as a solid. LCMS ESI (-ve) (m / z): 190.0 (MH).

[1491] Synthesis of 3,5-dichlorothiophene-2-sulfonamide (Int-B-2.22)

[1492]

[1493] Step-1: The reaction was carried out in three separate batches of 3 g each. To a solution of 2,4-dibromothiophene (9.0 g, 37.2 mmol) in pyridine (30 mL) was added copper (I) chloride (11.1 g, 41.22 mmol) and the mixture was stirred at 140°C overnight. After TLC indicated the reaction was complete, the reaction mixture was poured into water (250 mL) and extracted with diethyl ether (2 x 300 mL). The combined organic layers were dried over Na2SO4 and concentrated in vacuo (5.9 g, quantitative).

[1494] Step-2: Chlorosulfuric acid (22.46 g, 192.78 mmol) was added dropwise to a stirred solution of 2,4-dichlorothiophene (5.9 g, 38.56 mmol) in DCM (100 mL) at -78 ° C and stirred at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into water (200 mL) and extracted with DCM (2 × 200 mL). The combined organic layer was dried over Na2SO4 and evaporated under vacuum. It was used directly in the next step.

[1495] Step-3: A solution of 3,5-dichlorothiophene-2-sulfonyl chloride (9.7 g, 38.56 mmol) in THF was added to a stirred saturated ammonia solution (50 mL) at -78° C. A solid precipitated and was evaporated to dryness, and the crude product was purified by silica gel column chromatography to give the title compound Int-B-2.22 (0.8 g, 08.93% over three steps).

[1496] Synthesis of 4-methylthiophene-2-sulfonamide (Int-B-2.23)

[1497]

[1498] Step-1: To a stirred solution of 3-methylthiophene (1.0 g, 10.18 mmol) in acetic acid (10 mL) and DCM (10 mL) was added NBS (1.9 g, 10.69 mmol) at room temperature and stirred at 50 ° C for 1.5 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into cold water (100 mL) and extracted with ethyl acetate (3×50 mL). The combined organic layer was washed with brine and 1M NaOH solution, dried over Na SO and evaporated in vacuo to give a crude product. The crude product was used directly in the next step.

[1499] Step-2-3: Reaction was carried out using a similar reaction procedure as described for Int-B-2.15 to give 5-bromo-4-methylthiophene-2-sulfonamide. LCMS ESI (m / z): LCMS ESI (-ve) (m / z): 254.0 (MH).

[1500] Step-4: To a suspension of 10% Pd / C (1 g, W / W) in methanol (10 mL) was added 5-bromo-4-methylthiophene-2-sulfonamide (0.9 g, 3.5 mmol) at room temperature. Hydrogen was purged through the reaction mixture for 2 hours. After TLC indicated the completion of the reaction, the reaction mixture was filtered through a bed of celite. The filtrate was concentrated in vacuo to give 4-methylthiophene-2-sulfonamide as a solid. LCMS ESI (-ve) (m / z): 176.0 (MH).

[1501] Synthesis of 4-chlorothiophene-2-sulfonamide (Int-B-2.24)

[1502]

[1503] Step-1: At 0 ° C, bromine solution (4.3 mL, 84.7 mmol) was added to a solution of 3-chlorothiophene (10 g, 84.7 mmol) in CCl4. The reaction was stirred at room temperature for 12 hours. After the reaction was completed, the reaction mixture was poured into water and extracted with DCM. The combined organic layer was dried over Na2SO4 and evaporated under vacuum. The crude product was used directly in the next step.

[1504] Step-2: To a solution of chlorosulfonic acid (34 mL, 508.4 mmol) in DCM was added a solution of 2-bromo-3-chlorothiophene (16.7 g, 84.7 mmol) in DCM (20 mL) at -78 ° C. The reaction was stirred at -78 ° C for 15 minutes, then at room temperature for 1 hour. After completion of the reaction, the reaction mixture was poured into water and extracted with DCM. The combined organic layers were dried over Na2SO4 and evaporated under vacuum. The crude product was used in the next step without further purification.

[1505] Step-3: At -78 ° C, a solution of 5-bromo-2-methylthiophene-3-sulfonyl chloride (25 g, 84.7 mmol) in THF (30 mL) was added to a saturated ammonia solution (100 L). The reaction mixture was stirred for another 30 minutes. After TLC indicated that the reaction was complete, the reaction mixture was evaporated under vacuum to obtain a mixture of 5-bromo-4-chlorothiophene-2-sulfonamide and 5-bromo-3-chlorothiophene-2-sulfonamide. After the reaction was complete, the reaction mixture was evaporated under vacuum and the crude product was used directly in the next step. LCMS ES (-ve) (m / z): 274.03 & 276.1 (M & M-2).

[1506] Step-4: To a solution of a mixture of 5-bromo-4-chlorothiophene-2-sulfonamide and 5-bromo-3-chlorothiophene-2-sulfonamide (17.5 g, 63.2 mmol) in acetic acid was added zinc powder (20.6 g, 316.0 mmol) and stirred at 100°C for 12 hours. After completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were dried over Na2SO4 and evaporated in vacuo to give a crude material containing a mixture of isomers 4-chlorothiophene-2-sulfonamide and 3-chlorothiophene-2-sulfonamide. The mixture was purified by normal phase flash chromatography using hexane:ethyl acetate (8:2) to give 4-chlorothiophene-2-sulfonamide (1.5 g, 9.37%) as a light yellow solid. 1 H NMR (400MHz, DMSO) δ7.89-7.89 (d, J = 1.6 Hz, 1H), 7.83 (s, 2H), 7.53-7.53 (d, J = 1.2 Hz, 1H).

[1507] Synthesis of 4-(difluoromethyl)thiazole-2-sulfonamide (Int-B-2.25)

[1508]

[1509] Step-1: To a cooled solution of 2-bromothiazole-4-carbaldehyde (5 g, 26.03 mmol) in DCM (50 mL) was added DAST (6.29 g, 39.05 mmol) and stirred at room temperature for 1 hour. The reaction mixture was quenched with ice water and extracted with DCM (2×150 mL). The combined organic layers were dried over Na 2 SO 4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography to give Int-B-2.25-A1 (2.6 g, 46.65%). 1 H NMR (400MHz, DMSO-d6) δ8.19 (s, 1H), 7.08 (t, J = 54Hz, 1H).

[1510] Step-2: To a degassed solution of 2-bromo-4-(difluoromethyl)thiazole (2.6 g, 12.14 mmol) and DIPEA (3.14 g, 24.29 mmol) in dioxane (26 mL) was added Xantphos (0.702 g, 1.21 mmol), Pd2dba3 (0.556 g, 0.6 mmol) and benzyl mercaptan (1.5 g, 12.14 mmol) and the reaction mixture was heated at 100 ° C for 2 hours. After TLC indicated the completion of the reaction, the reaction mixture was filtered through celite and the filtrate was poured into water and extracted with ethyl acetate (2×80 mL). The combined organic layers were washed with brine (2×150 mL), dried over Na2SO4 and evaporated under vacuum. The crude product was subjected to silica gel column chromatography to obtain Int-B-2.25-A2 (2.35 g, 75.18%). LCMS ESI (m / z): 258.38 (M+H).

[1511] Step-3: To a stirred solution of 2-(phenylmethylthio)-4-(difluoromethyl)thiazole (2.35 g, 9.13 mmol) in acetic acid (47 mL) and water (4.7 mL) was added N-chlorosuccinimide (6.09 g, 45.66 mmol) in portions at room temperature and stirred for 2 hours. After TLC indicated the completion of the reaction, the reaction mixture was evaporated under vacuum to remove acetic acid and then partitioned between water (100 mL) and ethyl acetate (100 mL). The organic layer was washed with water (100 mL), dried over Na2SO4 and evaporated under vacuum. The crude mixture was used directly in the next step (3 g, quantitative).

[1512] Step-4: A solution of 4-(difluoromethyl)thiazole-2-sulfonyl chloride (3 g, 12.84 mmol) in THF (15 mL) was added to a saturated ammonia solution in THF (20 mL) at -78°C. A solid precipitated and was evaporated to dryness, and the crude product was purified by silica gel column chromatography to give the title compound Int-B-2.25 (1.4 g, 50.90%). LCMS ESI (-ve) (m / z): 213.3 (MH).

[1513] Synthesis of 4,5-dimethylthiazole-2-sulfonamide (Int-B-2.26)

[1514]

[1515] Step-1: To a solution of 4,5-dimethylthiazole (5.0 g, 44.17 mmol) in CHCl3 (50 mL) was added bromine (21.17 g, 132.52 mmol) at 0 ° C and stirred at room temperature for 5 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into ice-cold water (150 mL) and extracted with DCM (2×150 mL). The combined organic layers were washed with saturated sodium thiosulfate solution (2×150 mL), dried over Na2SO4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography to give Int-B-2.26-A1 (5.0 g, 58.96%). LCMS ESI (m / z): 192.2 & 194.2 (M & M+2).

[1516] Step-2-4: The reaction was carried out using a similar reaction procedure as described for Int-B-2.25 to give 5-bromo-4-methylthiophene-2-sulfonamide. LCMS ESI (m / z): 193.3 (M+H).

[1517] Synthesis of 2-methylthiazole-4-sulfonamide (Int-B-2.27)

[1518]

[1519] Step-1: To a solution of 2,4-dibromothiazole (8 g, 32.92 mmol) in THF (80 mL) was added potassium phosphate (20.98 g, 98.78 mmol) and methylboronic acid (2.08 g, 34.90 mmol) and the mixture was degassed for 30 minutes. Afterwards, Pd(OAc) 3 (0.02 g, 0.82 mmol) and Xanthphos (0.46 g, 0.82 mmol) were added to the reaction mixture and stirred at 60 ° C for 18 hours. After TLC indicated that the reaction was complete, the reaction mixture was filtered through celite and washed with DCM, then evaporated under vacuum. (3.8 g, 64.80%). LCMS ESI (m / z): 178.2 & 180.2 (M & M + 2).

[1520] Step-2-4: The reaction was carried out using a similar reaction procedure as described for Int-B-2.25 to give 2-methylthiazole-4-sulfonamide. LCMS ESI (m / z): 179.2 (M+H).

[1521] Synthesis of 4-phenylthiophene-3-sulfonamide (Int-B-2.28)

[1522]

[1523] Step-1: To a degassed solution of 3,4-dibromothiophene (5 g, 20.66 mmol) and DIPEA (7.1 mL, 41.33 mmol) in dioxane (50 mL) was added benzylmercaptan (2.5 g, 20.66 mmol), Xantphos (1.2 g, 2.06 mmol) and Pd2(dba)3 (0.94 g, 1.03 mmol) and the reaction mixture was heated at 100 ° C for 16 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (200 mL) and extracted with ethyl acetate (4×100 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude mixture was purified by silica gel column chromatography to give Int-B-2.28-A1 (3 g, 84.88%). DMSO-d6)δ:7.80(d,J=3.2Hz,1H),7.44(d,J=3.2Hz,1H),7.32-7.23(m,5H),4.17(s,2H).

[1524] Step-2: To a degassed solution of 3-(phenylmethylthio)-4-bromothiophene (1 g, 35.08 mmol), phenylboronic acid (0.64 g, 52.63 mmol) and Cs2CO3 (3.4 g, 10.52 mmol) in dioxane (10 mL) was added Pd(dppf)Cl2.DCM complex (0.28 g, 35.08 mmol)) and the reaction mixture was heated at 100°C for 2 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (2×100 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated under vacuum. The crude mixture was purified by silica gel column chromatography to give Int-B-2.28-A2 (0.9 g, 90.83%). 1 H-NMR (400MHz, DMSO-d6) δ: 7.63 (d, J = 4Hz, 1H), 7.50-7.35 (m, 6H), 7.30-7.20 (m, 5H), 4.04 (s, 2H).

[1525] Step-3-4: The reaction was carried out using a similar reaction procedure as described for Int-B-2.25 to give 4-phenylthiophene-3-sulfonamide, Int-B-2.28. LCMS ESI (m / z): 179.2 (M+H).

[1526] Synthesis of Thieno[3,2-b]pyridine-3-sulfonamide (Int-B-2.29)

[1527]

[1528] Step-1: To a suspension of 10% Pd / C (5 g) in methanol (100 mL) was added 7-chlorothieno[3,2-b]pyridine (5 g, 29.47 mmol) at room temperature. Hydrogen was purged through the reaction mixture for 0.5 h. After TLC indicated the reaction was complete, the reaction mixture was filtered through a bed of celite. The filtrate was concentrated in vacuo to afford thieno[3,2-b]pyridine as a solid. LCMS (m / z): 136.01 (M+H).

[1529] Step-2: To a stirred solution of thieno[3,2-b]pyridine (4.6 g, 34.04 mmol) in acetic acid (24 mL) and DCM (46 mL) was added NBS (9.09 g, 35.75 mmol) at room temperature and stirred at 50 ° C for 1.5 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into cold water and extracted with ethyl acetate. The combined organic layer was washed with brine and NaOH solution, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was used directly in the next step. 1H-NMR (400MHz, DMSO-d6) δ: 7.48-7.51 (m, 1H), 8.38 (s, 1H), 8.57-8.59 (d, J = 8.4Hz, 1H), 8.77-8.78 (d, J = 4.4Hz, 1H).

[1530] Step-3-4: The reaction was carried out using a similar reaction procedure as described for Int-B-2.25 to give thieno[3,2-b]pyridine-3-sulfonamide. LCMS ESI (m / z): 215.3 (M+H) 。

[1531] Synthesis of 4-bromothiophene-2-sulfonamide (Int-B-2.30)

[1532]

[1533] Step-1: At 0 ° C, 2M iPrMgCl (23 mL, 45.454 mmol) was added to a stirred solution of 2,4-dibromothiophene (10 g, 41.322 mmol) in THF (100 mL) and stirred at room temperature for 1 hour. The reaction mixture was cooled to -40 ° C and purged with SO2 gas at -40 ° C for 30 minutes. The reaction mixture was cooled to 0 ° C and N-chlorosuccinimide (8.24 g, 61.983 mmol) was added and stirred at room temperature for 1 hour. After the reaction was completed by TLC monitoring (mobile phase: 100% ethyl acetate), the reaction mixture was quenched in 10% HCl (100 mL) and extracted with diethyl ether (2 × 100 mL), and the organic layer was dried over Na2SO4 and concentrated under reduced pressure to give Int-B-2.30-A1 (10 g, 92.50%) as a yellow liquid. The crude product was used in the next step without any further purification and without any analytical confirmation.

[1534] Step-2: The reaction was carried out using a similar reaction procedure as described for Int-B-2.6 to give 4-bromothiophene-2-sulfonamide, Int-B-2.30. LCMS ESI (-ve) (m / z): 242.2 & 240.2 (M & M-2).

[1535] Synthesis of 5-cyanothiophene-3-sulfonamide (Int-B-2.31)

[1536]

[1537] Step-1: To a solution of 4-bromothiophene-2-carboxaldehyde (1 g, 26.1 mmol) in THF (10 mL) was added aqueous ammonia solution (100 mL) at 0°C and stirred for 10 minutes. Afterwards, I2 (iodine) (9.9 g, 39.6 mmol) was added and the reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into a saturated sodium thiosulfate solution and extracted with ethyl acetate (3×100 mL). The combined organic layers were dried over Na2SO4 and evaporated under vacuum. The crude product was purified by column chromatography to give 4-bromothiophene-2-carbonitrile (0.65 g, 66.3%). 1 H NMR (400MHz, DMSO) δ8.19(s,1H),8.10(s,1H).

[1538] Step-2-4: The reaction was carried out using a similar reaction procedure as described for Int-B-2.25 to give 5-cyanothiophene-3-sulfonamide. LCMS ESI (-ve) (m / z): 187.0 (MH).

[1539] Synthesis of 4-cyanothiophene-2-sulfonamide (Int-B-2.32)

[1540]

[1541] Step-1: To a solution of thiophene-3-carbonitrile (1 g, 9.16 mmol) in CHCl 3 (10 mL) and acetic acid (5 mL) was added N-bromosuccinimide (2.52 g, 13.74 mmol) portionwise and the mixture was stirred at 70 ° C overnight. The reaction mixture was quenched with water and extracted with DCM (2×50 mL). The combined organic layers were washed with dilute NaOH solution (3×100 mL), dried over Na 2 SO 4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography to give Int-B-2.32-A1 (0.540 g, 31.34%). 1 H NMR (400MHz, DMSO-d6) δ8.58(s,1H),7.72(s,1H).

[1542] Step-2-4: The reaction was carried out using a similar reaction procedure as described for Int-B-2.25 to give 4-cyanothiophene-2-sulfonamide, Int-B-2.32. LCMS ESI (-ve) (m / z): 186.9 (MH).

[1543] Synthesis of 4-methylthiophene-3-sulfonamide (Int-B-2.33)

[1544]

[1545] Step-1: To a degassed solution of 3-bromo-4-methylthiophene (1 g, 5.6 mmol) and DIPEA (1.46 g, 11.2 mmol) in dioxane (5 mL) was added Xantphos (0.40 g, 0.7 mmol), Pd2dba3 (0.32 g, 0.35 mmol) and benzylmercaptan (0.510 g, 0.5 mmol) and the reaction mixture was heated at 120 ° C for 16 hours. After TLC indicated the completion of the reaction, the reaction mixture was filtered through celite and the filtrate was poured into water (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was subjected to silica gel column chromatography to give Int-B-2.33-A1 (1 g, 80.44%). 1 H NMR (400MHz, DMSO) δ7.33-7.23(m,7H),4.07(s,2H),2.08(s,3H).

[1546] Step-2: To a stirred solution of 3-(phenylmethylthio)-4-methylthiophene (2 g, 9.085 mmol) in acetic acid (18 mL) and water (2 mL) was added N-chlorosuccinimide (4.8 g, 36.3 mmol) portionwise at room temperature and stirred for 30 minutes. After TLC indicated the completion of the reaction, the reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (3×150 mL). The combined organic layers were washed with brine, dried over Na 2 SO 4 and evaporated in vacuo to afford Int-B-2.332-A2 (2 g, crude), which was used directly in the next step without analysis. 1 H NMR (400MHz, DMSO) δ 8.01 (d, J = 3.2 Hz, 1H), 7.35 (bs, 2H), 7.33 (d, J = 1.6 Hz, 1H), 2.36 (s, 3H).

[1547] Step-3: Ammonia gas was bubbled into a solution of 4-(difluoromethyl)thiazole-2-sulfonyl chloride (2 g, 10.20 mmol) in THF (10 mL) at -78°C for 2 hours, followed by stirring at room temperature. The reaction mixture was quenched with water (100 mL) and extracted with ethyl acetate (2×100 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under vacuum to give the crude title compound, Int-B-2.33 (2 g, quantitative). 1H NMR (400 MHz, DMSO) δ 8.01 (d, J = 3.2 Hz, 1H), 7.35 (bs, 2H), 7.33 (d, J = 1.6 Hz, 1H), 2.36 (s, 3H).

[1548] Synthesis of 5-chloro-4-methylthiophene-3-sulfonamide (Int-B-2.34)

[1549]

[1550] Step-2: To a stirred solution of 3-(phenylmethylthio)-4-methylthiophene (1.2 g, 5.44 mmol) in acetic acid (7 mL) and water (1 mL) was added N-chlorosuccinimide (2.9 g, 21.78 mmol) portionwise at room temperature and stirred for 2 hours. After TLC indicated the reaction was complete, the reaction mixture was poured into water (100 mL) and extracted with ethyl acetate (3×150 mL). The combined organic layers were washed with brine, dried over Na 2 SO 4 , and evaporated in vacuo to give the title compound (1 g, 80%), which was used directly in the next step without purification or analysis.

[1551] Step-3: The reaction was carried out using a similar reaction procedure as described for Int-B-2.33 to give 4-methyl-5-chlorothiophene-3-sulfonamide, Int-B-2.34. LCMS ESI (-ve) (m / z): 210.01 (M-1).

[1552] Synthesis of benzo[d]isothiazole-3-sulfonamide (Int-B-2.51)

[1553]

[1554] Step-1: To a stirred solution of 3-chlorobenzo [d] isothiazole (5.0 g, 29.5 mmol) in DMF (30 mL) was added Na2S and the reaction mixture was heated at 80 ° C for 1 hour. After TLC indicated the completion of the reaction, the reaction mixture was poured into cold water (100 mL) and acidified with 2N HCl (about pH 2) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give Int-B-2.51-A1 (5.0 g, quantitative) in crude form. LCMSESI (m / z): 168.2 (M+H).

[1555] Step-2: To a solution of benzo[d]isothiazole-3-thiol (5 g, 29.5 mmol) in dichloromethane (40 mL) was added concentrated HCl (40 mL) and 5% NaOCl solution (11.1 g, 215.74 mmol) at -5°C, followed by stirring at -5°C for 1 hour. After TLC indicated the completion of the reaction, the reaction mixture was diluted with water (100 mL) and extracted with dichloromethane (3×25 mL). The combined organic layers were dried over Na 2 SO 4 and used directly in the next step without evaporation.

[1556] Step-3: Benzo[d]isothiazole-3-sulfonyl chloride in DCM (75 mL) was added to a freshly prepared saturated ammonia solution in THF (30 mL) at -78°C and stirred for 1 hour. After TLC indicated the reaction was complete, the reaction mixture was evaporated under vacuum. The crude product was purified by silica gel column chromatography (50% ethyl acetate / hexane) to give benzo[d]isothiazole-3-sulfonamide, Int-B-2.51 (1.4 g, 21.85% over 3 steps). 1 H NMR (400MHz, DMSO) δ 8.44 (d, J = 8.4 Hz, 1H), 8.36 (d, J = 8.4 Hz, 1H), 8.10 (s, 2H), 7.73 (t, J = 7.6 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H).

[1557] The following intermediates were prepared following similar procedures to those shown above.

[1558]

[1559]

[1560]

[1561]

[1562] Synthesis of 4,5-difluorothiophene-2-sulfonyl chloride (Int-C-4.0)

[1563]

[1564] Step-1: The starting material Int-C-1 (450 mg, 2.5 mmol) was dissolved in dioxane (5 mL). Xanthphos (143.83 mg), Pd2(dba)3 (113.82 mg), DIPEA (860 uL, 643 mg, 5 mmol) and benzylmercaptan (309 mg, 2.5 mmol) were added to the solution. The mixture was heated at 90 ° C. under an Ar atmosphere for 4 hours in a pressure vessel. After cooling to room temperature, the mixture was applied to a silica gel column and the product Int-C-2 (480 mg, 86%) was isolated by elution with a mixture of hexane and ethyl acetate (20:1–10:1). 1 H NMR (400MHz, CDCl3) δ7.32–7.21(m,3H),7.20–7.15(m,2H),6.73–6.58(m,2H),3.97(s,2H).

[1565] Step-2: At a temperature below -78 ° C, nBuLi (2.5M / hexane, 0.72 mL, 1.79 mmol) was added dropwise to a solution of Int-C-2 (365 mg, 1.62 mmol) in THF (15 mL) under Ar. After the mixture was stirred for 1 hour, N-fluorobenzenesulfonamide (923.6 mg, 2.9 mmol) in THF (5 mL) was added dropwise. The reaction mixture was warmed to room temperature. Aqueous NH4Cl solution was added to the reaction mixture, which was then extracted with Et2O (80 mL), washed with water, dried over MgSO4 and concentrated. Column chromatography (silica, hexane) was performed to give Int-C-3 (119 mg, 30%). The product was subjected to the next step without characterization.

[1566] Step-3: To a mixture of 2M HCl aqueous solution (1 mL) and CH3CN (3 mL) was added NCS (304.2 mg, 2.29 mmol) and the solution was cooled to 10 ° C., and a solution of Int-C-3 (138 mg, 0.57 mmol) in CH3CN (5 mL) was slowly added. The mixture was stirred at low temperature for 30 minutes (UPLC control). The reaction mixture was diluted with Et2O and washed with water. The organic phase was dried over MgSO4 and evaporated. The residue was purified by column chromatography on silica gel, eluting with a mixture of hexane and ethyl acetate (15: 1) to give the product Int-C-4 (102 mg, 82%). 1 H NMR (400 MHz, chloroform-d) δ 7.59 (d, J = 3.8 Hz, 1H).

[1567] Synthesis of 5-cyano-2-fluorobenzenesulfonamide (Int-D-2.0)

[1568]

[1569] Int-D-1.0 (1.0 g, 4.55 mmol) was dissolved in DCM and the solution was cooled to -78°C. Ammonia gas was passed through the solution to reach saturation. The mixture was warmed to room temperature and the solvent was evaporated. The residue was purified by flash chromatography on silica gel eluting with a mixture of light petroleum ether and ethyl acetate to give Int-D-2.0 (720 mg, 79%). 1 H NMR (300MHz, DMSO-d6) δ8.25–8.14(m,2H),7.94(s,2H),7.71(dd,J=9.9,9.2Hz,1H).

[1570] The following intermediates were prepared according to the procedure described for Int-D-2.0.

[1571]

[1572]

[1573] Synthesis of 2-bromo-3-phenylthiophene (Int-E-3)

[1574]

[1575] Step-1: To a mixture of bromobenzene (1.65 mL, 15.6 mmol), 3-thiopheneboronic acid (Int-E-1) (2.0 g, 15.6 mmol) and 1,2-dimethoxyethane (32 mL) were added 2 M aqueous sodium carbonate solution (12 mL) and tetrakis(triphenylphosphine)palladium(0) (903 mg) at ambient temperature. The mixture was heated at 90 ° C for 3 hours. After cooling, the reaction mixture was diluted with ethyl acetate (200 mL) and washed with water (50 mL×3) and brine (50 mL). The organic layer was dried over magnesium sulfate and filtered. After evaporation, the residue was purified by chromatography on silica gel eluting with a mixture of ethyl acetate and n-hexane (1:2) to give Int-E-2 (2.0 g, 79%).

[1576] Step-2: To a solution of Int-E-2 (1.1 g, 6.9 mmol) in DMF (30 mL) was added NBS (1.34 g, 7.55 mmol) in one portion. The reaction mixture was stirred overnight, then diluted with water and the product was extracted with EtOAc. The organic phase was separated and dried over Na2SO4, filtered and evaporated to give the product as a yellow oil (1.6 g 97%), which was used further without additional purification.

[1577] Synthesis of 3-bromo-1-(4-methoxybenzyl)-1H-pyrazole (Int-E-5)

[1578]

[1579] Int-E-4 (2.0 g, 13.6 mmol) was dissolved in MeCN (20 mL) and KCO (2.85 g, 20.6 mmol) was added to the solution followed by p-methoxybenzyl chloride (2.3 mL, 16.6 mmol). The reaction mixture was refluxed for 18 hours, cooled to room temperature and diluted with water (30 mL). The resulting mixture was extracted with EtOAc, the organic phase was separated and washed with saturated aqueous NaCl solution. The organic extract was dried over NaSO, the solvent was evaporated and the residue was purified by flash chromatography on silica gel eluting with a mixture of light petroleum ether and ethyl acetate (5:1) to give Int-E-5 (3.17 g, 87%). 1H NMR (300MHz, CDCl3) δ7.41–7.20(m,3H),6.98–6.88(m,2H),6.33(d,J=2.3Hz,1H),5.27(s,2H),3.88(s,3H).

[1580] Synthesis of N-((4-bromothiophen-2-yl)methyl)-N-(4-methoxybenzyl)acetamide (Int-E-7)

[1581]

[1582] Step-1: 4-Bromo-2-thiophenecarboxaldehyde (Int-E-6) (2.77 g, 14.5 mmol) was dissolved in MeOH (27 mL) and the mixture was stirred at room temperature overnight. Then, NaBH4 (880 mg, 23.3 mmol) was added portionwise. After stirring at room temperature for 2 hours, water and ethyl acetate were added, and the organic layer was separated, washed with brine and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (Hex:EtOAc=5:1 to 3:1) to give Int-E1-6 (3.14 g, 69%) as an off-white amorphous solid. 1 H NMR (300 MHz, chloroform-d) δ 7.32–7.23 (m, 2H), 7.15 (d, J = 1.5 Hz, 1H), 6.94–6.89 (m, 2H), 6.88–6.86 (m, 1H), 3.96 (d, J = 1.0 Hz, 2H), 3.84 (s, 3H), 3.79 (s, 2H).

[1583] Step-2: To a solution of Int-E1-6 (1.27 g, 4.06 mmol) in DCM (30 mL) was added DIPEA (1.4 mL, 8.1 mmol), acetic anhydride (0.58 mL, 6.1 mmol) and DMAP (149 mg, 1.2 mmol). The mixture was stirred at room temperature overnight. Extractive workup gave virtually pure Int-E-7 (1.4 g, 97%). 1 H NMR (400MHz, CDCl3) δ7.22–7.05(m,3H),6.98–6.62(m,3H),4.64–4.36(m,4H),3.81(d,J=7.5Hz,3H),2.40–1.99(m,3H).

[1584] Synthesis of 2-fluoro-3-bromothiophene (Int-E-9)

[1585]

[1586] Under Ar, n-BuLi (2.5M / hexane, 8.0mL, 19.9mmol) was added dropwise to a solution of Int-E-8.0 (2mL, 18.1mmol) in anhydrous ether (70mL) at a temperature below -60°C. After the mixture was stirred for 1 hour, N-fluorobenzenesulfonamide (11.4g, 36.2mmol) in THF (70mL) was added dropwise. The reaction mixture was warmed to room temperature. Aqueous NH4Cl solution was added to the reaction mixture, followed by extraction with Et2O, washed with water, dried over MgSO4 and concentrated. The product was purified by column chromatography on silica gel eluting with pentane to give Int-E-9.0 (2.1g, 64%). 1 H NMR (300 MHz, chloroform-d) δ 6.74–6.65 (m, 2H). GC / MS m / z 181 (M).

[1587] The following intermediates were prepared according to the procedure described for Int-F-3.0.

[1588]

[1589] Synthesis of 5-fluorothiophene-3-sulfonamide (Int-G-3.0)

[1590]

[1591] Step-1: A mixture of Int-E-8.1 (1.159 g, 6.6 mmol), methyl 3-mercaptopropionate (1.42 mL, 13.2 mmol), Pd2(dba)3 (181 mg, 0.2 mmol), xanthphos (229 mg, 0.4 mmol) and DIPEA (2.85 mL, 16.5 mmol) was heated in dioxane (20 mL) at 90°C for 2 h. The mixture was cooled to room temperature and filtered through a short celite column. The solvent was evaporated and the residue was purified by column chromatography on a silica gel column using a mixture of light petroleum ether and EtOAc (10: 1) to give Int-G-1.0, which was subjected to step-2.

[1592] Step-2: Under an Ar atmosphere, the starting material Int-E-3.0 (1.33 g, 6.02 mmol) was dissolved in anhydrous DCM (16 mL). The solution was cooled to 0 ° C and m-CPBA (2.6 g, 15.04 mmol) was added in portions. The mixture was stirred at the same temperature for 1 hour, and then the mixture was warmed to room temperature. After 2 hours, m-CPBA (1 equivalent) was added. The mixture was stirred until the starting material was exhausted. The reaction mixture was diluted with an aqueous solution of NaHCO 3 . The organic phase was separated, and the aqueous phase was extracted with DCM (twice). The combined organic phases were dried over Na 2 SO 4 , filtered and evaporated. The product was purified by column chromatography on silica gel, eluting with a mixture of light petroleum ether and EtOAc (10: 1 to 3: 1). The fraction containing the product and defluorinated impurities was purified again (same eluent system). The desired product Int-G-2.0 was obtained as a colorless oil, which was subjected to step-3.

[1593] Step-3: Int-G-2.0 (1.05 g, 4.16 mmol, 1 equivalent) was dissolved in anhydrous MeOH (9 mL). NaOMe (0.81 mL, 4.37 mmol, 1.05 equivalents) was added to the solution. The solution was stirred at room temperature until the starting material was exhausted (TLC control). The solvent was evaporated under reduced pressure (in the presence of toluene). At 0 ° C, the crude residue was suspended in anhydrous DCM (9 mL) and NCS (583.55 mg, 4.37 mmol) was added. The mixture was stirred at the same temperature until completion (TLC control). Then, water was added. The phases were separated and the aqueous layer was extracted with DCM (twice). The combined organic phases were dried over anhydrous Na2SO4, filtered, and the solvent was partially evaporated under reduced pressure (until about 20-30 mL). The solution was cooled to 0 ° C and ammonia (gas) was passed through. The reaction mixture was evaporated onto silica and the product was purified by column chromatography on silica gel, eluting with a mixture of light petroleum ether and EtOAc (10:1 to 1:1). 1 H NMR (400MHz, DMSO-d6) δ7.55 (dd, J=3.9, 2.1Hz, 1H), 7.45 (s, 2H), 6.98 (dd, J=2.1, 1.2Hz, 1H).

[1594] The following intermediates were prepared according to the procedures described for Int-G-3.0.

[1595]

[1596]

[1597] Synthesis of 4-fluorothiophene-2-sulfonamide (Int-G-3.4)

[1598]

[1599] Under Ar atmosphere, the starting material Int-F-3.0 (267g, 1.6mmol) was dissolved in a mixture of anhydrous DCM (16mL) and DME (4mL). The solution was cooled to 0 ° C and m-CPBA (517mg, 2.1mmol) was added. The mixture was warmed to room temperature and stirred at room temperature overnight. The reaction mixture was diluted with a NaHCO3 aqueous solution. The organic phase was separated and the aqueous phase was extracted with DCM (twice). The combined organic phases were dried over Na2SO4, filtered, and evaporated. The product Int-G-3.4 (290mg, 99%) was purified by column chromatography on silica gel using a mixture of light petroleum ether and EtOAc (2: 1) for elution. 1 H NMR (300MHz, CDCl3) δ7.43 (dd, J = 1.8, 1.1 Hz, 1H), 7.01 (dd, J = 1.8, 0.7 Hz, 1H), 4.98 (s, 2H).

[1600] Synthesis of 4-methoxythiophene-2-sulfonamide (Int-G-3.8)

[1601]

[1602] Step-1: Under nitrogen, n-BuLi solution (14.4 mL of 2.5 M / hexane, 36.0 mmol) was added dropwise to a solution of 3-methoxythiophene (Int-G-3.5) (3.0 mL, 30.0 mmol) in anhydrous Et2O (20 mL) at -70 ° C. The mixture was stirred for 2 hours at -70 ° C. Chlorotrimethylsilane (5.0 mL, 39.0 mmol) was slowly added to the solution. The mixture was warmed to room temperature and stirred overnight. The reaction mixture was quenched with water (50 mL) and hexane (100 mL) was added. The organic phase was separated, and the aqueous layer was extracted with hexane (50 mL). The combined organic extracts were dried over Na2SO4, filtered and concentrated. The crude product was purified by chromatography on silica gel, eluting with hexane to give Int-G-3.6 (2.05 g, 37%). 1 H NMR (300MHz, CDCl3) δ7.32 (d, J = 4.9 Hz, 1H), 6.84 (d, J = 4.9 Hz, 1H), 3.73 (s, 3H), 0.20 (s, 9H).

[1603] Step-2: Under nitrogen, a solution of n-BuLi (6.6mL of 2.5M / hexane, 16.5mmol) was added dropwise to a solution of Int-G-3.6 (2.05g, 11.0mmol) in anhydrous THF (40mL) at -70°C. The mixture was stirred for 2 hours, and then sulfur dioxide was passed through the solution for 5 minutes. The reaction mixture was evaporated and dissolved in DCM (40mL). N-chlorosuccinimide (1.47g, 11.0mmol) was added and the mixture was stirred at room temperature for 1 hour. Water was added, and the organic phase was separated and washed with water. The organic phase was dried and evaporated. The residue was dissolved in THF (40mL), the mixture was cooled in a dry ice bath, and NH3 gas was passed through. The mixture was warmed to room temperature and kept overnight, then evaporated. The product was purified by chromatography on silica gel, eluting with a mixture of light petroleum ether and ethyl acetate (2:1, 1:1) to afford Int-G-3.7 (1.7 g, 58%). 1 H NMR (300MHz, DMSO-d6) δ7.61(s,2H),7.50(s,1H),3.80(s,3H),0.27(s,9H).

[1604] Step-3: To a solution of Int-G-3.7 (1.7 g, 6.4 mmol) in THF (30 mL) was added tert-butylammonium fluoride (4.04 g, 12.8 mmol). The reaction mixture was stirred at room temperature for 2 hours. THF was removed under reduced pressure. The residue was dissolved in EtOAc (200 mL). The organic layer was washed with brine, then dried (Na2SO4), filtered, and concentrated in vacuo. The crude product was chromatographed on silica gel and eluted with Hex:EtOAc (3:1) to give Int-G-3.8 (yield 1.2 g, 98%). 1 H NMR (300MHz, DMSO-d6) δ7.64 (s, 2H), 7.20 (d, J = 2.0 Hz, 1H), 6.91 (d, J = 2.0 Hz, 1H), 3.76 (s, 3H).

[1605] Synthesis of N-(tert-butyldimethylsilyl)pyridine-4-sulfonamide (Int-B-3.1)

[1606]

[1607] Step-1: At 0 ° C, sodium hydride (0.33 g, 8.23 ​​mmol) was added to a stirred solution of pyridine-4-sulfonamide (0.65 g, 4.11 mmol) in THF (26 mL) and stirred for 20 minutes. TBDMS-Cl (0.65 g, 1.05 mmol) was added to the reaction mixture and stirred at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude material, which was ground using n-pentane to give Int-B-2.1 (1 g, 49%) as a white solid. Then, it was used in the next step.

[1608] Step-2: To a stirred solution of triphenylphosphine (0.5 g, 1.91 mmol) in chloroform (5 mL) was added hexachloroethane (0.45 g, 1.91 mmol) and stirred at 75° C. for 16 hours. After TLC indicated the completion of the reaction, the product 1,1-dichloro-2-4-diphosphane was used directly in the next step.

[1609] At 0 ° C, DIPEA (0.43 g, 3.31 mmol) was added to a solution of 1,1-dichloro-2-4-diphosphine (0.63 g, 1.90 mmol) in chloroform (5 mL) and the reaction mixture was stirred for 10 minutes. A solution of Int-B1-3.1 (0.45 g, 1.6544 mmol) in chloroform (4.5 mL) was added to the reaction mixture and stirred for another 30 minutes. Ammonia gas was blown into the reaction mixture and stirred at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was poured into a 5% aqueous citric acid solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude material, which was ground using n-pentane to give the title compound Int-B-3.1 (0.93 g, quantitative) as a yellow oil. LCMS ESI (m / z): 272.5 (M + 1).

[1610] Step-1: Synthesis of Int-B-3.2

[1611]

[1612] Step-1: Under N2 atmosphere, to a stirred solution of Int-B-2.2 (300 mg, 1.68 mmol) in THF (3 mL) was added 60% NaH (130 mg, 3.37 mmol) at 0 ° C., followed by TBDMS-Cl (300 mg, 2.02 mmol) and stirred at room temperature for 4 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layer was washed with brine, dried over Na2SO4 and evaporated in vacuo to give Int-B-2.2 (350 mg, 71.42%) as an off-white solid.

[1613] Step-2: Under stirring, a solution of triphenylphosphine (800mg, 3.05mmol) and hexachloroethane (720mg, 3.05mmol) in CHCl (24mL) was heated overnight at 70°C. At room temperature, DIPEA (0.25mL, 1.4mmol) was added and stirred for 30 minutes under N atmosphere. Subsequently, at 0°C, N-(tert-butyldimethylsilyl)-4-methylthiazole-2-sulfonamide (350mg, 1.19mmol) in CHCl (5mL) was added thereto and stirred for 30 minutes at 0°C. At 0°C, NH gas was passed into the reaction mixture for 1 hour, and the mixture was stirred for 30 minutes at room temperature. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with DCM. The combined organic layer was washed with brine, dried over NaSO, and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 4:6) to give the title compound Int-B-3.2 (130 mg, 38.23%) as a white solid. 1 H-NMR (400MHz, DMSO-d6) δ: 7.48 (s, 1H), 7.17 (s, 2H), 2.37 (s, 3H), 0.86 (s, 9H), 0.01 (s, 3H), 0.015 (s, 3H).

[1614] The following intermediates were prepared according to the procedure described for Int-B-3.2.

[1615]

[1616]

[1617]

[1618]

[1619]

[1620]

[1621]

[1622]

[1623]

[1624]

[1625]

[1626] Synthesis of pyridine-4-sulfonylimide amide (Int-B-4.1)

[1627]

[1628] To a stirred solution of (Int-B-3.1) (0.93 g, 3.43 mmol) in dichloromethane (20 mL) was added 4M HCl in dioxane (0.25 g, 6.86 mmol) at 0°C, followed by stirring at room temperature for 1 hour. After TLC indicated the reaction was complete, the reaction mixture was concentrated in vacuo. The crude product was purified by trituration with ethyl acetate to give the title compound Int-B-4.1 (0.2 g, 37%). LCMS ESI (m / z): 158.1 (M+1).

[1629] The following intermediates were prepared according to the procedure described for Int-B-4.1.

[1630]

[1631]

[1632]

[1633]

[1634]

[1635] Synthesis of ((2S)-1-((amino(oxo)(pyridin-4-yl)-λ6-sulfanylidene)amino)-4-methyl-1-oxo tert-Butyl (pentan-2-yl)carbamate (Int-B-5.1, Int-B-5.1-Fr-1 and Int-B-5.1-Fr-2)

[1636]

[1637] To a stirred solution of pyridine-4-sulfonylimide amide (Int-B-4.1) (0.1 g, 0.64 mmol) in DMF (4 mL) was added sodium hydride (46 mg, 1.91 mmol) at 0 ° C. and the reaction mixture was stirred for 20 minutes. Int-X1 (0.209 g, 0.63 mmol) was added to the reaction mixture and stirred for 6 hours. After TLC indicated that the reaction was complete, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude material, which was purified by reverse phase flash chromatography using water: acetonitrile (3: 1) to give Int-B-5.1 (90 mg, 38%) as a mixture of diastereomers. LCMS ESI (m / z): 371.3 (M + 1).

[1638] The diastereomers were separated by chiral preparative HPLC (DIACEL Chiral PAK_IG, mobile phase: A = heptane, B = IPA: MeOH (70:30), A: B = 70:30) to give Isomer-1 and Isomer-2. These isomers eluted at retention times of 9.62 minutes (Isomer-1) and 12.50 minutes (Isomer-2).

[1639] The following intermediates were prepared according to the procedure described for Int-B-5.1.

[1640]

[1641]

[1642]

[1643]

[1644]

[1645]

[1646]

[1647]

[1648]

[1649]

[1650]

[1651]

[1652]

[1653]

[1654]

[1655]

[1656]

[1657]

[1658]

[1659]

[1660]

[1661]

[1662]

[1663]

[1664]

[1665]

[1666]

[1667]

[1668]

[1669] Synthesis of ((2S)-1-((amino(4-methylthiazol-2-yl)(oxo)-λ6-sulfanylidene)amino)-4-methyl-1- tert-Butyl 2-oxopentan-2-yl)carbamate (Int-B-5.2)

[1670] Pathway A

[1671]

[1672] At room temperature, to a stirred solution of Int-B-3.2 (70 mg, 0.24 mmol) in DMF (0.7 mL) was added 60% NaH (28 mg, 0.72 mmol), followed by addition of Int-X1 (78 mg, 0.24 mmol) and stirred for 3 hours. After TLC indicated the completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4 and evaporated in vacuo to give a crude product. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane: 4: 6) to give the title compound Int-B-5.2 (35 mg, 28.92%) as a white solid. It was observed that the TBDMS group cracked during treatment / purification. LCMS ESI (m / z): 413.1 (M+Na).

[1673] Pathway B

[1674]

[1675] Step-1: Int-B-4.2 was prepared according to the procedure described for Int-B-4.1. 1 HNMR (400MHz, DMSO) δ7.63 (s, 1H), 2.43 (s, 3H).

[1676] Step-2: Int-B-5.2 was prepared according to the procedure described for Int-B-5.1.

[1677] In addition, the diastereomers were separated by chiral preparative HPLC (chiral preparative HPLC: YMC CHIRALARTCELLULOSE_SC, mobile phase: heptane_IPA-ACN(70-30)_85:15) to give Isomer-1 and Isomer-2. These isomers eluted at retention times of 13.16 minutes (Isomer-1) and 18.41 minutes (Isomer-2).

[1678] The following intermediates were prepared according to the procedure described for Int-B-5.2.

[1679]

[1680]

[1681]

[1682]

[1683]

[1684] Synthesis of (2S)-2-amino-N-(amino(oxo)(pyridin-4-yl)-λ 6 -sulfanylidene)-4-methylpentanamide(2S)-2-amino-N-(amino(oxo)(pyridin-4-yl)-λ 6 -sulfanylidene)-4-methylpentanamide

[1685] (ANASIA-059)

[1686]

[1687] At 0 ° C, to a solution of Int-B-5.1-Fr-1 (isomer-1) (16 mg, 0.04 mmol) in dichloromethane (1 mL) was added 4M HCl in 1,4-dioxane solution (0.1 mL). The reaction mixture was stirred at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure and then triturated with n-pentane and diethyl ether to give the title compound ANASIA-059-1 (11 mg, 94%) as a hydrochloride salt. 1 H-NMR (400 MHz, DMSO-d6) δ: 8.90 (d, J = 5.6 Hz, 2H), 8.33 (brs, 2H), 8.10 (brs, 3H), 7.89 (d, J = 6 Hz, 2H); 3.80-3.70 (m, 1H); 1.79-1.57 (m, 3H), 0.91-0.87 (two d, 6H). LCMS ESI (m / z): 271.44 (M+1). Purity at 210 nm: 95.04%.

[1688] At 0 ° C, to a solution of Int-B-5.1-Fr-2 (isomer-2) (30 mg, 0.08 mmol) in dichloromethane (1 mL) was added 4M HCl in 1,4-dioxane solution (0.1 mL). The reaction mixture was stirred at room temperature for 1 hour. After TLC indicated that the reaction was complete, the reaction mixture was concentrated under reduced pressure and then triturated with n-pentane and diethyl ether to give the title compound ANASIA-059-2 (13 mg, 59.38%) as a hydrochloride salt. 1 H-NMR (400 MHz, DMSO-d6) δ: 8.97 (brs, 2H), 8.39 (brs, 2H), 8.14 (brs, 3H), 7.93 (brs, 2H); 3.66 (brs, 1H); 1.74-1.45 (m, 3H), 0.87-0.84 (both d, 6H). LCMS ESI (m / z): 271.40 (M+1). Purity at 210 nm: 97.87%.

[1689] Synthesis of (2S)-2-amino-N-(amino(4-methylthiazol-2-yl)(oxo)-λ6-sulfanylidene)-4-methylpentane Amide hydrochloride (ANASIA-004)

[1690]

[1691] A solution of Int-B-5.2 (33 mg, 0.06 mmol) in 4M HCl in 1,4-dioxane (0.5 mL) was stirred at room temperature for 2 hours. After TLC indicated completion of the reaction, the reaction mixture was concentrated under reduced pressure and then triturated with n-pentane and diethyl ether to afford the title compound ANASIA-004 (11 mg, 57.89%) as a hydrochloride salt. 1 H-NMR (400 MHz, DMSO-d6) δ: 8.50-8.45 (m, 2H), 8.06 (m, 3H), 7.73 (s, 1H), 3.69-3.65 (m, 1H), 2.41-1.47 (m, 3H), 2.31 (s, 3H), 0.91-0.86 (m, 6H). LCMS ESI (m / z): 291.0 (M+H), purity at 210 nm: 100%.

[1692] The following compounds were prepared according to the procedure described for compound ANASIA-004 using HCl or TFA.

[1693]

[1694]

[1695]

[1696]

[1697]

[1698]

[1699]

[1700]

[1701]

[1702]

[1703]

[1704]

[1705]

[1706]

[1707]

[1708]

[1709]

[1710]

[1711]

[1712]

[1713]

[1714]

[1715]

[1716]

[1717]

[1718]

[1719]

[1720]

[1721]

[1722] Synthesis of 3-(N'-(L-leucyl)sulfonamidoimido)thiophene-2-carboxamide hydrochloride

[1723] (ANASIA-093)

[1724]

[1725] Step-1: In an autoclave, methyl 3-(N'-((tert-butoxycarbonyl)-L-leucyl)sulfonamidoimido)thiophene-2-carboxylate (0.11 g, 0.26 mmol) was dissolved in THF (2 mL) and a saturated ammonia solution in THF (5 mL) was added. The reaction mixture was stirred at 40°C for 1 hour. After TLC indicated the reaction was complete, the reaction mixture was concentrated in vacuo. The crude product was purified by reverse phase column chromatography (water / acetonitrile: 6:4) to give Int-B-5.37-A1 (0.05 g, 47.08%). LCMS ESI (m / z): 419.4 (M+H).

[1726] Step-2: Boc deprotection of Int-A-5.37-A1 was carried out as described for ANASIA-059 using 4M HCl in dioxane.

[1727] 1H NMR (400 MHz, DMSO) δ 8.29 (bs, 2H), 8.22-8.17 (m, 2H), 8.08 (bs, 2H), 7.85 (t, J = 5.6 Hz, 1H), 7.44 (t, J = 5.8 Hz, 1H), 3.75 (bs, 1H), 1.75-1.57 (m, 2H), 1.45-1.44 (m, 1H), 0.92-0.85 (m, 6H). LCMS ESI (m / z): 319.3 (M+H). Purity at 210 nm: 100%.

[1728] Synthesis of 4-(N'-(L-leucyl)sulfonamidoimido)thiophene-3-carboxamide 2,2,2-trifluoroacetate

[1729] (ANASIA-097)

[1730]

[1731] Step-1: A stirred solution of methyl 4-(N'-((tert-butoxycarbonyl)-L-leucyl)sulfonamido)thiophene-3-carboxylate (0.24 g, 0.55 mmol) in THF (20 mL) was bubbled with ammonia gas for 20 minutes, followed by stirring at 60°C for 3 hours. After TLC indicated the completion of the reaction, the reaction mixture was evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give tert-butyl ((2S)-1-((amino(4-carbamoylthiophen-3-yl)(oxo)-λ6-sulfanylidene)amino)-4-methyl-1-oxopentan-2-yl)carbamate (1.5 g, 40%). LCMS ESI (m / z): 419.5 (M+1).

[1732] Step-2: Boc deprotection of Int-B-5.38-A1 was carried out as described for ANASIA-059 using 4M HCl in dioxane. 1 H NMR (400 MHz, DMSO) δ 8.35 (d, J = 3.2 Hz, 1H), 8.30-8.20 (m, 2H), 7.91-7.81 (m, 6H), 3.66-3.65 (m, 1H), 1.71-1.58 (m, 2H), 1.43-1.23 (m. 1H), 0.88 (d, J = 6 Hz, 6H). LCMS ESI (m / z): 319.2 (M+H). Purity at 210 nm: 100%

[1733] Synthesis of (S)-2-amino-N-((S)-amino(4-ethylthiophen-2-yl)(oxo)-λ6-sulfanylidene)-4-methyl Valeramide and (S)-2-amino-N-((R)-amino(4-ethylthiophen-2-yl)(oxo)-λ6-sulfanylidene)-4-methylvaleryl amine

[1734] (ANASIA-133-1 and ANASIA-133-2)

[1735]

[1736] Step-1: To a degassed solution of tert-butyl ((2S)-1-((amino(4-bromothiophen-2-yl)(oxo)-λ-sulfanylidene)amino)-4-methyl-1-oxopentan-2-yl)carbamate (0.25 g, 0.55 mmol) in 1,4-dioxane (2.5 mL) was added CsCO (0.536 g, 1.65 mmol), trifluoro(vinyl)-I4-borane potassium salt (0.09 g, 0.66 mmol), and PdCl(dppf).DCM (0.045 g, 0.055 mmol), and stirred at 100° C. for 16 hours. After completion of the reaction as determined by TLC monitoring (50% ethyl acetate / hexane), the reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (2×20 mL). The combined organic layers were dried over NaSO and concentrated under reduced pressure. The crude product was purified by column chromatography (35% ethyl acetate / hexanes) to afford Int-B-5.29-A1 (0.20 g, 77.60%) as a yellow oil.

[1737] Step-2: To a suspension of 10% Pd / C (0.050 g) in methanol (2 mL) was added a solution of tert-butyl ((2S)-1-((amino(oxo)(4-vinylthiophen-2-yl)-λ-sulfanylidene)amino)-4-methyl-1-oxopentan-2-yl)carbamate (0.20 g, 0.498 mmol, 1 eq) in methanol (4 mL) at room temperature. Hydrogen gas was purged through the reaction mixture for 2 hours. After completion of the reaction as determined by TLC monitoring, the reaction mixture was filtered using celite and the filtrate was concentrated under reduced pressure. The crude product was purified by column chromatography (27% ethyl acetate / hexane) to give the title compound Int-B-5.29 (0.120 g, 49.75%) as a yellow sticky solid. LCMS ESI (m / z): 404.7 (M+1).

[1738] The diastereomers were separated by chiral preparative HPLC (YMC CHIRALART CELLULOSE-SC, mobile phase: n-heptane:IPA (82:18)) to give Isomer-1 (Fr-1): retention time: 14.70 minutes; and Isomer-2 (Fr-2): retention time: 32.61 minutes.

[1739] Step-3: Boc deprotection of Int-A-5.29-Fr-1 and Int-A-5.29-Fr-2 was carried out as described for ANASIA-059 using 4M HCl in dioxane to afford ANASIA-133-1 and ANASIA-133-2.

[1740] Isomer-1: 1 H NMR (400 MHz, DMSO-d6) δ 8.09 (s, 5H), 7.61 (m, 2H), 3.66 (bs, 1H), 2.63-2.57 (q, 2H), 1.77-1.61 (m, 2H), 1.50-1.48 (m, 1H), 1.17 (t, J = 7.4 Hz, 3H), 0.88-0.87 (d, J = 6 Hz, 6H). LCMS ESI (m / z): 304.1 (M+H). Purity at 210 nm: 99.01%.

[1741] Isomer-2: 1 H NMR (400 MHz, DMSO-d6) δ 8.22 (bs, 2H), 8.02 (bs, 3H), 7.62 (m, 2H), 3.66 (bs, 1H), 2.61-2.57 (q, 2H), 1.80-1.77 (m, 1H), 1.72-1.66 (m, 1H), 1.59-1.54 (m, 1H), 1.81 (t, J = 7.6 Hz, 3H), 0.90 (both d, J = 7 Hz, 6H). LCMS ESI (m / z): 304.1 (M+H). Purity at 210 nm: 100%.

[1742] Synthesis of (S)-2-amino-N-((S)-amino(oxo)(5-vinylthiophen-2-yl)-λ6-sulfanylidene)-4-methyl Pentamide and (S)-2-amino-N-((R)-amino(oxo)(5-vinylthiophen-2-yl)-λ6-sulfanylidene)-4-methyl Valeramide

[1743] (ANASIA-105-1)

[1744]

[1745] Step-1: To a degassed solution of tert-butyl ((2S)-1-((amino(5-bromothiophen-2-yl)(oxo)-λ-sulfanylidene)amino)-4-methyl-1-oxopentan-2-yl)carbamate (0.2 g, 0.44 mmol), potassium vinyltrifluoroborate (0.795 g, 5.94 mmol) and CsCO (1.16 g, 3.56 mmol) in THF:HO (5:0.5 mL) was added Pd(PPh) (0.13 g, 0.11 mmol) and heated at 100°C for 48 hours. After completion of the reaction as indicated by TLC, the reaction mixture was poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over NaSO, and evaporated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate / hexane) to give the title compound Int-B-5.15-A1 (207 mg, 43.38%) as a mixture of diastereomers. LCMS ESI (m / z): 402.5 (M+H).

[1746] The diastereomers were separated by chiral preparative HPLC (YMC CHIRALART Cellulose_SC, mobile phase: n-heptane_IPA-ACN(70-30)+2%MTBE_94:6) to give Isomer-1 (Fr-1): retention time: 26.71 minutes and Isomer-2 (Fr-2): retention time: 44.50 minutes.

[1747] Step-3: Boc deprotection of Int-A-5.15-Fr-1 and Int-A-5.15-Fr-2 was carried out as described for ANASIA-059 using 4M HCl in dioxane to give ANASIA-105-1 and ANASIA-105-2.

[1748] Isomer-1: 1 H NMR (400 MHz, DMSO d6) δ 8.31 (bs, 2H), 8.04 (s, 3H), 7.61 (d, J = 3.8 Hz, 1H), 7.20 (d, J = 3.4 Hz, 1H), 6.96-6.89 (m, 1H), 5.75 (d, J = 17.4 Hz, 1H), 5.38 (d, J = 10.9 Hz, 1H), 3.68 (bs, 1H), 1.76-1.48 (m, 3H), 0.88 (d, 6H). LCMS ESI (m / z): 302.3 (M+H). Purity at 210 nm: 94.53%.

[1749] Isomer-2: LCMS ESI (m / z): 302.4 (M+H). Purity at 210 nm: 84.46%.

[1750] Synthesis of (2S)-2-amino-N-(amino(oxo)(3-vinylthiophen-2-yl)-λ6-sulfanylidene)-4-methyl Valeramide hydrochloride

[1751] (ANASIA-106)

[1752]

[1753] Step-1: To a degassed solution of tert-butyl ((2S)-1-((amino(3-bromothiophen-2-yl)(oxo)-λ-sulfanylidene)amino)-4-methyl-1-oxopentan-2-yl)carbamate (0.440 g, 0.96 mmol) and CsCO (0.945 g, 2.90 mmol) in dioxane:water (9:1) (4.4 mL) were added tributylstannylethylene (1.53 g, 4.84 mmol) and PdCl(dppf)DCM complex (0.095 g, 0.11 mmol) and the reaction mixture was heated at 100° C. under microwave for 2 hours. After completion of the reaction as indicated by TLC, the reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (2×25 mL). The combined organic layers were dried over NaSO and concentrated in vacuo. The crude product was subjected to silica gel column chromatography to give Int-B-5.41-A1 (0.090 g, 23%). LCMS ESI (m / z): 402.5 (M+H).

[1754] Step-2: Boc deprotection of Int-B-5.41-A1 was carried out as described for ANASIA-059 using 4M HCl in dioxane.

[1755] 1 H NMR (400 MHz, DMSO d6) δ 8.3-8.8 (bs, 2H), 7.97 (bs, 3H), 7.89 (d, J = 5.2 Hz, 1H), 7.55 (d, J = 5.2 Hz, 1H), 7.24–7.15 (m, 1H), 5.93 (d, J = 17.6 Hz, 1H), 5.49 (t, J = 11.2 Hz, 1H), 3.70–3.66 (m, 1H), 1.78–1.57 (m, 2H), 1.43–1.38 (m, 1H), 0.92–0.87 (m, 6H). LCMS ESI (m / z): 302.1 (M+H). Purity at 210 nm: 95.32%.

[1756] Synthesis of (2S)-2-amino-N-(amino(2-hydroxyphenyl)(oxo)-λ6-sulfanylidene)-4-methylpentanamide

[1757] (ANASIA-113)

[1758]

[1759] Step-1: Boc deprotection of Int-B-5.53 was carried out as described for ANASIA-059 using 4M HCl in dioxane to afford ANASIA-113.

[1760] 1H NMR (400 MHz, DMSO) δ 10.94 (bs, 1H), 7.91 (bs, 3H), 7.76 (d, J = 6.4 Hz, 1H), 7.45-7.44 (m, 3H), 7.03-6.94 (m, 2H), 3.63-3.58 (m, 1H), 1.74-1.70 (m, 1H), 1.55-1.44 (m, 2H), 0.91-0.88 (m, 6H). LCMS ESI (m / z): 286.2 (M+1). Purity at 210 nm: 100%.

[1761] Synthesis of ((2S)-1-((((tert-butyldimethylsilyl)amino)(3-methoxyphenyl)(oxo)-16-sulfuryl tert-Butyl (4-(2-(2-methyl-1-oxopentan-2-yl)alkyl)amino)carbamate (Int-I-1.0)

[1762]

[1763] Int-B-3.52 (400 mg, 1.33 mmol, 1 eq) was dissolved in anhydrous DMF (7 mL). The solution was cooled to 0 ° C and NaH (60% in oil, 138 mg, 3.46 mmol, 2.6 eq) was added (the solution turned yellow). The mixture was stirred for 10 minutes at the same temperature. Then, Boc-Leu-OSu Int-X1 (437 mg, 1.33 mmol, 1 eq) was added. The mixture was warmed to room temperature and stirred until TLC indicated completion, then poured into water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, and evaporated in vacuo to give the crude material, which was purified by chromatography to give the title compound Int-I-1.0 (120 mg, 18%) as a mixture of diastereomers. UPLCMS ESI (m / z): 514.78 (M + H) + .

[1764] The following intermediates were prepared according to the procedures described for Int-I-1.0.

[1765]

[1766]

[1767]

[1768] Synthesis of (2S)-2-amino-N-(amino(3-methoxyphenyl)(oxo)-16-sulfanylidene)-4-methylpentanamide

[1769] (ANASIA-102)

[1770]

[1771] Int-I-1.0 (120 mg, 0.23 mmol, 1 eq) was dissolved in DCM (0.5 mL). HCl (4 M in dioxane, 4 eq) was added to the solution and stirred until Boc group deprotection was complete. The solvent was evaporated under reduced pressure and the crude product was purified by reverse phase chromatography (HO / MeCN) (100:0 to 80:20) to afford ANASIA-102 (26 mg, 37%). 1 H NMR (400MHz, ACN) δ7.67–7.34(m,3H),7.34–7.11(m,1H),3.89–3.80(m,3H),3.80–3.71(m,1H),1.77–1.52(m,3H),0.97–0.81(m,6H). 13 C NMR (101 MHz, ACN) δ 176.66, 176.53, 160.81, 142.66, 142.62, 131.51, 120.49, 120.46, 120.05, 120.01, 112.79, 112.76, 56.64, 55.27, 55.24, 40.61, 25.18, 22.69, 22.60, 22.14, 22.10. Purity at 210 nm: 93.14%; at 254 nm: 89.21%. UPLCMS ESI (m / z): 300.49 (M+H).

[1772] The following compounds were prepared according to the procedure described for compound ANASIA-102 using HCl or TFA.

[1773]

[1774]

[1775]

[1776]

[1777]

[1778] Synthesis of (2S)-2-amino-N-(amino(oxo)(1H-pyrazol-5-yl)-16-sulfanylidene)-4-methylpentanamide

[1779] (ANASIA-064)

[1780]

[1781] Step-1: A flask was charged with Int-I-1.7 (320 mg, 0.54 mmol), CH3CN (12 mL), HO (4 mL) and ceric ammonium nitrate (1.18 mg, 2.15 mmol). After stirring at room temperature for 3 hours, HO (50 mL) was added to the reaction mixture. The product was extracted with ethyl acetate (70 mL×3), and the organic layers were combined, washed with saturated sodium bicarbonate and brine, and dried over anhydrous MgSO4. The mixture was purified by column chromatography to give the product Int-J-1.0 (148 mg, 76%): UPLCMS ESI (m / z): 360 (M+H)+.

[1782] Step-2: Int-J-1.0 (148 mg, 0.41 mmol) was dissolved in DCM (1 mL) and TFA (0.5 mL) was added. The mixture was evaporated and the residue was subjected to reverse phase chromatography to afford ANASIA-064 (175 mg, 87%). 13 C NMR(101MHz,MeOD):177.13,177.07,152.59,131.72,131.68,107.75,107.69,55.65,55.60,49.80,48.26,48.25,48.23, 48.22, 48.20, 48.19, 48.17, 48.16, 48.14, 48.13, 48.11, 48.08, 41.50, 41.43, 25.61, 25.56, 22.95, 22.93, 22.17, 22.14. 1 HNMR(400MHz,MeOD):7.81(dd,J=2.5,1.2Hz,1H),6.87(dd,J=3.8,2.4Hz,1H),3.7 7(dd,J=8.3,5.6Hz,1H),1.93-1.72(m,2H),1.67-1.51(m,1H),1.03-0.94(m,6H). 19 F NMR (376 MHz, MeOD): -77.22 (TFA).Purity at 210 nm: 98.09%.

[1783] Biological methods

[1784] Study 1—Enzyme Inhibition

[1785] The aminoacylation reaction catalyzed by aminoacyl-tRNA synthetase (aaRS) occurs in two steps. In the first step, aaRS activates its cognate amino acid in the presence of ATP; in the second step, the activated amino acid is loaded onto its corresponding tRNA. This reaction can be summarized as follows:

[1786] aaRS+aa+ATP=aaRS-aa-AMP+PPi

[1787] aaRS-aa-AMP+tRNA=aa-tRNA+AMP+aaRS

[1788] Wherein: aaRS, aminoacyl-tRNA synthetase; aa, amino acid; aaRS-aa-AMP, enzyme-bound aminoacyl-adenylate; AMP, adenosine monophosphate; aa-tRNA, aminoacyl-tRNA; PPi, inorganic pyrophosphate.

[1789] Leucyl-tRNA synthetase

[1790] a. Single point inhibition percentage

[1791] The activity of pathogenic aaRS was monitored by measuring AMP production using the commercially available kit AMP-Glo ​​(Promega, Madison, USA).

[1792] A 10 mM concentration of ligand stock solution was prepared in 100% DMSO. An assay buffer consisting of 100 mM Tris HCl pH 7.6, 40 mM MgCl, 20 mM KCl, and 150 mM NaCl was prepared in dH2O. In the assay, an enzyme solution containing 72.95 μM LeuRS was prepared in assay buffer to provide a 20 nM final assay concentration and a 50 nM reservoir concentration, diluted 1:2.5. Separately, a substrate solution containing 50 mM L-leucine, 10 mM ATP, and 100 mg / mL tRNA was prepared in assay buffer. In the assay, a 1:1.66 dilution was performed using a final assay concentration of 500 μM L-leucine, 16.7 μM ATP, and 0.5 mg / mL tRNA, and a reservoir concentration of 833.33 μM L-leucine, 27.83 μM ATP, and 0.83 mg / mL tRNA.

[1793] The enzyme was assayed in triplicate and the percentage inhibition value was reported at a single concentration of 100 μM. If the test compound inhibited the aminoacylation reaction by more than 25% in at least two replicates, the IC was determined using the same enzyme assay. 50 .

[1794] b.IC 50 Determination

[1795] A ten-point concentration-response curve was generated for each compound using the same enzyme assay in a 384-well plate format, using a top concentration of 10 μM. A known inhibitor, LeuAMS, was used as a positive control for the LeuRS assay. 100% DMSO was used as a negative control. IC was calculated based on nonlinear regression analysis. 50 .

[1796] Isoleucyl-tRNA synthetase

[1797] a. Single point inhibition percentage

[1798] The activity of pathogenic aaRS was monitored by measuring AMP production using the commercially available kit AMP-Glo ​​(Promega, Madison, USA).

[1799] A 10 mM concentration of ligand stock solution was prepared in 100% DMSO. An assay buffer consisting of 100 mM Tris HCl pH 7.6, 40 mM MgCl, 20 mM KCl, and 150 mM NaCl was prepared in dH2O. In the assay, an enzyme solution containing 51.77 μM IleRS was prepared in assay buffer to provide a 30 nM final assay concentration and a 75 nM reservoir concentration, diluted 1:2.5. Separately, a substrate solution containing 50 mM L-isoleucine, 10 mM ATP, and 100 mg / mL tRNA was prepared in assay buffer. In the assay, a 1:1.66 dilution was performed using final assay concentrations of 500 μM L-isoleucine, 5 μM ATP, and 1 mg / mL tRNA, and a reservoir concentration of 833.33 μM L-isoleucine, 8.33 μM ATP, and 1.67 mg / mL tRNA.

[1800] The enzyme was assayed in triplicate and the percentage inhibition value was reported at a single concentration of 100 μM. If the test compound inhibited the aminoacylation reaction by more than 25% in at least two replicates, the IC was determined using the same enzyme assay. 50 .

[1801] b.IC 50 Determination

[1802] A ten-point concentration-response curve was generated for each compound using the same enzyme assay in a 384-well plate format, using a top concentration of 100 μM. A known inhibitor, IleAMS, was used as a positive control for the IleRS assay. 100% DMSO was used as a negative control. IC values ​​were calculated based on nonlinear regression analysis. 50 .

[1803] Valyl-tRNA synthetase

[1804] a. Single point inhibition percentage

[1805] The activity of pathogenic aaRS was monitored by measuring AMP production using the commercially available kit AMP-Glo ​​(Promega, Madison, USA).

[1806] A 10 mM concentration of ligand stock solution was prepared in 100% DMSO. An assay buffer consisting of 100 mM Tris HCl pH 7.6, 40 mM MgCl, 20 mM KCl, and 150 mM NaCl was prepared in dH2O. In the assay, an enzyme solution containing 42.33 μM ValRS was prepared in assay buffer to provide a 30 nM final assay concentration and a 75 nM reservoir concentration, diluted 1:2.5. Separately, a substrate solution containing 50 mM L-valine, 10 mM ATP, and 100 mg / mL tRNA was prepared in assay buffer. In the assay, a 1:1.66 dilution was performed using a final assay concentration of 500 μM L-valine, 2.5 μM ATP, and 0.5 mg / mL tRNA, and a reservoir concentration of 833.33 μM L-valine, 9.3 μM ATP, and 0.83 mg / mL tRNA.

[1807] The enzyme was assayed in triplicate and the percentage inhibition value was reported at a single concentration of 100 μM. If the test compound inhibited the aminoacylation reaction by more than 25% in at least two replicates, the IC was determined using the same enzyme assay. 50 .

[1808] b.IC 50 Determination

[1809] A ten-point concentration-response curve was generated for each compound using the same enzyme assay in a 384-well plate format, using a top concentration of 100 μM. A known inhibitor, ValAMS, was used as a positive control for the ValRS assay. 100% DMSO was used as a negative control. IC values ​​were calculated based on nonlinear regression analysis. 50 .

[1810] The data are summarized in the table below.

[1811]

[1812]

[1813]

[1814]

[1815]

[1816]

[1817] Study 2—Antibacterial Activity

[1818] Minimum inhibitory concentration (MIC) is determined by the microbroth dilution method performed according to the Clinical Laboratory Standards Institute guideline. For test, 5 mg / mL DMSO solution is prepared by dissolving the solid in DMSO. According to the CLSI guideline, 5 mg / mL stock solutions of standard antibiotics are prepared. After preparing the DMSO stock solution, a working solution in MH culture medium is prepared by adding 38.4 μL stock solutions to 1461.6 μL MH culture medium. From these working solutions, 100 μL are transferred to the holes in the third row of 96-well assay plates. 50 μL MH culture medium are pre-filled in all holes except each hole in the third row of the assay plate. After adding compound and antibiotic, 50 μL are transferred from the third row to the fourth row, then from the fourth row to the fifth row, and so on. In this way, a serial two-fold dilution of compound and antibiotic is spread in a 96-well assay plate, and the dilution is from 256 μg / mL or 64 μg / mL maximum concentration.

[1819] MIC values ​​were determined by visual inspection of bacterial growth within the 96-well plate. The first row with no apparent bacterial growth was determined as the MIC value for the compound or antibiotic tested in that particular row. ATCC strains were used as reference strains for determining the MIC values ​​of standard antibiotics. The assay was considered valid when the MIC values ​​of the standard antibiotics were within the range specified by the CLSI for the tested ATCC strains.

[1820] The data are summarized in the table below.

[1821]

[1822]

[1823]

[1824]

[1825]

[1826]

[1827] legend

[1828] A = Escherichia coli ATCC 25922

[1829] B=Enterobacter cloacae B1966

[1830] C = Klebsiella pneumoniae ATCC 700603

[1831] D = Pseudomonas aeruginosa ATCC 27853

[1832] E = Acinetobacter baumannii B1931

[1833] F = Haemophilus influenzae ATCC 49247

[1834] G = Escherichia coli BAA-2469

[1835] Study 3—Human Cell Viability

[1836] The potential nonspecific cytotoxic effects of the compound on a human hepatocyte cell line (HepG2 ATCC HB-8065) ​​were assessed. 96-well plates were inoculated with HepG2 cells at a concentration of 15,000 cells per well in 100 μL MEM growth medium supplemented with 1% NEAA and 1% sodium pyruvate. Border wells were filled with 100 μL sterile PBS. After two days of incubation, the compound was added. Compound dilutions were prepared in pure DMSO in a 96-well V-bottom plate. The growth medium in 5 plates was aspirated and replaced with 98.7 μL fresh growth medium. 1.28 μL of the compound prepared in the V-bottom plate was transferred to a test plate (78.1× dilution) using a multichannel pipette. The final DMSO concentration was 1.28% per well. In the control wells, 1.28 μL DMSO was added to 98.7 μL culture medium. The test compound was tested in duplicate. When cell viability is assessed by measuring ATP levels, cells are incubated with compounds for 24 hours. ATP levels are measured by adding 50 μL of CellTiter-Glo reagent to each well and, after a 5-minute incubation, luminescence is measured using a SpectraMax i3. The potential effect of the test compound on cell viability is determined by comparing the signal obtained in the presence of different concentrations of the compound with the signal obtained in the presence of DMSO alone. The potential effect is then calculated and reported as IC 50 The values ​​(μg / mL) are presented.

[1837] The data are summarized in the table below.

[1838]

[1839]

[1840]

[1841] Study 4—Efficacy in a Murine Model of Urinary Tract Infection (E. coli UTI89)

[1842] method

[1843] animal

[1844] All animal studies were performed under UK Home Office license number PA67E0BAA (protocol E9 for the UTI model) with approval from the local ethical review committee. All studies were performed by technicians who had completed parts A, B, and C of the UK Home Office personal licensing course and held a current personal license. All experiments were performed in a dedicated Biohazard 2 facility (the site holds a designated certificate).

[1845] Female mice used in these studies were provided by Janvier Laboratories and were specific pathogen-free. The mouse strain used was C3H / HeNRj, a well-characterized inbred strain. Mice weighed 16-20 g at arrival and were acclimated for at least 7 days prior to any intervention. Five days prior to infection, mice were transferred to drinking water containing 5% glucose.

[1846] Test object

[1847] Ciprofloxacin was provided as a 2 mg / mL stock solution (POM, Claris) and administered intravenously at 5 mL / kg to achieve a 10 mg / kg dose. It was stored at 4°C between doses. The test article was prepared by dissolving in water for injection, taking into account a salt correction factor. The study vehicle was water for injection (Braun) and was clear and colorless.

[1848] program

[1849] Immediately before injection, dilute the previously prepared frozen stock of E. coli UTI89 to 2.3 × 10 9 cfu / mL. Mice (n=6 / group) were infected by transurethral administration of 0.05 mL of inoculum directly into the bladder under parenteral anesthesia. No water was consumed two hours prior to infection, and the bladder was emptied before infection. After infection, the infection catheter was retained in the urinary tract for 10 minutes to reduce the risk of organism reflux.

[1850] Mice were monitored at a frequency appropriate to the clinical situation. Mouse body weights were recorded at least once daily to ensure animals were maintained within ethical boundaries and to monitor treatment efficacy.

[1851] Twenty-four hours after infection, urine was collected from the animals before treatment and used to assess infection levels. Urine samples were quantitatively cultured on MacConkey agar plates and incubated at 37°C for 24 hours, followed by colony counts. In addition, five mice were euthanized using an overdose of pentobarbital to provide a control group 24 hours before treatment.

[1852] Forty-eight hours after infection, urine was collected from all mice. Seventy-two hours after infection, the clinical condition and body weight of all remaining animals were assessed, and urine samples were collected. Animals were then euthanized using an overdose of pentobarbital, and the kidneys and bladders were removed and weighed. Tissue samples were homogenized in 2 mL of ice-cold sterile phosphate-buffered saline using a Precellys 24dual bead mill. Homogenates and urine samples were quantitatively plated on MacConkey agar plates and incubated at 37°C for 24 hours, after which colonies were counted.

[1853] Data Analysis

[1854] Data obtained from culture burden were analyzed using StatsDirect software using appropriate nonparametric statistical models (Kruskal-Wallis with Conover-Inman for all pairwise comparisons between groups) and compared to pre-treatment and vehicle controls.

[1855] Experiment 1

[1856] Compound ANASIA-103-1 was administered subcutaneously with water for injection at 5, 15, and 45 mg / kg per dose via pinports 24 hours after infection and then every 4 hours. The efficacy was compared with ciprofloxacin (10 mg / kg per dose) administered intravenously 24, 36, 48, and 60 hours after infection. Mice were inoculated with 7.5×10 7 Before treatment, the geometric mean microbial load in urine was 7.42 log 10 cfu / mL and remained relatively constant throughout the experiment: 7.31 log cfu / mL at 48 h in the vehicle-treated group. 10 cfu / mL, and 7.33 log at harvest (72 hours) 10 cfu / mL. The microbial load in the bladder also remained fairly constant: 8.16 log before treatment. 10 cfu / g; and 7.99 log at harvest 10 cfu / g. The microbial load in the kidney decreased from 5.31 log in the pre-treatment group. 10 cfu / g increased to 6.20 log at harvest 10 The reduction in microbial burden in the test article treated groups relative to the vehicle control group is shown in the table below.

[1857]

[1858]

[1859] NS, not significant

[1860] Experiment 2

[1861] Compound ANASIA-124-1 was administered subcutaneously with water for injection at 15 and 45 mg / kg per dose 24 hours after infection and then every 4 hours. The efficacy was compared with ciprofloxacin (10 mg / kg per dose) administered intravenously 24, 36, 48, and 60 hours after infection. Mice were inoculated with 1.3×10 7 In the vehicle-treated group, the geometric mean microbial load in urine was 7.05 log before treatment. 10 cfu / mL and increased to 7.01 log at 48 hours 10 cfu / mL and increased to 7.12 log at harvest (72 hours) 10 cfu / mL. The microbial load in the bladder remained fairly constant: 8.20 log before treatment. 10 cfu / g; and 7.98 log at harvest 10 cfu / g. The microbial load in the kidney decreased from 5.54 log in the pre-treatment group. 10 cfu / g increased to 6.37 log at harvest 10 The reduction in microbial burden in the test article treated groups relative to the vehicle control group is shown in the table below.

[1862]

[1863] NS, not significant

[1864] Study 5—Efficacy in a Murine Model of Disseminated Infection (E. coli ATCC 25922)

[1865] method

[1866] animal

[1867] All animal studies were performed under UK Home Office license number PA67E0BAA (protocol E1 for sepsis efficacy) with approval from the local ethical review committee. All experiments were performed by technicians who had completed Part AC of the Home Office Personal Licensing Course and held a current Personal Licensing.

[1868] The mice used in these studies were provided by Charles River (Margate, UK) and were specific pathogen-free. The mouse strain used was ICR (also known as CD1 mice), a well-characterized outbred mouse strain. Mice (male) were 15-18 g when received at the facility and were acclimated for at least 7 days.

[1869] Mice were housed in individually ventilated sterile cages, exposed to HEPA-filtered sterile air at all times. Food and water were freely available to the mice, and aspen chip bedding was used (changed at least once a week). The room temperature was 22°C + / - 1°C, the relative humidity was 60%, and the maximum background noise was 56 dB. Mice were exposed to a 12-hour light / dark cycle.

[1870] Test object

[1871] The test articles were prepared by dissolving in water for injection, taking into account the salt correction factor. The study vehicle was water for injection (Braun) and was clear and colorless.

[1872] program

[1873] Mice (n = 5 / group) were not immunosuppressed. The bacterial strain used was Escherichia coli ATCC 25922. Immediately before infection, an aliquot of a previously prepared frozen stock of the strain was thawed and diluted in sterile PBS and porcine mucin to the desired inoculum containing 5% porcine mucin. Mice were infected intravenously with 0.2 mL of the bacterial strain suspension.

[1874] The test article was administered subcutaneously 1 and 3 hours after infection. Additional control groups were included, including: a pre-infection treatment group that was euthanized 1 hour after infection; a vehicle-treated group that was dosed 1 and 3 hours after infection; and a group that received a single 30 mg / kg SC dose of the comparator test article, tigecycline, 1 hour after infection.

[1875] Five hours after infection, the clinical condition of all animals was assessed and terminal cardiac blood was drawn under terminal anesthesia. The spleen and kidneys were dissected out and homogenized in 2 mL of ice-cold sterile PBS; the homogenate and blood were quantitatively plated on CLED agar plates and incubated at 37°C for 18-24 hours, after which colonies were counted.

[1876] Data Analysis

[1877] Data obtained from culture burden were analyzed using StatsDirect software using appropriate nonparametric statistical models (Kruskal-Wallis with Conover-Inman for all pairwise comparisons between groups) and compared to vehicle controls.

[1878] Experiment 1

[1879] At 1 hour and 3 hours after infection, 1.875, 7.5 and 30 mg / kg of compound ANASIA-103-1 were administered subcutaneously with water for injection. At the same time points, different groups of animals were given 7.5 and 30 mg / kg by oral gavage. The efficacy was compared with tigecycline (30 mg / kg) administered subcutaneously 1 hour after infection. Mice were inoculated with 4.8×10 7 cfu Escherichia coli ATCC 25922. In the vehicle-treated group, the geometric mean microbial load in the blood before treatment was 5.46 log 10 cfu / mL, increased to 6.08 log at 5 h harvest time 10 cfu / mL. The microbial load in the kidney was 6.19 log before treatment. 10 cfu / mL, increased to 8.09 log at harvest 10 cfu / mL. The microbial load in the spleen before treatment was 6.75 log 10 cfu / mL, increased to 8.68 log at harvest 10 The reduction in microbial burden in the test article treated groups relative to the vehicle control group is shown in the table below.

[1880]

[1881]

[1882] NS, not significant

[1883] The foregoing has described the principles, preferred embodiments, and modes of operation of the present invention. However, the present invention should be construed as being limited to the specific embodiments discussed. In fact, the above-described embodiments should be considered illustrative rather than restrictive. It should be understood that those skilled in the art may modify these embodiments without departing from the scope of the present invention.

[1884] References

[1885] A number of publications are cited herein to more fully describe and disclose the invention and the prior art to which the invention pertains. Full citations for these references are provided below.

[1886] These references are hereby incorporated by reference into the present disclosure in their entirety to the same extent as if each individual reference was specifically and individually indicated to be incorporated by reference.

[1887] Finn et al.,2018,“2-Amino-N-(arysulfinyl)-acetamide compounds asinhibitors of bacterial aminoacyl-tRNA synthetase”,international(PCT)patentpublication number WO 2018 / 065611 A1 published 12 April 2018.

[1888] Gadahk et al.,2012,“Aminoacyl-tRNA synthetase inhibitors asantimicrobial agents:a patent review from 2006 till present”, Expert Opin.Ther.Patents ,Vol.22,No.12,pp.1453-1465.

[1889] Hurdle et al.,2005,“Prospects for aminoacyl-tRNA synthetaseinhibitors as new antimicrobial agents”, Antimicrobial Agents and Chemotherapy ,Vol.49,pp.4821-4833.

[1890] Jirgensons et al.,2016,“Novel N-acyl-sulfonamide derivatives asaminoacyl-tRNA synthetase inhibitors”,international(PCT)patent publicationnumber WO 2016 / 129983 A1 published 18 August 2016.

[1891] Laupand et al.,2003,“Treatment of staphylococcus aureus colonizationand prophylaxis for infection with topical intranasal mupirocin:An evidence-based review”, Clinical Infectious Diseases ,Vol.37,pp.933-938.

[1892] Ochsner et al.,2007,“Aminoacyl-tRNA synthetases:essential and stillpromising targets for new anti-infective agents”, Expert Opinion on Investigational Drugs ,Vol.16,pp.573-593

[1893] Pham et al.,2014,“Aminoacyl-tRNA synthetases as drug targets ineukaryotic parasites”, Int.J.Parasitol.Drugs Drug Resist. ,Vol.4,lssue 1,pp.1-13.

[1894] Vondenhoff et al.,2011,“Aminoacyl-tRNA synthetase inhibitors aspotential antibiotics”, Eur.J.Med.Chem. ,Vol.46,pp.5227-5236.

Claims

1. A compound selected from the group consisting of the following compounds, and pharmaceutically acceptable salts thereof: in: -A is independently -A C or -A H ; -A C is independently phenyl or naphthyl, and is optionally substituted by one or more -R X replace; -A H are independently thienyl, pyrazolyl, thiazolyl, pyridinyl, benzothienyl, benzisothiazolyl, thienopyridinyl, thienothiphenyl or quinolinyl, and are optionally substituted by one or more substituents -R X replace; And among them: Each-R X Independently selected from: -R XX 、-R XXU , -F, -Cl, -Br, -OH、-OR XX , -CF3, -CHF2, -OCF3, -OCHF2, -C(=O)NH2, -C(=O)R XX and -CN; And additionally, two adjacent groups -R X When present, they may together form: -O-CH2-O- or -CH2-CH2-O-; in: Each-R XX are independently straight-chain or branched saturated C 1-4 Alkyl or phenyl, wherein each phenyl is optionally substituted with one or more groups selected from: -F and -Cl; Each-R XXU Independently straight or branched chain C 2-4 alkenyl; -R 1 Yes-R 11 ; -R 11 Yes-R 11A ; -R 11A Independently are: -R A1 or -L A -R A2 ; Each-R A1 independently -iBu, -sBu or -iPr; Each-R A2 is cyclopropyl; Each -L A - is -CH2-; -R 2 Yes - H; And among them: -R N1 Yes - H; -R N2 Yes -H.

2. The compound according to claim 1, wherein the compound is selected from the compounds of the following formula, and pharmaceutically acceptable salts thereof:

3. The compound according to claim 2, wherein -R 11A Yes-R A1 .

4. The compound according to claim 3, wherein -R A1 It is -iBu.

5. The compound according to claim 3, wherein -R A1 It's -sBu.

6. The compound according to claim 3, wherein -R A1 Yes-iPr.

7. The compound according to claim 2, wherein: -R 1 are independently -CH(CH3)CH2CH3 or -CH2CH(CH3)2.

8. The compound according to claim 2, wherein -R 11A Yes-L A -R A2 .

9. The compound according to claim 2, wherein -A is -A C .

10. The compound according to claim 9, wherein -A C is phenyl or naphthyl, and is optionally substituted by 1 or 2 -R X replace.

11. The compound according to claim 9, wherein -A C is phenyl and is optionally substituted by 1 or 2 -R X replace.

12. The compound according to claim 2, wherein -A is -A H .

13. The compound according to claim 12, wherein -A H is thienyl, pyrazolyl, thiazolyl, pyridinyl, benzothienyl, benzisothiazolyl, thienopyridinyl, thienothiphenyl or quinolinyl, and is optionally substituted by 1 or 2 groups -R X replace.

14. The compound according to claim 12, wherein -A H is thienyl, pyrazolyl, thiazolyl or pyridinyl, and is optionally substituted by one or more -R X replace.

15. The compound according to claim 4, wherein -A is -A H ; and -A H is thienyl, and is optionally substituted by one or more -R X replace.

16. The compound according to claim 12, wherein -A H is thienyl, and is optionally substituted by one or more -R X replace.

17. The compound according to claim 4, wherein -A is -A H ; and -A H is thien-2-yl and is optionally substituted by one or more -R X replace.

18. The compound according to claim 12, wherein -A H is thien-2-yl and is optionally substituted by one or more -R X replace.

19. The compound according to claim 4, wherein -A is -A H ; and -A H Independently selected from: Each of these -R X3 and -R X4 Independently as about-R X defined.

20. The compound according to claim 12, wherein -A H Independently selected from: Each of these -R X3 and -R X4 Independently as about-R X defined.

21. The compound according to claim 12, wherein -A H is thien-3-yl and is optionally substituted by one or more -R X replace.

22. The compound according to claim 12, wherein -A H is thiazolyl, and is optionally substituted by one or more -R X replace.

23. The compound according to claim 12, wherein -A H is pyrazolyl and is optionally substituted by one or more -R X replace.

24. The compound according to claim 12, wherein -A H is pyridinyl and is optionally substituted by one or more -R X replace.

25. The compound according to claim 12, wherein -A H is benzothienyl, benzisothiazolyl, thienopyridinyl, thienothiphenyl or quinolinyl, and is optionally substituted by one or more -R X replace.

26. The compound according to claim 12, wherein -A H is benzothienyl and is optionally substituted by one or more -R X replace.

27. The compound according to claim 12, wherein -A H is thienopyridinyl and is optionally substituted by one or more -R X replace.

28. The compound according to claim 12, wherein -A H is thienothiphenyl and is optionally substituted by one or more -R X replace.

29. The compound according to claim 12, wherein -A H is quinolinyl and is optionally substituted by one or more -R X replace.

30. The compound according to claim 2, wherein: -A C is phenyl and is optionally substituted by 1 or 2 -R X Replacement; and -A H is thienyl, and is optionally substituted by one or more -R X replace.

31. The compound according to claim 7, wherein: -A C is phenyl and is optionally substituted by 1 or 2 -R X Replacement; and -A H is thienyl, and is optionally substituted by one or more -R X replace.

32. The compound according to claim 30, wherein each -R X When present, independently selected from: -R XX , -F, -Cl, -Br, -OH、-OR XX , -CF3, -CHF2, -OCF3, -OCHF2, -C(=O)NH2, -C(=O)R XX ,and -CN.

33. The compound according to claim 31, wherein each -R X When present, independently selected from: -R XX , -F, -Cl, -Br, -OH、-OR XX , -CF3, -CHF2, -OCF3, -OCHF2, -C(=O)NH2, -C(=O)R XX ,and -CN.

34. The compound according to claim 30, wherein each -R X When present, independently selected from: -R XX , -F, -Cl, -Br, -OH、-OR XX , -CF3, -CHF2, -OCF3, -OCHF2, and -CN.

35. The compound according to claim 31, wherein each -R X When present, independently selected from: -R XX , -F, -Cl, -Br, -OH、-OR XX , -CF3, -CHF2, -OCF3, -OCHF2, and -CN.

36. The compound according to claim 34, wherein each -R XX When present, it is a straight or branched chain saturated C 1-4 alkyl.

37. The compound according to claim 35, wherein each -R XX When present, it is a straight or branched chain saturated C 1-4 alkyl.

38. The compound according to claim 30, wherein each -R XXU When present is independently -CH=CH2 or -CH2-CH=CH2.

39. The compound according to claim 31, wherein each -R XXU When present is independently -CH=CH2 or -CH2-CH=CH2.

40. The compound according to claim 30, wherein each -R X When present, independently selected from -R XX , -F and -Cl; Each of these -R XX Yes-Me.

41. The compound according to claim 31, wherein each -R X When present, independently selected from -R XX , -F and -Cl; Each of these -R XX Yes-Me.

42. The compound according to claim 1, which is selected from the compounds of the following formula, and pharmaceutically acceptable salts thereof:

43. A pharmaceutical composition comprising a compound according to any one of claims 1 to 42 and a pharmaceutically acceptable carrier or diluent.

44. A method of preparing a pharmaceutical composition, the method comprising the step of mixing a compound according to any one of claims 1 to 42 and a pharmaceutically acceptable carrier or diluent.

45. A method of inhibiting a bacterial aminoacyl-tRNA synthetase in vitro, the method comprising contacting the synthetase with an effective amount of a compound according to any one of claims 1 to 42.

46. ​​A method of inhibiting bacterial aminoacyl-tRNA synthetase function in a cell in vitro, the method comprising contacting the cell with an effective amount of a compound according to any one of claims 1 to 42.

47. Use of a compound according to any one of claims 1 to 42 in the manufacture of a medicament for treating a condition in the human or animal body that is ameliorated by inhibition of bacterial aminoacyl-tRNA synthetases.

48. Use of a compound according to any one of claims 1 to 42 in the manufacture of a medicament for the treatment of a bacterial infection.

49. Use according to claim 48, wherein the bacterium is a Gram-positive bacterium.

50. The use according to claim 48, wherein the bacterium is a Gram-negative bacterium.

51. The use according to claim 48, wherein the bacteria are aerobic bacteria.

52. The use according to claim 48, wherein the bacteria is an anaerobic bacteria.

53. The use according to claim 48, wherein the bacterium is an intracellular bacterium.

54. The use according to claim 48, wherein the bacterium is: Staphylococcus; Enterococcus spp.; Streptococcus; Haemophilus spp.; Moraxella spp.; Klebsiella spp.; Acinetobacter spp.; Pseudomonas; Proteus; Neisseria spp.; Clostridium spp.; Campylobacter spp.; Salmonella spp.; Shigella spp.; Enterobacter spp.; Citrobacter; Serratia spp.; or Escherichia spp.

55. The use according to claim 48, wherein the bacterium is: Staphylococcus aureus; Enterococcus faecalis; Streptococcus pneumoniae; Haemophilus influenzae; Moraxella catarrhalis; Klebsiella pneumoniae; Acinetobacter baumannii; Pseudomonas aeruginosa; Proteus mirabilis; Neisseria gonorrhoeae; Clostridium difficile; Campylobacter jejuni; Salmonella Typhi; Shigella flexneri; Enterobacter cloacae; Citrobacter fraudii; Serratia marcescens; or Escherichia coli.

56. The use according to claim 48, wherein the infection is: Central nervous system infections; Outer ear infection; Middle ear infections, including acute otitis media; Cranial sinus infection; Eye infections; Oral infections, including infections of the teeth, gums, or mucous membranes; Upper respiratory tract infection; Lower respiratory tract infection; Urogenital tract infections; Urinary tract infection Intra-abdominal infection; Gastrointestinal infections; Gynecological infections; septicemia; Bone or joint infection; Skin or skin structure infections; Bacterial endocarditis; or Burn infection.